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Abstract
Protein functions are regulated by the post-translational addition of covalent modifications on
certain amino acids. Depending on their distance within the 3-dimensional structure,
addition/removal of individual post translational modifications (PTMs) can be impacted by
others. This PTM interplay constitutes an essential regulatory mechanism that interconnects
the molecular networks in the cell. Protein CK2, a clinically relevant acidophilic Ser/Thr
kinase, may be responsible for 10-20% of the human phosphoproteome. Such estimates agree
with the number of known substrates, which continues to expand. Furthermore, the
demonstration that CK2 participates in hierarchical phosphorylation and has similar sequence
determinants to caspases suggest extensive PTM interplay in CK2-dependent signaling.
In this thesis, we explore the role of lysine acetylation in the vicinity of the phosphorylatable
residue(s) as a modulator of phosphorylation by CK2. To explore this association a
biochemistry approach was followed to decipher the impact of lysine acetylation in CK2
specificity and a proteomics approach was employed for profiling the affected sites in cells.
In solution peptides conforming to the CK2 consensus containing lysine or acetyllysine at
positions +1, +2, or +3 downstream the phosphorylatable site, were found only to be
phosphorylated by CK2 when either determinant was present at position +2. Linear patterns
were generated to reflect this specificity and the PTM databases and the human proteome
were searched for substrate hits. The boundaries and cellular conditions of the hits were
assessed including conservation, mutations, regulatory role, and enzyme-substrate
relationships. Several hits matching the patterns were observed in the cells to be both
acetylated and phosphorylated. Since chromatin organization proteins were hits the
regulatory role of CK2 in this process was summarized. The data processing and analysis
steps followed were incorporated in a data-driven R Shiny web application visualRepo.
Collectively, our work shows how CK2-dependent phosphorylation and lysine acetylation
network integration could contribute to the complexity of cellular processes. It also provides
a computational and analytical framework for further studies exploring the PTM interplay
occurring at a kinase consensus sequence. Finally, given the druggability of CK2, our results
ii

offer new molecular insights for exploring the combination of CK2 and lysine deacetylase
inhibitors.

Keywords
protein kinase CK2, post-translational modifications, modification interplay, lysine
acetylation, phosphorylation, proteomics, bioinformatics.

iii

Summary for Lay Audience
Proteins are main components of the cell and are subjected to many chemical changes or
modifications, affecting their function. Some chemical modifications in proteins have been
described to interplay with one another resulting in intricate regulatory networks. If we were
to look at a protein as a sequence of characters, where two proximal characters were to be
substituted, i.e., modified, an interplay between these can occur preventing or facilitating the
addition of the second modification once the first is added. The protein CK2 is one of many
proteins that modify other proteins in the cell, referred to as substrates. CK2 prefers
modifying characters (amino acids) contained in a negatively charged sequence. In this
thesis, we decipher how modification by CK2 is enabled by a pre-existing modification
(lysine acetylation) that removes a positive charge two amino acids away. Biological
databases were searched for protein sequences conforming to this view and several
candidates were identified. The sequence features and cellular functions of the candidates
were also mined from the databases and the literatures. Finally, for the first time a list of hits
containing both modifications occurring in the cell were identified. All the steps in the
processing and analysis were incorporated into a web application, visualRepo, for facilitating
the reuse and reanalysis of the data. Overall, our work can be extended to identify other
modifying proteins and the interplay that can occur. Given CK2 is a therapeutic target, our
results provide us with information that can be used to devise combination therapies
involving CK2 in the future.
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Chapter 1 - Introduction
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Protein Kinase CK2: Intricate Relationships within
Regulatory Cellular Networks

Since its original discovery more than 50 years ago, protein kinase CK2 has been
implicated in a continually expanding array of biological processes [1]. In this respect,
CK2 has been shown to be a participant in the regulation of cellular processes such as
transcription [2,3] and translation [4,5,6,7], control of protein stability [8,9,10] and
degradation [11,12], cell cycle progression [13], cell survival [14,15,16], and circadian
rhythms [17]. CK2 has also been linked to various aspects of tumor progression and
suppression and has been shown to be elevated in many forms of cancer [18,19] as well
as in virally infected cells [20,21,22]. Consequently, CK2 has recently emerged as a
potential therapeutic target with two CK2 inhibitors, namely CX-4945 [23,24] and CIGB300 [25,26], currently in clinical trials [27,28,29] for cancer treatment.
In humans, CK2 is typically considered to be a tetrameric enzyme comprised of two
catalytic subunits (CK2α and/or CK2α′ subunits that are encoded by the CSNK2A1 and
CSNK2A2 genes, respectively) and two regulatory CK2β subunits [1,30] (encoded by the
CSNK2B gene). Although typically classified as a protein serine/threonine kinase based
on sequence relationships to other members of the protein kinase superfamily, CK2 has
also been shown to exhibit protein tyrosine kinase activity [31,32,33,34]. Biochemical
characterization of its enzymatic activity has demonstrated that CK2 is an acidophilic
kinase with a consensus recognition motif that features aspartic acid and glutamic acid
residues as well as some phosphorylated residues as its dominant specificity determinants
[35,36,37]. Characterization of its specificity determinants has contributed to the
identification of many CK2 substrates that have been shown to be directly
phosphorylated by CK2 [38,39]. Phosphoproteomic profiling has also revealed many
putative substrates that have been shown to be phosphorylated in cells at sites that match
the consensus for phosphorylation by CK2 [40,41]. In fact, analysis of phosphoproteomic
datasets typically suggests that CK2 could be responsible for more than 10% of the
phosphoproteome [42].
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While there is ample evidence that CK2 is an important constituent in the regulation of
many fundamental biological processes, there are unresolved issues regarding its
regulation in cells. In this respect, questions regarding its regulation arise because the
catalytic subunits of CK2 are enzymatically active in the presence or absence of the
regulatory CK2β subunit. The role of the regulatory subunit is to provide a negatively
charged docking site required for the phosphorylation of a certain group of CK2
substrates that contain a positive stretch of amino acids downstream the CK2α/ α’ target
site [39]. Furthermore, the activity of CK2 is generally unaffected by second messengers,
and unlike many kinases that are regulated by phosphorylation within an activation loop,
the activation loop of CK2 is devoid of regulatory phosphorylation sites [43,44]. The fact
that the catalytic subunits of CK2 are fully active when expressed as recombinant
proteins in bacteria further suggests that the enzyme may be constitutively active
[45,46,47]. Consequently, it is unclear how a constitutively active enzyme can be a key
regulatory participant in tightly regulated cellular processes. To investigate this apparent
paradox, we have examined the relationship between CK2 and other constituents of the
regulatory networks within cells by performing text mining of the published literature and
mining of proteomic databases. Furthermore, motivated by our demonstration that CK2
phosphorylation sites overlap with other post-translational modifications to enable CK2
to modulate caspase cleavage [48,49,50] and to participate in hierarchical
phosphorylation relationships, we have analyzed proteomic databases to identify posttranslational modifications that may regulate, or be regulated by, CK2 phosphorylation. A
similar analysis was performed with phosphoproteomic data generated by our group to
corroborate and expand the previous findings.
Overall, in this study, we explore database and literature information available and our
own high-throughput data in the context of CK2-dependent signaling with the objective
of highlighting and discussing the extensive interplay of CK2 with regulatory networks in
the cell. The analysis that we have provided is also intended to provide functional
perspectives to the data available in the databases since these data are often isolated from
the information regarding CK2 that exists within the literature; especially for non-experts
in the field and for interpreting data related to CK2 emerging from existing or new highthroughput studies.
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1.1 Functional Networks Involving CK2
The impact of CK2 in the cell can be, to some extent, predicted by considering the
number of biological processes in which it has been implicated and the number of
substrates that have been reported to date [39]. Furthermore, it is anticipated that the
published literature will represent an important resource for deciphering and validating
information that is emerging from genome- and proteome-wide analyses. Consequently,
we performed text mining to identify publications that highlight CK2 and aspects of its
function or regulation. To this point, CK2 substrate information remains “sparse” in the
published literature that is represented by more than 2600 papers (PubMed [51] search:
“Casein Kinase II” [Mesh]) directly describing CK2 function and more than 5000 papers
mentioning the kinase (GoPubMed [52] search). Nevertheless, assembling this
information to obtain a global but detailed view of CK2-dependent networks is one step
towards deciphering genome and proteome scale analyses of CK2.
An initial evaluation of the functional relationship of CK2 with other cellular proteins can
be obtained by querying STRING v10.0 [53], a database with known and predicted
functional associations between proteins (see Fig. 1.1A for a representation of the top 50
proteins functionally associated to CK2, Supp. Table 1.1). According to this analysis,
CK2 regulates the activity of at least 15 cancer-related proteins such as the tumor
suppressor TP53, the histone deacetylases HDAC1 and HDAC2, and the NFKB subunit
RELA (Fig. 1.1B,C, Supp. Table 1.1). CK2-dependent phosphorylation of these proteins
has been reported either in vitro or in vivo [54,55,56,57] with the majority of the target
sites identified conforming to the minimum CK2 consensus sequence: [ST]xx[DEpS].
The CK2 functional relationship to these substrates places the kinase in a central position
in human protein-protein interaction networks since such proteins are considered
“information hubs” [58]. For instance, the proteins TP53, HDAC1, HDAC2, and RELA
bind to at least 997, 554, 323, and 271 unique interactors based on the BioGRID proteinprotein interaction repository [59] (accessed 30 November 2016). In fact, in a human
protein-protein interaction network (built from the BioGRID database in Cytoscape
[60,61] v3.4.0, self-loops and duplicated edges removed) CK2 can “influence”
approximately 23% of the established interactions (63,988 interaction pairs out of
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270,000) if we assume a ‘guilt by association’ approach considering CK2 direct
interactions (meaning step 1 interactors: 629 proteins, Supp. Table 1.2) and that of its
indirect interactors (meaning step 2 interactors: 11,869 proteins, Supp. Table 1.2).

Figure 1.1. CK2-centered functional association network represented with the database
STRING v10.0. (A) The network shows the top 50 human genes related to CK2 subunits
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CSNK2A1, CSNK2A2, and CSNK2B (number of nodes and edges: 53 and 369,
respectively) based on neighborhood, experiments, text mining, and database sources.
Briefly, the human CK2 subunits were searched in STRING by gene name using the
multiple protein search functionality. The functional association network was then
retrieved by selecting 50 as the maximum number of interactors to show from the first
shell (step 1) and checking the mentioned interaction sources (these options are found
within the “data settings” drop-down menu); (B) A clone of network A with the red
nodes representing proteins connected to deregulated pathways (KEGG pathway:
hsa05200); (C) A network representation of the map: Pathways in cancer (KEGG
pathway: hsa05200). The map was downloaded from the KEGG PATHWAY [63]
database (accessed 30 November 2016) and imported to Cytoscape with the
CyKEGGParser v1.2.7 plugin [64]. A high-resolution image of this figure is also
available in the Appendix A.
A summary of the number of CK2 interactors for each human CK2 subunit is presented
in Table 1.1. Based on this analysis and a search using the “find a gene” functionality of
the Enrichr tool [62], further hub interactors of CK2 that can be identified include CDK1,
XRCC6, CREB1, HNRNPA1, LYN, YWHAQ, FOS, and MAPK1 (Supp. Table 1.3).
Table 1.1. CK2 subunits interactors extracted from a human protein-protein interaction
network built by retrieving the human interactome from the BioGRID database build
3.4.129 using Cytoscape v3.4.0. *Interaction pairs: a pair of interactors including CK2CK2 substrate and CK2 substrate-CK2 substrate.
Direct interactors of

Number of interactors

CSNK2A1 (1457)

398 unique direct interactors; 435 interaction pairs*

CSNK2A2 (1459)

155 unique direct interactors; 171 interaction pairs.

CSNK2B (1460)

247 unique direct interactors; 270 interaction pairs.

All CK2 subunits

632 unique direct interactors from which 36 are shared by the three
subunits and 95 by two.

All CK2 subunits and their direct
interactors

12502 unique direct interactors (632 step 1 and 11875 step 2);
63988 interaction pairs.

1.2 Protein-Protein Interaction Networks Involving CK2
In a complementary analysis, the direct interactors of CK2 subunits were represented in a
protein-protein interaction network (Fig. 1.2, Supp. Table 1.4) using BisoGenet [65]
v3.0.0 Cytoscape plugin for the retrieval of physical interaction information. As expected
from Table 1.1, differences in the number and identity of the panel of interactors can be
observed for each CK2 subunit which suggests a certain degree of functional divergence
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as previously highlighted in the literature [66,67,68,69,70], and encourages the
development of tools that allow us to differentiate the contributions of the endogenous
catalytic subunits to the phosphoproteome. In addition, it points to CSNK2B as a hub
itself, suggesting that it may have a role in coordinating interactions with the catalytic
subunits of CK2 to modulate phosphorylation of certain substrates. Furthermore, since
the interaction network for CSNK2B does not completely overlap that of the catalytic
CK2 subunits (Fig. 1.2, Supp. Table 1.4), this analysis reinforces the prospect that
CSNK2B has CK2-independent roles within cells as previously described in the literature
[67]. In fact, the CSNK2B-dependent interactome has been previously profiled using
mouse brain homogenates [71] where CSNK2B is thought to have a crucial role since its
mRNA expression levels are 2–3-fold higher compared with other organs, except the
testis [72]. In this setting, CSNK2B was found to interact with both cytoplasmic and
nuclear-localized proteins involved in protein synthesis, RNA and DNA processing, the
cytoskeleton, cell signaling, and transport [71]. Although not included among the
references retrieved by BisoGenet, the functional classification of the proteins identified
as part of the CSNK2B-dependent interactome is in agreement with the network
generated by BisoGenet.

Figure 1.2. Protein-protein interaction network of human CK2 subunits generated using
Cytoscape v3.4.0 and the BisoGenet v3.0.0 plugin. The three networks are clones, each
of which highlights the interactors of CSNK2A1 (red nodes), CSNK2A2 (orange nodes),
and CSNK2B (green nodes) subunits, respectively. Briefly, the network was represented
by querying SysBiomics (BisoGenet’s interaction database) through the plugin’s
interface using the human CK2 subunit gene names and selecting “protein-protein
interaction” as the biorelation type and the input nodes and neighbors to step 1 method as

7

the criteria for building the network. A high-resolution image of this figure is also
available in the Appendix A.

1.3 CK2 Networks Derived from Text Mining of the
Published Literature
A way of summarizing and systematizing CK2 knowledge relies on the use of text
mining to access literature information. In this regard, the analysis of GO cellular
component annotations using GoPubMed revealed more than 200 subcellular locations
and protein complexes studied in the context of CK2 (summarized in Fig. 1.3, Supp.
Table 1.5). This analysis also reflects the functional pleiotropy of CK2, which can
associate with molecular machineries such as the ribosome, spliceosome, proteasome,
and chromatin remodeling complexes, and to other smaller more dynamic complexes
such as TRAIL-death inducing complex and the Ikappa-NFkB complex. Directly
interrogating the literature followed by data extraction can provide information that
otherwise may be missed if we only consider specialized databases such as the
mammalian protein complexes database CORUM [73] where CSNK2A1, CSNK2A2,
and CSNK2B (Supp. Table 1.5) are listed only as members of the “PDGF treated Ksr1CK2-MEK-14-3-3 complex”, the “MKP3-CK2alpha complex”, the “Casein kinase IIHMG1 complex”, and the “UV-activated FACT complex” with CSNK2B also listed as a
member of the “Fgf2-Ck2 complex” (accessed 30 November 2016). However, protein
complex data extracted from the CORUM database has been manually curated whereas
the data extracted from the literature needs to be critically analyzed since the extraction
process may be ambiguous and biased towards the algorithm used by the tool [74], in this
case, GoPubMed. A similar analysis can be made for the GO biological processes. The
retrieval of CK2 related GO biological process from literature highlights frequently
studied core processes such as cell cycle, cell proliferation, DNA damage, cell death, and
viral infectious cycle, as well as other hot topics in the field (Fig. 1.3B, Supp. Table 1.5).
The latter includes the involvement of CK2 in embryogenic development [75,76,77,78],
T cell-mediated immunity [79,80], inflammation [81], glucose homeostasis
[82,83,84,85], ion transport [86], bone remodeling [78,87], neurogenesis [88,89],
neurological system process [90], response to misfolded and unfolded protein [90], stem
cell differentiation and maintenance [91], and response to muscle activity [92,93].
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Figure 1.3. CK2 Functional association networks represented in Cytoscape v3.4.0 for
illustrating the: (A) Cellular components mentioned together with CK2 in the literature
identified by GoPubMed search. The green nodes represent protein complexes and the
node size highlights terms frequently co-occurring with CK2; (B) Biological processes
mentioned together with CK2 in the literature identified by GoPubMed search; the red
label-nodes indicate hot topics in CK2 research. Briefly, the term “Casein Kinase
II”[Mesh] was queried using the GoPubMed text mining tool and the output was
downloaded to generate a network in SIF format [61] for Cytoscape input by specifying
CK2 and the GO subcellular components/biological processes as nodes and their cooccurrence in the literature as the interactions (binary type: yes/no). The node size was
not set differentially for the biological processes network as this will affect the
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visualization and readability. A high-resolution image of this figure is also available in
the Appendix A.
Text mining of the CK2-related literature can also provide insights regarding
holoenzyme-dependent regulation, which relates to the events where CK2-mediated
phosphorylation of a given substrate is positively or negatively regulated by holoenzyme
formation and the presence or absence of CSNK2B [45]. In this case, the analysis of
protein-protein interaction data for CK2 subunits alone is insufficient for assuming
holoenzyme-dependent regulation. A recent in silico study relied on text mining for
retrieving known holoenzyme-dependent substrates and generated sequence patterns for
predicting novel candidates based on structural information of the known substrates [39].
Information on the holoenzyme-dependent substrates can also be obtained from the
PhosphoSitePlus database [94,95] by querying “substrates of CK2B”; however the list
obtained is not comprehensive (accessed February 2017) when compared to the text
mining study [39]. Furthermore, substrates known to be holoenzyme-dependent such as
PDX1 [96] and CFTR [97] are cataloged as phosphorylated by the catalytic subunit in
this database (query: “substrates of CK2A1”). To avoid such inconsistencies and
misleading information, researchers are encouraged to carefully review the evidence
provided in databases such as PhosphoSitePlus, which are obtained through automated
literature text mining and thus error prone.
In addition to text mining, systematic proteomic studies represent rich resources for
potentially uncovering CK2-regulated biological processes and pathways when datasets
from these studies are uploaded to repositories [98] such as PRIDE and MassIVE and/or
provided as supplementary information. To explore the availability of proteomics data for
CK2, we performed a Pubmed search and, as a result, retrieved two proteome studies
[99,100], one interactome study [71], and four phosphoproteome studies [40,41,101,102].
However, a PRIDE search only returned one of these studies, which explores the function
of CSNK2A1 from Ostreococcus Tauri, in a minimal circadian system [101] (ID:
PXD000975). Consequently, for the remainder of these studies, information available
(e.g., protein and/or phosphorylation site identification and/or relative quantification
values) is limited to that provided in the original paper or by direct request to the authors.
We also searched PhosphoSitePlus and found that only one phosphoproteome study out
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of the four identified in Pubmed was included (accessed February 2017). This
phosphoproteomic study explores the short-term response of HEK-293T cells treated
with the CK2 inhibitor quinalizarin [102]. However, PhosphoSitePlus only mentions the
proteins and phosphosites identified without providing any quantitative results.
The quinalizarin phosphoproteomic study [102] identified 28 downregulated putative
CK2 phosphosites with several of the target proteins displaying a role in cell death and/or
survival including TPD52 (isoform 2), STX12, BCLAF1, AKAP12, RAD50, and PDCD4
(isoform 2). Overall, most of the phosphorylation-modulated substrates were classified as
nuclear and were found to be involved in biological processes classified as transcription,
mRNA and rRNA processing, gene expression, and DNA replication. Comparable
functional annotations were obtained in two of the other CK2 phosphoproteomic studies
where the phosphosites identified to belong to proteins mostly localized to the nucleus as
components of the spliceosome [40,41].
Intriguingly, the quinalizarin phosphoproteomic study also revealed that several “CK2
attributable” phosphosites increased upon treatment with the inhibitor. As this result
seems paradoxical, the authors proposed both technical and biological explanations for
this observation including off-target effects of the inhibitor and an increase in the protein
abundance of those substrates in particular [102]. Since it is evident that CK2 is
connected to a plethora of regulatory hubs through protein-protein interaction and
hierarchical phosphorylation, we performed a kinase-motif matching analysis using the
PhosphoMotif Finder functionality of the HPRD database [103] to determine if other
kinases could, in theory, be responsible for the upregulation of phosphosites that had
been putatively identified as CK2-dependent phosphosites. As a result of this analysis, we
identified at least two instances where the modulated phosphosite matched motifs for
other kinases besides CK2. For example, the vicinity of the residue S1068 of TP53BP1
matches the minimal CK2 consensus sequence pSXX[E/D] as well as the pSQ and XpSQ
substrate motifs of the ATM kinase and the DNA-dependent protein kinase, respectively.
Interestingly, TP53BP1 does interact with ATM, which phosphorylates several residues
in the protein upon DNA damage to promote its tumor suppressor functions [104].
Another example is AKAP12 where the vicinity of S627 matches substrate recognition

11

motifs pSXX[E/D], RXRXX[pS/pT], [R/K]XRXXpS, RVRRPpSESDK, and RRPpS
conforming to CK2, AKT, MAPKAPK1, AMP-activated protein kinase 2, and PKA/PKC
motifs, respectively. AKAP12 has been shown to interact at least with PKC and PKA
[105], with PKA phosphorylating S627 and three other residues [106] of the protein.
Moreover, in proteomic databases, arginine and lysine residues proximal to S627 of
AKAP12, are reported to be methylated [98]. Altogether, these observations illustrate the
complexity of CK2-signaling networks and the challenges associated with interpreting
changes in the phosphoproteome arising from the modulation of CK2. Accordingly, all
possible sources of information for other kinases and modifying enzymes that may act
upon CK2 target sequences (e.g., arginine-methyltransferases and lysineacetyltransferases) need to be taken into consideration.

1.4 Extension of CK2 Networks to Include Other
Constituents of Regulatory Networks
As a logical extension of examining direct interactions with CK2, understanding how
CK2 integrates with other signaling networks in the cell requires consideration of how
CK2 substrates may be acted upon by other constituents of signaling networks. For
example, we have considered phosphorylation information regarding CK2 substrates with
other kinases that also modify the CK2 substrates and/or interactors (Fig. 1.4). In this
respect, Fig. 1.4 shows that at least 171 other kinases (Supp. Table 1.6) are capable of
phosphorylating sites in CK2 interactors, which suggests a likelihood of functional
interplay among phosphorylation sites. This is reflected, for example, in the fact that
CK2-dependent phosphorylation often participates in hierarchical phosphorylation with
other kinases, which generates a CK2 target sequence with a phosphorylated serine that
functions as the dominant specificity determinant [36].
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Figure 1.4. Protein-protein interaction network of CK2 subunits expanded to include
kinase information of the interactors retrieved from PhosphositePlus, the network was
represented with Cytoscape v3.4.0 using the BisoGenet v3.0.0 plugin and the
PhosphositePlus Web Service Client Module. The yellow nodes represent CK2
interactors and the brown nodes represent kinases that phosphorylate (edges with arrow)
the interactors. The red edges represent phosphorylation events. The network was
represented as explained in Fig. 1.2. Briefly, all the proteins were selected, and the kinase
data was added by importing the information from PhosphoSitePlus using the plugin and
selecting the gene name as the matching key. A high-resolution image of this figure is
also available in the Appendix A.
As noted above, there is evidence that many CK2 substrates are also phosphorylated by
other kinases. When considering the prospect for hierarchical phosphorylation involving
CK2, analysis of the phosphorylation events in the vicinity of the CK2 phosphosites may
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further contribute to identifying such relationships. Consequently, we searched
PhosphoSitePlus database serine, threonine, and tyrosine phosphorylation and CK2
substrate data, mostly reflecting data generated through a proteomics approach [95], for
those phosphosites occurring in the primary structure at different distance windows up- or
downstream of the CK2 target site (Table 1.2, Supp. Table 1.6). This analysis was also
extended to other post-translational modifications reported in the PhosphoSitePlus
database, such as ubiquitination and acetylation (Table 1.2, Supp. Table 1.6). Although
this analysis is restricted to CK2 substrate data available in PhosphoSitePlus, it is useful
to illustrate the importance of considering the modification status of target sequences
when studying CK2-dependent phosphorylation, a concept that also applies to other
kinases. For example, the link between AKT-mediated phosphorylation and arginine
methylation has been previously reported [107,108,109]. The post-translational
modification analysis indicated that the vicinity of CK2 sites may constitute ‘hot spots’
for phosphorylation. Consideration of these sites brings together at least 76 different
kinases including CDK7, STK1, PRKCA, PLK1, GSK3, CDC7, SRC, CDK2, MAPK3,
GRK2, PRKCZ, CDK9, MAPK1, and IKBKE.
Table 1.2. Post-translational modifications (PTMs) in the vicinity of CK2 1 target sites
retrieved from PhosphoSitePlus (accessed August 2016).
PTM type

# sites at -4/+4

# sites at -7/+7

# sites at -36/+36

Acetylation

15

25

146

O-N-acetylgalactosamine

2; overlap: 1

5; overlap: 1

19; overlap: 1

O-N-acetylglucosamine

1; overlap: 2

1; overlap: 2

5; overlap: 2

Methylation (m1,m2,m3,me)

4, 3, 1, -

8, 7, 1, -

29, 22, 2, 3

Phosphorylation

262; overlap: 482

395; overlap: 482

1177; overlap: 482

Sumoylation

1

8

50

Ubiquitination

11

21

171

* CK2 sites were retrieved for bovine CSNK2A1 (P68399), human CSNK2A1 (P68400), human CSNK2A2
(P19784), human CSNK2B (P67870), mouse CSNK2A1 (Q60737), rat CSNK2A1 (P19139). Overlap:
Modification occurring at the CK2 target site.
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1.5 Rationale for the Study
Taken together, systematic analysis of the literature and databases strongly reinforces the
view that CK2 is involved in a broad spectrum of biological processes. At the same time,
it is important to recognize that there are significant limitations with information that is
available both within the peer-reviewed literature and in databases. In addition to clearly
highlighting the involvement of CK2 in a broad array of biological processes, database
mining and network analysis clearly reveals the extensive interplay between CK2 and
other constituents of signaling networks. This interplay is evident from the identification
of ‘hot spots’ where CK2 phosphorylation sites are localized proximal to other
phosphorylation sites or other post-translational modifications within the primary
sequence of its substrates. The proximity of post-translational modifications to one
another raises the very interesting prospect of one post-translational modification being
regulated by others. As noted earlier, we have previously demonstrated that CK2 can
modulate the cleavage of caspase substrates when CK2 phosphorylates residues adjacent
to the cleavage site [48]. This is a clear example of how phosphorylation by CK2 can
modulate susceptibility to another post-translational modification. The demonstration that
phosphorylated residues can sometimes ‘prime’ a substrate for hierarchical
phosphorylation by CK2 demonstrates that phosphorylation by CK2 can also be regulated
by other modifications [36]. Considering the prevalence of post-translational
modifications that reside within CK2 substrates within close proximity of the CK2
phosphorylation site (Table 1.2), it will be important to consider the relationship between
CK2 phosphorylation and these other modifications. From the perspective of its
participation in regulatory processes, the interplay between CK2 and other pathways
could yield very intricate and precise control of processes. Considering the emergence of
CK2 as a potential therapeutic target, the intricate relationships of CK2 within the
regulatory networks also have important implications for the application of CK2
inhibitors. From this perspective, the modulation of CK2 could impact other pathways
since phosphorylation by CK2 could have regulatory consequences for other pathways.
Similarly, modulation of other pathways could also affect CK2 or its functions as the
modification status of the target sequence may ultimately regulate its recognition by
CK2.

15

1.6 Scope of Thesis
Given the intricacies of CK2 signaling and its integration with other modification
networks in the cell beyond phosphorylation, we set out to decipher CK2’s functional
relationships with such networks. For this the following hypothesis was tested: PTMs, in
particular acetyllysine, occurring in the vicinity of the phosphorylatable residue
modulates phosphorylation of substrates by protein kinase CK2. Correspondingly, in
Chapter 2 in vitro, in silico, and cell experiments are presented that determine the CK2
specificity against peptide substrates containing lysine or acetyllysine residues, the extent
of modification and acetylation interplay at candidate CK2 target sites containing lysine
or acetyllysine, the cellular and functional boundaries of the candidate hits, the CK2dependent phosphoproteome upon modulation of the acetylome, and the acetylome and
phosphoproteome overlap as pairs of co-occurring sites. Interestingly, lysine and
acetyllysine were found to be tolerated by CK2 when present in position +2 from the
phosphorylatable residue and at positions +1 and +3, in a highly negative sequence
environment. A list of candidate sites was generated including known CK2 target sites,
previously annotated sites in PTM databases and the literature, and known regulatory
sites which can be validated in further studies. But equally important, experimental
evidence was gathered of the co-occurrence of lysine acetylation and phosphorylation in
the cell at many modified peptide instances including tentative CK2 sites and at sites that
are frequently observed by mass spectrometry(MS)-based proteomics and annotated in
databases. The latter includes sites in writers, erasers, and/or readers of acetylation,
phosphorylation, and methylation and components of cellular complexes involved in
transcription repression and chromatin remodeling among other functions. Given that
CK2 is known to phosphorylate and as a result regulate the activity of several writers of
acetylation in the cell and that a number of these are part of the transcriptional repression
and chromatin remodeling machinery the link between CK2 and chromatin organization
was summarized and expanded upon by integrating literature mining with
phosphoproteomic and molecular interaction data in Chapter 3.
Finally, the experiments performed required the processing and analysis of large data
sets; the individual scripts used for this were integrated into an analytical framework and
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used to develop a data-driven R Shiny web application called visualRepo. The
development process and the features of visualRepo are covered in Chapter 4 along with
strategies for the functional analysis of lists of modification sites applied in Chapter 2 and
coded into visualRepo. Importantly, visualRepo can be applied and extended if necessary,
for exploring the association between modification sites and other modification writers
and erasers of interest.
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1.8 Supplemental Materials
The supplemental materials are provided within this thesis or as separate files whenever
necessary due to their size (see Appendices).
Supp. Table 1.1. STRING network, function, and annotations of the top 50 CK2-related
genes.
Sheet
1
2
3

Name
STRING
network
Protein function
Functional
enrichment

Appendix A

Content
Top 50 related proteins according to STRING v10.0 analysis.
Function of the CK2-related proteins downloaded from STRING v10.0 analysis.
Gene Ontology annotations (biological process, molecular function, and cellular
component) and KEGG PATHWAY enrichment downloaded from STRING v10.0
analysis.
Supplemental Material – Chapter 1

Supp. Table 1.2. CK2-interacting proteins in the human interactome.
Sheet

Name

1

Step 1 interactors
of CK2 (direct)

2

Step1, CK2
network

3

Step 2 interactors
of CK2 (indirect)

Appendix A

Content
Step 1 CK2 (CSNK2A1(GeneID:1457), CSNK2A2(GeneID:1459),
CSNK2B(GeneID:1460)) interacting proteins retrieved from a human protein-protein
interaction network built in Cytoscape from BioGRID data*
SIF format of the network in sheet#1
Step 2 CK2 (CSNK2A1(GeneID:1457), CSNK2A2(GeneID:1459),
CSNK2B(GeneID:1460)) interacting proteins retrieved from a human protein-protein
interaction network built in Cytoscape from BioGRID data*
Supplemental Material – Chapter 1

Supp. Table 1.3. CK2-interacting hub proteins.
Sheet

Name
CK2 hub
1
interactors
Appendix A

Content
Proteins that interact with CK2 and are highly connected in human protein-protein
interaction networks.
Supplemental Material – Chapter 1

Supp. Table 1.4. CK2-interacting proteins of each subunit.
Sheet
1
2
3

Name
CSNK2A1
interactors
CSNK2A2
interactors
CSNK2B
interactors

Content
CSNK2A1 interactors retrieved from SysBiomics database using BioGenet plugin of
Cytoscape
CSNK2A2 interactors retrieved from SysBiomics database using BioGenet plugin of
Cytoscape
CSNK2AB interactors retrieved from SysBiomics database using BioGenet plugin of
Cytoscape
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Interactors
intersection
Appendix A
4

Interactors intersection across the three subunits, includes the unique interactors
Supplemental Material – Chapter 1

Supp. Table 1.5. CK2-related GO annotations extracted from the literature and protein
complex data.
Sheet

Name
GO cellular
1
component
GO biological
2
process
GO molecular
3
function
4
CK2 complex
Appendix A

Content
Cellular components retrieved using GoPubmed text mining tool for the query:
"Casein Kinase II"[mesh]*
Biological processes retrieved using GoPubmed text mining tool for the query:
"Casein Kinase II"[mesh]*
Molecular functions retrieved using GoPubmed text mining tool for the query:
"Casein Kinase II"[mesh]*
CORUM database information extracted for CSNK2A1, CSNK2A2, CSNK2B
Supplemental Material – Chapter 1

Supp. Table 1.6. PTM sites in the vicinity of CK2 phosphorylated sites.
Sheet

Name

1

Kinases

2

Kinases, CK2
sites vicinity

PTM sites, CK2
sites vicinity
Appendix A
3

Content
Regulatory kinases of CK2 interactors and substrates extracted from
PhosphoSitePlus.
Kinases that phosphorylate resides in the vicinity of CK2-phosphorylated sites. CK2
sites were retrieved for bovine CSNK2A1 (P68399), human CSNK2A1 (P68400),
human CSNK2A2 (P19784), human CSNK2B (P67870), mouse CSNK2A1
(Q60737), rat CSNK2A1 (P19139).
PTM sites in the vicinity of CK2-phosphorylated sites (-+7, -+36 distance window)
Supplemental Material – Chapter 1

Supp. Table 1.7. High-resolution images.
Content
Appendix A

High resolution images
Supplemental Material – Chapter 1
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Chapter 2

2

Protein Kinase CK2: Interplay Between Cellular
Acetylation and Phosphorylation Networks.

Proteoform diversity
Protein CK2 target sites and residues in their vicinity can be targeted by different posttranslational modification (PTM) types [1]. Furthermore, additional sources of biological
variation exist that can modify the primary sequence of such sites, e.g., coding singlenucleotide polymorphisms (cSNP), mutations, and alternative splicing of RNA. These
changes result from biological events and their biological relevance may not be fully
grasped when considered as separate instances. This points to a need for studying CK2
targets, and those of other kinases, as proteoforms, i.e., “each individual molecular form
of an expressed protein” [2]. Here, we were particularly interested in identifying the
proteoforms of CK2 targets where other PTMs co-occur.
Briefly, the main sources of proteoform diversity at the DNA level are cSNPs and
mutations whereas at the RNA level alternative splicing is the main source and to a lesser
extent errors in translation. At the protein level, the modification of the lateral chain of
amino acids is the main source of variation, which can occur co- and post-translational
(i.e., PTM). An example of the complexity introduced by PTMs is the histone code,
where several modifications co-occur at the tails of histones generating histone
proteoforms with different functions. Other examples are the branching of
monosaccharide and ubiquitin moieties attached to proteins. When combined in a single
protein like the core histone H4, a study calculated that 13 of the most common PTMs
and a single cSNP could give rise to more than 98,000 H4 proteoforms [2]. Considering
that the number of PTM sites is between 0-90 modifications per protein the same study
estimated that the number of proteoforms generated by any two modifications could be
larger than 1 × 1027 [2]. However, such an explosion of proteoforms is not likely due to
cellular regulation of protein copy number (1,000 copies of a proteins equals 1,000
proteoforms), abundance threshold (10,000 genes expressed at 100 copies per gene),
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protein dynamic-range, cell type, spatial distribution, and enzymatic activity. A closer
number based on database analyses is thought to be 6 million [3].
Notably, studying proteoforms remains a technological challenge, with proteoforms
belonging to the same protein (proteoform families) being almost impossible to
differentiate in some cases. In addition, proteomic techniques are starting to tackle the
challenges of global PTM identification and discrimination of co-occurring PTMs [4].
Because of this, the number of proteoforms in each cell or cell population is a highly
debated topic, with some researchers willing to consider the possibility of such high
numbers and others considering that PTMs are mutually exclusive. However, given the
functional diversity generated by proteoforms, it is essential to accept the fact that the
primary sequence of a protein alone does not dictate its function and that protein
networks in the cell are the results of functional associations between proteoform
families.
PTM interplay and integration of signaling
Biological systems are composed of modular and robust molecular networks that
integrate and communicate information at different scales to create emergent properties.
Such properties of complex systems change dynamically in response to the environment
and cannot be predicted, even with an understanding of the parts alone [5]. Adopting this
Systems Biology perspective posed a technological and scientific challenge and
contributed to the development of OMICs and Bioinformatics.
The interaction of pathways to shape a specific response or biological process over time
constitutes an example of an emergent property of systems [6]. At this level, PTM
interplay, i.e., the directed positive/negative functional relations established between two
modified amino acids in a protein, constitutes a pivotal regulatory mechanism of signal
convergence [7]. A recent in silico study profiled global PTM coordination across
protein-protein interaction networks (PPIN) highlighting around 400 “PTM spots” in 300
proteins [7]; this protein list contains hub proteins like P53 and CDK1, master regulators
of signal transduction. Complementary studies have also been published, where PTM
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interplay has been inferred based on amino acid co-evolution [8] and PTM conservation
across functional domains [9].
Historically, PTM interplay has been associated with modifications targeting the tail of
core histone proteins. Several models propose a histone “code”, which dictates what
signaling complexes will be recruited to the DNA, modify the chromatin, and in turn
gene expression [10–13]. However, this PTM interplay has also been described for nonhistones proteins [14]. An example is the regulation of the stability of the tumor
suppressor protein TP53 where different PTM combinations protect from or promote
protein degradation, which in turn can dictate, for example, if a cell undergoes
programmed cell death or not [15,16].
Briefly, interplaying PTMs can occur in the same or different proteins, cis- and transeffect, respectively. Depending on the location of the sites in the protein the cis-effects
can then be classified as adjacent or distant [10,17]. Functionally, the cis and trans-effects
can be either direct or indirect; a direct effect involves only the PTMs whereas an indirect
effect is mediated by other molecules through protein-protein interaction [10,17].
Another functional classification refers to the activating or inhibitory effect on one of the
interplaying sites [10,17].
Recent studies by our group following a systems-approach have yielded important
insights into the interplay between phosphorylation sites. The results obtained indicate a
regulatory role of hierarchical phosphorylation in CK2-dependent phosphorylation such
as priming of CK2-dependent phosphorylation by Proline-directed kinases [18].
Important insights were also obtained describing a regulatory role of CK2-dependent
phosphorylation in modulating cell survival by attenuating caspase pathways through
phosphorylation of residues adjacent to caspase cleavage sites [19–21] Altogether, these
exemplify the intriguing connections between PTM interplay and kinase-dependent
signaling.
Here, we continue the work of exploring the relevance of PTM interplay at CK2 target
sites. We focus on describing a regulatory role between phosphorylation and lysine
acetylation on CK2 signaling. As mentioned in the introductory part, lysine acetylation
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can occur in neighboring residues of known CK2 target sites [1]. Lysine acetylation
changes the local electrostatic properties of the sequence being acetylated by removing
the positive charge of lysine [22]. Interestingly, positively charged residues, such as
lysine, are considered negative determinants of CK2-dependent phosphorylation since
CK2 acts upon acidic motifs in the substrate. Thus, we hypothesized that acetyllysine,
occurring in the vicinity of the phosphorylatable residue modulates phosphorylation of
substrates by protein kinase CK2. This functional association is intriguing since, like
phosphorylation, lysine acetylation is dynamically maintained in the cell by wellcharacterized writers (lysine acetyltransferases) and erasers (lysine deacetylases) [22].
Global studies of PTMs
Cell signaling involves the integration of different biological networks to adapt to
external stimuli and perform cellular functions while maintaining homeostasis. Such
networks are frequently found deregulated in cancer and other diseases, which has
prompted extensive efforts to target their components. In this regard, proteomics has
become an indispensable tool for understanding the impact of chemical probes/drugs that
inhibit network effectors such as kinases and lysine deacetylases [23]. These studies
provide invaluable information on the plasticity of cellular systems and how the
phosphoproteome, acetylome, etc. dynamically respond and adapt to external
perturbations. As mentioned before, an integrative view also demands an understanding
of how such networks communicate to give rise to emergent properties of biological
systems. Therefore, several studies aim to identify/predict PTM interplay by integrating
the available proteomics data using a variety of bioinformatic tools and methods [9,14].
An extensive study by Scholz et al. published in 2015 profiled the changes in the
acetylome of HeLa cells treated with 19 different deacetylase inhibitors, providing
information on more than 8,000 acetylated sites [24]. Several such inhibitors are currently
undergoing clinical trials [25]. The number of sites identified in this study compares to
that of any given phosphoproteomic experiment [26] allowing a global assessment of the
biological processes and subcellular compartments targeted by acetylation. For instance,
it was found that treatment with nicotinamide, a pan-Sirtuin deacetylase inhibitor,
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increased the acetylation of more than 500 sites belonging to proteins involved in
transcription, RNA processing, gene expression, and chromatin modification, among
others [24]. Other assessed compounds displayed high affinities for individual
deacetylases causing the modulation of a specific set of biological processes, such as the
regulation of microtubule polymerization by Tubacin and Bufexamac both of which are
inhibitors of HDAC6 [24]. From the findings provided in this study, and others [27–29],
it can be concluded that, just like phosphorylation, lysine acetylation has a global
regulatory role.
By gathering information provided by acetylome and phosphoproteomic experiments, the
literature, and PTM databases it comes as no surprise that an increasing number of
proteins are being frequently reported as targets of different PTM types [1,30], much like
histones and TP53. With the increasing flow of experimental information and advances in
areas such as computational proteomics [4,31] integrative analysis of PTMs is becoming
a more feasible strategy for uncovering proteome-wide PTM functional associations. In
fact, a study by Grimes et al. in 2018 [32] used multiplexed proteomics to compare the
phosphorylation, methylation, and acetylation patterns of 45 lung cancer cell lines to
normal lung tissue and cell lines treated with anticancer drugs and integrated the PTM
profiles obtained. The authors found that in proteins targeted by more than one PTM type
the presence of those PTMs was inversely correlated, suggesting a pivotal functional role
of this exclusivity in the functioning of signaling networks [32]. However, the latter is a
highly debated topic. For instance, experimental evidence indicates that histone
modifications can interplay positively and negatively. In fact, several interplay
mechanisms have been observed (summarized in [12]): 1) competitive antagonism for
modifications targeting the same residue, e.g., lysine acetylation, methylation, and
ubiquitination; 2) dependence upon the addition of other modification in cis or trans, e.g.,
in yeast, methylation of H3K4 and H3K79 requires H2BK12 ubiquitination; and 3)
cooperation between modifications, e.g., stronger binding of PHF8 to H3K4me3 when
H3K9 and H3K14 are acetylated in cis.
As mentioned, treatment with deacetylase inhibitors increases the acetylation of hundreds
of proteins in the cell [24,29]. Given the regulatory role of acetylation, a priori these
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changes are likely to be sensed and acted upon by cellular signaling pathways of which
kinases play prominent roles. Here, we make use of proteomics and bioinformatics to
explore the connection between the acetyllysine and phospho-networks in U2OS (human
osteosarcoma) and HeLa (cervix adenocarcinoma) cells treated with deacetylase
inhibitors. Thus, the main goal of our study is to obtain experimental insights on the
extent of the interplay between both networks by exploring the fraction of the
phosphoproteome that is acetylated. It is anticipated that a study of this nature would
likely provide information on an array of kinases and thus a wide range of signaling
pathways. However, we focused on CK2-dependent signaling given its clinical relevance.
Importantly, CK2 is a kinase with previous experimental connections to the regulation of
the enzymatic activity of lysine deacetylases [33–37]. Regardless, the bioinformatics and
experimental strategies devised in this study are of wide use and can be applied to
understanding the functional association between any two types of modifications and/or
regulatory protein of interest.

2.1 CK2-dependent signaling and lysine acetylation
Protein CK2 functional pleiotropy and the high frequency of the CK2 consensus motif
throughout the proteome makes the CK2 literature broad and disperse. Given our
hypothesis of a potential regulatory role for lysine acetylation proximal to a
phosphorylation site matching the CK2 consensus, we initially looked for already
established connections in the literature using the text mining tool Chilibot [38] and the
Cytoscape v3.8.0 plugin stringApp v1.5.1 [39]. Using these tools, several instances were
observed highlighting potential functional relationships between CK2 and lysine
acetylation (Supp. Table 2.1, Supp. Fig. 2.1). In this regard, literature mining highlighted
several functional links, for instance: CK2-SIRT1-FoxO3a acetylation in HCT116 and
MCF 7 cells [40]; CK2-H3K56 acetylation in yeast [41]; CK2-Ikaros HDAC1 complexJARID1B and H3K27 trimethylation and H3K9 acetylation [42]; CK2-P21-HDAC2 and
KLF4 acetylation [37]; CK2-HDAC2 [43] (Supp. Table 2.1).
To further explore the extent of the association, the PubMed query: “ck2” AND
“acetylation”, was graphically represented in a functional association STRING network
(confidence cut-off score, i.e., the likelihood that a given interaction is biologically
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meaningful, specific and reproducible, given the supporting evidence [39]): 0.7,
maximum number of proteins: 100) followed by GO biological process enrichment
analysis (Supp. Table 2.1, Supp. Fig. 2.1). As before, several meaningful associations
were established i.e., 703 functional associations between the top 100 proteins (Supp.
Table 2.1). Among the processes significantly enriched (FDR < 0.001) in the CK2 and
acetylation search output (Supp. Table 2.1) we observed histone deacetylation (Supp. Fig.
2.1A), chromatin organization (Supp. Fig. 2.1B), and chromatin silencing (Supp. Fig.
2.1C). In this regard, CK2 has been shown to regulate several main effectors on these
processes, such as erasers of lysine acetylation, including the lysine deacetylases
HDAC1, HDAC2, HDAC3, and HDAC6 [33–37,44]. See Chapter 3 for a detailed
summary of CK2’s regulatory role in these processes.
Although experimental evidence positioned CK2 as a regulator of acetylation networks in
the cell at the time of writing, no direct associations have been reported describing the
role of neighboring cis-acting interplay between CK2-dependent phosphorylation and
acetylation at the site level. However, an intriguing finding in a study of HDAC2
acetylation in response to hypertrophic stresses is that the substitution of the acetylation
residue K75 by R75 in HDAC2 resulted in a significant decrease in CK2-dependent
phosphorylation at Ser394 site [45]. However, it is not clear if this constitutes a direct or
indirect interplay. Here, we explore the co-occurrence of acetylation and phosphorylation
by CK2 in cis and the presence of acetylation sites in the phosphoproteome.

2.2 Tentative interplay between CK2-dependent
phosphorylation and other PTM types
A total of 267 known human CK2 substrates from the PhosphoSitePlus (PSP) database
[46] were found annotated in predicted within-protein (cis) PTM interplay data retrieved
from the database PTMcode v2 [47] (Table 2.1). A total of 469 acetylation sites (known
sites propagated to orthologs in Eukaryota) were predicted to interplay with the CK2
target sites (Table 2.1). The tentative interplay in the close vicinity of the CK2 substrates
was determined by selecting either +/-4 and +/-7 sequence window (Table 2.1). Similar
results to the analysis of known PTM sites in the vicinity of human CK2 substrates (see
Chapter 1) were obtained regarding the number and types of PTM represented (Table
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2.1). A limitation of the analysis is that PTMcode v2 data set is from 2014; since then
many more modification sites have been added to the databases. However, not many
PTM databases exist for PTM interplay. Another limitation is the incomplete annotation
of CK2 substrates in PSP. Despite this limitation, since the number of CK2 substrates in
PSP is in the hundreds, the dataset is sufficient to estimate the extent of the tentative
interplay.
Table 2.1. PTM interplay annotated for known human CK2 substrates, retrieved from
PSP, in the database PTMcode v2.
PTM type

No. interplaying sites

+/-4 amino acids

+/-7 amino acids

Phosphorylation

4836

202

292

Ubiquitination

536

1

5

Acetylation

469

2

10

Methylation

39

1

2

Sumoylation

39

-

2

Proteolytic Cleavage

27

-

-

N-linked Glycosylation

26

-

-

Nitrosylation

23

-

1

O-linked Glycosylation

19

2

5

Neddylation

14

-

1

O-glcnac Glycosylation

14

2

3

Oxidation

8

-

1

Caspase Cleavage Aspartic Acid

7

-

-

O-galnac Glycosylation

4

-

-

Hydroxylation

1

-

-

Myristoylation

1

1

1

Nitration

1

-

-

2.3 Phosphorylation of in solution peptides matching the
CK2 motif with lysine and acetyllysine as determinants
In solution peptides derived from the CK2 peptide substrate DSD (RRRDDDSDDD)
containing either lysine or acetyllysine at positions +1, +2, or +3, downstream of the
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phosphoacceptor site, were phosphorylated in vitro by CK2 at two different
concentrations (200 and 500µM) in triplicate. It was observed that both lysine and
acetyllysine residues behaved as negative determinants at positions +1, completely
abrogating phosphorylation compared to control (Fig. 2.1). The presence of lysine at
position +3 also dramatically inhibited phosphorylation, with a mean value of 2.27 %
phosphorylation compared to control (Fig. 2.1). Acetylation of lysine at position +3
showed modestly increased phosphorylation compared to the unmodified lysine variant,
with a mean value of 6.26 % respect to control (Fig. 2.1). Overall, both lysine and
acetyllysine behaved as negative determinants at positions +1 and +3. Conversely,
acetyllysine, and lysine at position +2 rescued phosphorylation to 71.13 % and 24.19 %
of the control, respectively (Fig. 2.1). This indicated that acetyllysine and lysine are
tolerated for CK2-dependent phosphorylation at position +2, with acetylation of the
lysine promoting phosphorylation as compared to the unmodified lysine. Peptide quality
was assessed by MALDI (Supp. Fig. 2.2).

Figure 2.1. In vitro phosphorylation of peptides containing K and AcK (acetyllysine) by
CK2. A) Phosphorylation of CK2 peptide substrate variants (200 µM, 500 µM); γ-32P-
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ATP incorporation. B) Phosphorylation of endogenous sequences (500 µM); γ-32P-ATP
incorporation. C) Phosphorylation stoichiometry in pmol of phosphate per µg of peptide.
p: position, ac: acetylation, DSD: CK2 peptide substrate, grey point: mean.
Phosphorylation of in solution peptides representing two endogenous sequences
containing lysine at position +2, Ser33 of CTTN (cortactin), and Thr23/Ser24 of SET-iso
2 (protein SET), was negligible compared to the peptide substrate containing lysine at +2
(Fig. 2.1). The phosphorylation of these endogenous sequences was increased by a
modest degree by acetyllysine (Fig. 2.1). CTTN was also immunoprecipitated from
U2OS cells but it was not possible to detect endogenous phosphorylation at the sites of
interest by LC-MS/MS analysis [48] (Supp. Fig. 2.3).
Since studies with peptides revealed that lysine is tolerated and that acetylation of lysine
could enhance CK2 phosphorylation when lysine is at the +2 position, we were interested
in determining how common lysine appears in this position in the known CK2 target sites
reported in the databases or in phosphoproteomic studies. Accordingly, linear patterns,
referred to as K motif variants, were generated matching the sequences studied with in
solution peptides (Table 2.2).
Table 2.2. Linear patterns (K motifs) matching the sequences studied in the in solution
peptides.
K motif variants
Position
K motif

K motif, extended

K motif, minimal

p+1

[ST]K[DE][DE]

[ST]K[DE][DE][DE]

[ST]K.[DE]

p+2

[ST][DE]K[DE]

[ST][DE]K[DE][DE]

[ST]{P}K[DE]

p+3

[ST][DE][DE]K

[ST][DE][DE]K[DE]

[ST]{P}[DE]K

ScanProsite format: . Any amino acid. []: either amino acid. {}: any amino acid but, p: position.

The linear patterns were used for scanning the CK2 substrates annotated in the database
PhosphoSitePlus (September 2019). After manual curation of the results several known
CK2 targets matching the patterns (K motifs) were observed (Fig. 2.2, Supp. Table 2.2).
Initially, a few instances of sites not matching the K motifs but containing Lys in the
vicinity were identified. However, after manual curation most of these sites were
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eliminated based on insufficient experimental information to confidently identify them as
CK2 target sites (Fig. 2.2). The remaining instance containing Lys at position +3 but not
matching the K motif or K motif minimal is an example of hierarchical phosphorylation
pattern for CK2 (Supp. Table 2.2). Most of the studies describing the CK2 target sites
identified as K motif hits apply in vitro phosphorylation and mutation of the amino acids
of interest. The observed proportion of K motif variant hits was significantly different
(Chi-squared test for given probabilities P value 0.015, Cohen’s w = 0.7483 (large
effect)). The higher proportion of sites matching the K motif variants was observed for
position +2 compared to +1 (Chi-squared test for given probabilities P value 0.1088,
Cohen’s w = 0.4286 (medium effect)) and +3 (Chi-squared test for given probabilities P
value 0.006656, Cohen’s w = 0.8182 (large effect)). The functions of the K motif variant
hits were found to be diverse including transcription regulation, cytoskeleton
organization, apoptosis, mRNA splicing, etc., (Supp. Table 2.2). The p-1 and p+4
positions were included to determine the number of K motif and K vicinity hits in
residues that are not considered determinants of CK2 phosphorylation. After manual
curation, a higher number of occurrences was observed for these positions compared to
p+1 and p+3 and comparable to p+2 (Fig. 2.2, Supp. Table 2.2).
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Figure 2.2. Known CK2 target sites in PhosphoSitePlus (PSP) containing Lys in the
vicinity of the phosphorylatable site. A) Minimal and extended K motif hits or sites
containing Lys (K) in the vicinity but not matching K motif variants. B) Hits after manual
curation removing inconsistencies such as evidence where the site reported does not
match the site of interest or no direct association to CK2. p: position.

2.4 Analysis of high-throughput datasets resulting from CK2
manipulation
2.4.1 In silico analysis of in vitro high-throughput CK2 kinase assay
Since lysine and acetyllysine at position +2 were tolerated by CK2-dependent
phosphorylation and acetyllysine enhanced phosphorylation compared to lysine it was
important to further investigate their relevance for CK2 phosphorylation events. The
occurrence of phosphorylation at these K motif variants was further explored in three
data sets obtained from a global screening of in vitro CK2 substrates by an integrated
phosphoproteomic workflow [49]. As a result, phosphorylation by CK2 of sites matching
all K motif variants was observed in the data sets analyzed (Supp. Table 2.3). In this
regard, phosphorylation of Ser24 of SET-isoform 2 by CK2 was observed (Supp. Table
2.3).
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The proportion of K motif hits among the sites containing Lys in the vicinity of a site
phosphorylated by CK2 (fold change >= 1.5) was significantly different between variants
(Fig. 2.3A), P value = 0.0001 (3-sample test for equality of proportions without
continuity correction), Cohen w = 0.5871. The proportions were calculated after filtering
ambiguous peptide hits (Supp. Table 2.3). As expected from the known CK2 substrate
analysis, the observed proportion of +2 hits was larger than that of +1 (P value = 0.003,
Cohen’s w = 0.5157) and +3 (P value = 0.0003, Cohen’s w = 0.5012) hits. These
differences do not stem from the observed differences in the coverage of variants after
quantification (P value = 0.0005, Cohen’s w = 0.4536) as a larger number of +3 hits were
quantified compared to +2 (P value = 0.001, Cohen’s w = 0.3935) (Fig. 2.3A). Contrary
to what was observed after filtering for CK2 substrates, fold change > 1.5, where the
number of +2 K motif hits (26) was larger than that for +3 (6 sites) and +1 (3 sites)
variants, in that order (Fig. 2.3A).

Figure 2.3. Sites phosphorylated in vitro by CK2 identified by Bian et al. 2013 [49] that
contained Lys in the vicinity of the phosphorylatable residue. A) Total number of hits
quantified in the workflow evaluation, Jurkat cells and HeLa cells data sets. CK2 sites,
fold change (FC) > 1.5. P values were calculated using a 3-sample test for equality of
proportions without continuity correction. In parenthesis hits for K motif extended. B)
Weblogo representing the hits of K motif +2 variant. C) Weblogo representing the hits of
K motif +3 variant. D) Sequence found phosphorylated for K motif +1 variant.
A weblogo representation of the K motif hits, not including minimal hits (Supp. Table
2.3), showed for the +2 variant an equal conservation of Asp and Glu residues at position
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+1 and a higher conservation for Glu at position +3 (Fig. 2.3B). For the +3 hits equal
conservation of Asp and Glu was observed at positions +1, +2, and +4 (Fig. 2.3C).
Special attention was given to the +1 hits as a complete abrogation of phosphorylation
was observed for this K motif variant in the peptide assays (Fig. 2.1). Noticeably, for the
+3 (4 sites) and +1 (1 site) hits (Fig. 2.3A) the presence of four acidic positions
downstream of the phosphorylated site by CK2 (Fig. 2.3C-D) was observed compared to
two acidic positions conserved for the +2 variant (Fig. 2.3B).

2.4.2 In silico analysis of CK2 inhibition experiments by CX-4945
treatment
Data from phosphoproteomic experiments profiling the response of HeLa and U2OS cells
to treatment with the ATP-competitive CK2 inhibitor CX-4945 [50] in a range of
concentrations was retrieved from the literature (HeLa mitosis, 5 µM CX-4945 for 45
min [51]) or generated by our group (HeLa cells 20 µM CX-4945 for 1-4 h [52] and
U2OS cells, 30 µM CX-4945 for 4 h (https://ir.lib.uwo.ca/etd/5164)) and analyzed for K
motif patterns occurrence (Supp. Table 2.4). From all the Ser and Thr phosphosites
identified 1.4-10.4 % from all data sets contained a Lys residue in the vicinity of the
phosphorylatable site, p-1-p+4 (Fig. 2.4A, top). Of these sites between 6.4-21.7%
matched the K motif minimal across all positions (Fig. 2.4A, middle) and between 1060% of the minimal hits matched the K motif patterns (Fig. 2.4A bottom). After
quantification and filtering (fold change <= -2, P value <= 0.05), 0.5-5.5 % of all
inhibited sites contained Lys in the vicinity of the phosphorylated residue (Fig. 2.4B,
top). From these, 10-50 % sites matched the K motif minimal patterns (Fig. 2.4B, middle)
and between 25-100 % of the minimal hits matched the K motif patterns (Fig. 2.4B
bottom). In the latter case, for positions -1, +2, and +4 the percentage was 60-100 %
whereas for +3 was 20-25 % (Supp. Table 2.4). Noticeably, inhibition of phosphosites
quantified in singly-phosphorylated peptides was observed for the +2 and +3 variants of
K motif (no K motif minimal) but no for +1 (Fig. 2.4B, Supp. Table 2.4). As before, the
functions of the tentative K motif substrates are diverse including transcriptional
regulation, apoptosis, cell cycle regulation, etc. (Supp. Table 2.4). The inhibition
observed for sites matching the K motif minimal patterns could result, at least in part,
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from downstream and/or off-target effects of CX-4945 treatment. Among the
downstream pathways that could be affected are those regulated by basophilic kinases
such as PKA and PKC [17], as the consensus motif for these kinases can overlap with the
K motif patterns (Fig. 2.4D).

Figure 2.4. Phosphosites identified and quantified in three different phosphoproteomic
studies of CX-4945 inhibition that match the K motif variants. A) Identified
phosphosites. B) Inhibited phosphosites, fold change <= -2; singly phosphorylated
peptides. The HeLa mitosis dataset does not have aggregated sites, meaning that the same
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site found in two different peptide charge states was not quantified as one. C) Tentative
CK2 target sites matching K motif variants. D) Examples of basophilic kinases
consensus. p: position.

2.4.3 Asp-N digestion experiment
The experiments analyzed rely on trypsin digestion for generating phosphopeptides
during protein digestion. Trypsin cuts towards the C-terminal of the amino acids Lys and
Arg generating what are referred to as tryptic peptides. To expand the search for K motif
a double-SILAC (Stable Isotope Labeling by/with Amino acids in Cell culture)
phosphoproteomic study in U2OS cells was performed after 6 h treatment with 30 µM
CX-4945 using the endoproteinase Asp-N as the enzyme for protein digestion [53]
(Appendix B). The endoproteinase Asp-N, as per its name, cuts proteins endogenously
towards the N-terminal of Asp residues. Since the K motif pattern was designed to match
Asp residues in several positions this experiment was of great value to uncover additional
hits. Also, since the K motif pattern also includes K, the SILAC approach is feasible for
quantification as both Lys and Arg are labelled. As a result, phosphorylation of Ser24 of
SET, a hit of K motif position +2 that was tested in the peptide assays (Fig. 2.1B), was
detected but did not show any changes after treatment compared to control (Table 2.3).
The adjacent phosphosite, Thr23 of SET, was also quantified but inhibition was not
observed (Table 2.3). Importantly, only the singly modified peptides were identified, not
the doubly-phosphorylated, if occurring in the cell. Other K motif hits quantified and
found non inhibited were: Ser375 of PACSIN2 (p+2) and Ser302 of GBF1 (p+1) (Table
2.3). The absence of inhibition of position +2 hits after CX-4945 treatment does not
necessarily reflect the expected outcome upon CK2 manipulation. However, not all CK2
sites should be expected to change upon treatment with a CK2 inhibitor in a cell line
given the regulatory pathways of protein phosphorylation in place. Interestingly,
inhibition of a site with an Arg at position +2, Ser371 of EZH2, but not for Arg position
+1 was observed. Finally, inhibition of phosphosites located in the vicinity of K motif
hits was observed for Ser160 and Ser158 of BAZ1B of, ~2 fold change (Table 2.3). This
is interesting as CK2-dependent signaling could not only be directly targeting the Ser161
of BAZ1B in this specific context, but neighboring residues (Table 2.3).
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Table 2.3. K motif hits represented in the Asp-N phosphoproteomic dataset.
Ratio H/L

Site

Motif

Gene

Modified sequence

-1.02

Ser375

SEKD

PACSIN2

_DEDDTGSTVS(ph)EK_

1.01

Ser24

SEKE

SET

_DETS(ph)EKEQQEAIEHI_

1.00

Ser24

SEKE

SET

_DGADETS(ph)EKEQQEAIEHI_

-1.13

Ser302

SKED

GBF1

_DSGLEFSSQTTS(ph)KE_

-1.01

Thr23

TSEK

SET

_DET(ph)SEKEQQEAIEHI_

-1.84

Ser160

SSDK

BAZ1B

_DSPS(ph)SDKENSSQIAQ_

-1.73

Ser158

SPSS

BAZ1B

_DS(ph)PSSDKENSSQIAQ_

1.23

Ser1236

STSS

RBBP6

_DYTS(ph)TSSTGGSPVRKSEEKT_

1.03

Ser911

SRDD

TMEM94

_DDLNQVS(ph)R_

-1.27

Ser178

SRED

TUBGCP5

_DQQPLS(ph)RE_

-2.92

Ser371

SDRE

EZH2

_DTDS(ph)DREAGTETGGENN_

Category

K motif

K motif in
vicinity

R motif

2.4.4 Acetylated proteins functionally linked to CK2
After determining the specificity of CK2 against peptides containing acetylated K motif
variants the functional link between CK2 and acetylation was explored by applying an
integrative prioritization algorithm (see Methods and Materials section). As a result, more
than 180 acetylated-proteins identified in the study by Scholz et al. 2015 [24] were
functionally linked to CK2, including 124 known CK2 substrates (Fig. 2.5A-B) and more
than 60 other proteins of interest (Fig. 2.5B-C).
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Figure 2.5. Acetyl-proteins identified by Scholtz et al. 2015 functionally linked to CK2.
A) Outliers detection (outlier.coef = 5, Tukey’s method). B) K-means clustering of
scores, centers (k) = 5. Cluster 2: 124 acetyl proteins (CK2 substrates); Cluster 1: acetyl
proteins 204 (score > 0.46); Cluster 3-5: not enough information to link to CK2. C)
Optimal k determined by Elbow method. D) KDAC inhibitors profiled by Scholz et al.
2015 [24] that can be used to explore the link between CK2-dependent phosphorylation
and lysine acetylation in the cell. UP: increased acetylation. Sequence windows were
used to calculate frequencies; fold change cut-off >= 1.5.
Next, the quantitative data provided by Scholz et al. 2015 were assessed to find the
treatments that induced an increased acetylation of the proteins functionally linked to
CK2. From this analysis, it was determined that treatment with the lysine deacetylase
inhibitors Bufexamac (HDAC6 inhibitor) and Nicotinamide (pan-SIRT inhibitor)
increased the acetylation of the acetyl-proteins linked to CK2 (Fig. 2.5D). The rest of the
inhibitors were found equally represented. Among them Trichostatin A (pan-HDAC
inhibitor) was chosen because of the scholarly literature available. The compound
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MGCD0103 (HDAC1, HDAC2, HDAC3, and HDAC11 inhibitor) could also be of
interest for future studies (Fig. 2.5D).

2.5 K motif representation in the proteome and modification
networks
2.5.1 Acetylation motif discovery
Previously we determined in vitro that the K motif variant hits are targeted by
phosphorylation. Here, we determined if the K motif variants can also be targeted by
acetylation in vivo by exploring the acetylation sites identified in Scholz et al 2015. For
this motif, discovery was performed with the tool MoMo v5.0.5 [54] from the MeMe
suite [55,56]. As a result, a total of 15 motifs out of the 34 discovered significantly
enriched (adjusted P value < 0.01, Supp. Table 2.5) showed acetylated Lys close to
negatively charged residues (Table 2.4). This indicated that acetylation of sites
conforming to the K motif variants in vivo is possible. The same analysis could have been
performed for all the lysine acetylation sequences reported in the PSP database, however,
the input dataset will be heterogeneous. On the other hand, by using the data from Scholz
et al. 2015 the results were circumscribed to an in vivo study with enough information
accessible (e.g., MS raw data) to assess the quality of the data.
Table 2.4. Significant motifs in an acidic environment discovered on acetylation sites
identified in Scholz et al. 2015 [24] using MoMo v5.0.5.
Id

Motif

Regexp

Score Fg_match Bg_match Fg/Bg Adjusted_p-value

1

xxxxxE_K_xxxxKK

.....EK....KK

122.2

24

1

24

0.00037

2

xxxxxE_K_xxxCxx

.....EK...C..

103.2

32

3

10.7

9.10E-05

6

xxxMxD_K_xxxxxx

...M.DK......

42.47

31

6

5.2

0.0083

7

xxxQxx_K_Dxxxxx

...Q..KD.....

35.3

50

10

5

3.10E-05

8

xxxTxD_K_xxxxxx

...T.DK......

62.84

48

10

4.8

9.30E-05

10

xxxxxE_K_xxxxxR

.....EK.....R

95.27

107

27

4

3.30E-10

13

xxxxxE_K_xxRxxx

.....EK..R...

48.46

99

27

3.7

1.40E-08

14

xxxxxD_K_xxRxxx

.....DK..R...

45.42

52

14

3.7

0.00056

15

xxxxxE_K_xIxxxx

.....EK.I....

78.15

104

29

3.6

7.60E-09

16

xxxxxG_K_Dxxxxx

.....GKD.....

46.89

88

27

3.3

1.90E-06

17

xxxxxE_K_xxxxxK

.....EK.....K

63.62

196

61

3.2

1.40E-15

18

xxxxxD_K_xxxxKx

.....DK....K.

53.48

89

28

3.2

2.60E-06

23

xxxxxE_K_xxxxxx

.....EK......

32.81

1372

769

1.8

1.70E-42

46

25

xxxxxD_K_xxxxxx

.....DK......

25.46

803

466

1.7

1.00E-20

31

xxxxxx_K_Dxxxxx

......KD.....

14.95

710

504

1.4

1.70E-07

2.5.2 K motif proteome-wide acetylation
The Scholz et al. 2015 data set, HeLa cells acetylome enrichment, was scanned for K
motif hits. Hits from all three K motif variants were observed among the identified or
increased acetylation sites (fold change > 1.5) after treatment with 1 or more of the 19
deacetylase inhibitors tested in the study (Table 2.5). No significant differences were
observed between K motif variants for the proportion of identified (P value = 0.05827,
Cohen’s w = 0.176) or increased (P value = 0.8623, Cohen’s w = 0.05853) acetylated hits
among sites with neighboring Ser/Thr residues (Table 2.5). Thus, contrary to CK2dependent phosphorylation, lysine acetylation near a phosphorylatable Ser/Thr site does
not seem to occur preferentially at K motif +2 variant, or any other variant(s). This
analysis is a snapshot and the results could change for acetylome data sets with a higher
coverage increasing the power to detect differences. It can also depend on the biological
context e.g., different treatment type, treatment duration, and cell line.
Table 2.5. Acetylation sites identified in Scholz et al. 2015 [24] matching the K motif
variants and total number of acetylation sites in the vicinity of Ser/Thr residues; unique
sequences.
Position

K motif

# Sequences (Up)

K Motif, extended

# Sequences (Up)

p+1

[ST]K[DE][DE]

48 (27)
S/T vicinity: 1340*

[ST]K[DE][DE][DE]

3(2)

p+2

[ST][DE]K[DE]

70 (27)
S/T vicinity: 1274*

[ST][DE]K[DE][DE]

11(5)

p+3

[ST][DE][DE]K

56 (30)
S/T vicinity: 1294*

[ST][DE][DE]K[DE]

6(3)

P value**

0.05827
(0.8623)

P value**

0.07685
(not enough hits)

Effect size

0.176, small effect
(0.05853, no effect)

Effect size

0.5001, large effect
(not enough hits)

Up: acetylation upregulated by treatment with deacetylase inhibitors (fold change > 1.5). *Vicinity: [ST]K, [ST].K,
[ST]..K. ** P values were calculated using a 3-sample test for equality of proportions without continuity correction.
Cohen’s w effect size.
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To further explore the occurrence in vivo/in vitro of lysine acetylation in K motif
variants, acetylation data were retrieved from the PSP database (September 2019) (Table
2.6). As before, no preference was observed in the acetylation of the K motif variants (P
value = 0.2126, Cohen’s w = 0.1272). Interestingly, around 23-36% of the acetylated K
motif hits retrieved from PSP are also targeted by phosphorylation, no co-occurrence
implied (Supp. Table 2.6). Contrary to what was observed in CK2 phosphorylation and
CX-4945 inhibition data (Fig. 2.3A, Fig. 2.4B) no differences were observed in the
occurrence of phosphorylation between variants (Table 2.6). This suggests that other
kinases besides CK2 also target these sites in the cell; this is expected, from the number
of basophilic kinases that exist (Fig. 2.4D). More importantly, 3 and 4 K motif extended
hits for positions +1 and +2, respectively, were found annotated as acetylated and as
phosphorylated (Table 2.6). Based on the peptide assay (Fig. 2.1) and the in vitro CK2
assay phosphoproteomic study (Fig. 2.3) these are candidate targets of CK2 (Supp. Table
2.6). As before, our results could change with the addition of new data to the PSP
database.
Table 2.6. Acetylation sites annotated in the PSP database (September 2019) conforming
to K motif variants and corresponding phosphorylation data, unique sites.
Position

K motif

# Acetylation sites

K motif, extended

# Acetylation sites

p+1

[ST]K[DE][DE]

63
S/T vicinity: 2695*
Phospho: 23 (36.51 %)**

[ST]K[DE][DE][DE]

5
Phospho: 3

p+2

[ST][DE]K[DE]

57
S/T vicinity: 2744*
Phospho: 18 (31.58 %)**

[ST][DE]K[DE][DE]

6
Phospho: 4

p+3

[ST][DE][DE]K

46
S/T vicinity: 2752*
Phospho: 11 (23.91 %)**

[ST][DE][DE]K[DE]

3
Phospho: 0

P value***

Acetyl: 0.2126
Phospho: 0.1068

P value***

not enough hits

Effect size

Acetyl: 0.1351, small effect
Phospho: 0.2919, small effect

Effect size

not enough hits

*Vicinity: [ST]K, [ST].K, [ST]..K; ** Overlap of acetylation with phosphorylation (does not imply co-occurrence). ***
P values were calculated using a 3-sample test for equality of proportions without continuity correction. Cohen’s w
effect size.
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2.5.3 K motif proteome-wide phosphorylation
The proportion of K motif variants annotated as phosphorylated in the PSP database
among all Ser/Thr phosphosites containing lysine in the vicinity was determined. As a
result, more than 200 hits matching each variant were found (Table 2.7, Supp. Table 2.7).
A small but significant difference between proportions was observed for K motif (P value
= 1.962e-13, Cohen’s w = 0.2568) and K motif extended (P value = 0.001, Cohen’s w =
0.2814) hits. The same small difference was observed when directly comparing the
number of hits for all variants independent of the Ser/Thr phosphosite background (Chisquared test for given probabilities P value = 0.04, Cohen's w = 0.09411). Importantly, >
40 phosphosites matching any K motif extended variants (Table 2.7) were identified and
these are tentative CK2 targets (Supp. Table 2.7). Again, results could change with the
addition of new data to the PSP database.
Table 2.7. K motif representation in PSP phosphorylation data, unique sites.
Position

K motif

# Phospho sites

K motif, extended

# Phospho sites

+1

[ST]K[DE][DE]

236
S/T vicinity: 8,509

[ST]K[DE][DE][DE]

41

+2

[ST][DE]K[DE]

278
S/T vicinity: 11,594

[ST][DE]K[DE][DE]

63

+3

[ST][DE][DE]K

224
S/T vicinity: 15,646

[ST][DE][DE]K[DE]

41

P value*

1.962e-13

P value***

0.001

Effect size

0.2568, small effect

Effect size

0.2814, small

K vicinity: [ST]K, [ST].K, [ST]..K. * P values were calculated using a 3-sample test for equality of proportions without
continuity correction. Cohen’s w effect size.

Phosphorylation and acetylation information was also retrieved from the database
iPTMnet [57] (September 2019) and combined with the Scholz et al. 2015 (acetylation)
data to expand the list of K motif hits targeted by acetylation and phosphorylation (Table
2.8). As with the PSP analysis, more than a dozen hits were found to be targeted by these
modifications although the existence of both modifications does not imply co-occurrence
(Table 2.8, Supp. Table 2.8). Of note, this analysis was carried because iPTMnet includes
data from PSP and other resources further increasing the wealth of data analyzed. In
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addition, these hits were also shown to be targeted by other PTMs including methylation,
sumoylation, and ubiquitination (Table 2.8, Supp. Table 2.8). The kinase-substrate
relationships retrieved provided information for a small subset of sites (Table 2.8, Supp.
Table 2.8). A few sites matched predicted cis interplaying sites annotated in the database
PTMcode v2 (October 2019) (Table 2.8). Results could change with the addition of new
data to the databases iPTMnet and PTMcode v2 as new potential sites could be added.
Table 2.8. K motif hits annotated phosphorylated in the database iPTMnet (September
2019) and reported acetylated in iPTMnet and/or the Scholz et al. 2015 data [24];
corresponding PTM interplay from PTMcode v2. Unique sites.
Position

Phospho-acetyl*
(iPTMnet)

Phospho-acetyl*
(Scholz et al. 2015)

Kinase-substrate
relationships

PTM co-regulation
(PTMcode v2)

p+1

Phospho-acetyl: 22
Methylation: 1
Sumoylation: 2
Ubiquitination: 12

Phospho-acetyl: 13
Sumoylation: 1
Ubiquitination: 11

CHEK1: YBX3 T112,
YBX1 T80, YBX2
T115

1 (Structural distance,
coevolution)

p+2

Phospho-acetyl: 17
Methylation: 1
Ubiquitination: 10

Phospho-acetyl: 11
Ubiquitination: 8

CSNK2A1: APEX1
S123, MAPRE2 S236

4 (Structural distance,
coevolution)

p+3

Phospho-acetyl: 12
Sumoylation: 3
Ubiquitination: 6

Phospho-acetyl: 8
Sumoylation: 2
Ubiquitination: 5

-

3 (Structural distance,
coevolution)

*Overlap of acetylation with phosphorylation (does not imply co-occurrence)

A similar number of K motif hits reported phosphorylated was found annotated in the
iPTMnet databases as compared to PSP (Table 2.7, Table 2.9). These results could
change with the addition of new data to the databases iPTMnet and PTMcode v2.
Additional PTM types were also observed targeting the Ser/Thr and K in the K motifs
(Table 2.9). Furthermore, an additional number of enzyme-substrate relationships was
uncovered (Table 2.9). Results could change with the addition of new data to the
databases iPTMnet and PTMcode v2.
Table 2.9. PTM types targeting the K motif hits annotated in the database iPTMnet
(unique sites).
Position
PTM type

Acetylation

p+1

p+2

p+3

61

56

44

Amino acid
modified
K

50

Methylation

4

6

4

Sumoylation

24

1

34

Ubiquitination

143

109

83

Phosphorylation

228

271

221

O-glycosylation

1

6

1

Enzyme

14

5

7

S/T

Target K or S/T

The fact that many other modification types were found to target the K motif (Table 2.9)
suggests that several of the endogenous sequences conforming to the motifs are hubs for
signal integration in the cell. This was supported by the retrieval of the corresponding
enzyme-substrate relationships from PSP and iPTMnet, with 27 kinases identified (Table
2.10, Supp. Table 2.9). CK2 was found to phosphorylate hits of position +2 and +1.
Regarding the latter, other acidophilic kinases were also found represented at position +1
pointing to a possible overlap of consensus which is especially relevant for non-extended
K motif variants (Fig. 2.3D, Fig. 2.4C). Basophilic kinases were found to phosphorylate
sites from all three variants as the lysine residue in the K motif variants provide the
required determinants (Table 2.10, Fig. 2.4D).
Table 2.10. Kinase-substrate relationships corresponding to K motif hits annotated
phosphorylated in the PSP and iPTMnet databases (September 2019).
Position

Enzyme

p+1

CDK5, CHEK1, FAM20C, GSK3B, MARK1, PKN1, PLK1**, PLK2**, PRKAA1, PRKACA*,
RPS6KA5, RPS6KB1, SGK1, TRPM7, CSNK2A1**

p+2

AKT1*, CSNK2A1**, GRK2, PRKACA*, PRKCA*

p+3

CAMK1*, EEF2K, FAM20C, PAK1, LRRK2, PRKACA, PKA

*basophilic kinase; **Acidophilic kinase

2.5.4 K motif representation in the human proteome
To determine the proteome-wide occurrence of the K motif the human proteome was
scanned for the K motif linear patterns using FIMO v5.0.5 [58] and the motifs discovered
with MoMo v5.0.5 using the Scholz et al. 2015 dataset as input (Supp. Table 2.5). As a
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result, > 100 K motif hits were identified with FIMO (log-likelihood ratio score) as a
significant match (q-value < 0.05, i.e., the minimal FDR threshold at which the P-value is
deemed significant) to the sequences reported acetylated in vivo in the HeLa cells by
Scholz et al. 2015 (Table 2.11, Supp. Table 2.10). This indicated that several K motif hits
in the proteome are potential candidates for acetylation in vivo as they are a significant
match for in vivo acetylation sequences. Interestingly, the best proteome match retrieved
for the discovered motif xxxMxD_K_xxxxxx (Table 2.4) in Scholz et al. 2015 was
KLAMSDKELMKAA (adjusted P value 0.0083), which matches the K motif variant at
position +2. According to our results, the proportion of candidate acetylation hits in the
proteome for the K motif +1, +2, and +3 variants is 1:7:19.25 (Chi-squared test for given
probabilities P value < 2.2e-16, Cohen’s w = 0.8361).
Table 2.11. K motif representation on the human proteome with FIMO v5.0.5 by using
the MoMo v5.0.5 motifs discovered in the acetylation sites identified in Scholz et al.
2015 [24] as input; unique sequences. UniProtKB human sequences reviewed and
isoforms April 26, 2019.
Position

K motif

# hits proteome
(q-value* < 0.05)

K motif, extended

# Sequences proteome
(q-value* < 0.05)

1

[ST]K[DE][DE]

8

[ST]K[DE][DE][DE]

2

2

[ST][DE]K[DE]

56

[ST][DE]K[DE][DE]

12

3

[ST][DE][DE]K

154

[ST][DE][DE]K[DE]

17

* q-value: The q-value of the motif occurrence. The minimum False Discovery Rate (FDR) required to consider this
match significant. FIMO estimates q-values from all the match p-values using the method proposed by Benjamini &
Hochberg.

The probability score of finding hits matching the K motif and K motif extended
(additional acidic position in the pattern, Table 2.2) by chance in any given human
protein (as calculated by ELM database using the amino acid probabilities from UniProt
[59]) was determined to be 0.00019 and 0.00003, respectively. Meanwhile, the
probability of occurrence by chance of the CK2 pattern annotated in ELM, ...([ST])..E, =
0.0145681 (MOD_CK2_1, ELME000064). This means that the ELM CK2 pattern is 76
and 485 times more likely to appear by chance in any human protein than the K motif and
K motif extended, respectively.
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To identify all possible K motif hits in the human proteome, all the reviewed canonical
and isoform sequences of UniProtKB [60] database (42,371 SwissProt sequences, Sep
2019) were scanned against the K motif linear patterns (Table 2.2) using ScanProsite [61]
and the patmatdb tool from EMBOSS suite [62]. As a result, > 3,000 and > 500 sites
matching the K motif and the K motif extended variants were identified, respectively
(Table 2.12). Thus, the observed probability of finding a K motif or K motif extended hit
in a protein sequence was 0.24916 and 0.03677, respectively. The values determined
were ~1,000 times higher than the expected probabilities. Furthermore, the number of K
motif hits equaled the number of K motif matches in a random proteome (shuffle k-mer
20, like k-mer 1/2) (Table 2.12). A very small yet significant difference was observed
between the number of K motif variant hits (Chi-squared test for given probabilities P
value = 1.545e-05, Cohen’s w = 0.04581) (Table 2.12). This was due to a smaller number
of hits for position +3 when compared with +1 and +2 (Pairwise comparisons using chisquared tests FDR adjusted P value 3.6e-05 and 0.0003, respectively). No differences
were observed in the number of K motif extended hits (Chi-squared test for given
probabilities P value = 0.2552, Cohen’s w = 0.04187) (Table 2.12). Regarding specific
sequences likely to be relevant for acetylation and CK2-dependent phosphorylation in
vivo 495 hits conforming to SDKE were retrieved.
Table 2.12. K motif representation on the human proteome using ScanProsite and
EMBOSS, unique sites.
Position

K motif

# hits proteome
(shuffle k-mer 20)

K motif, extended

# hits proteome
(shuffle k-mer 20)

p+1

[ST]K[DE][DE]

3,658 (3,654)

[ST]K[DE][DE][DE]

506 (506)

p+2

[ST][DE]K[DE]

3,606 (3,606)

[ST][DE]K[DE][DE]

502 (502)

p+3

[ST][DE][DE]K

3,293 (3,292)

[ST][DE][DE]K[DE]

550 (550)

Total

10,557 (10,552)

1,558 (1,558)

P value*

1.545e-05

0.2552

Effect size

0.04581, no effect

0.04187, no effect

* P values were calculated using a Chi-squared test for given probabilities. Cohen’s w effect size.
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2.5.5 K motif boundaries and cellular conditions
Given the thousands of candidate hits retrieved for each K motif variant, it is important to
be able to determine their boundary and cellular conditions to find those that constitute
“functional hits”. To study the boundary and cellular context of the K motif hits the
SLiMSearch4 framework [63] was used which allows proteome-wide discovery of
functional motifs with an expected number of instances returned (E) < 10,000 and
localized to regions with a IUPred disordered score (based on energy estimation
approach) >= 0.4. This score threshold is set as default by SLiMSearch for motifs as it
allows for a locally more ordered tendency compared to other applications of IUPred like
disordered binding regions [63]. As a result, > 700 and > 100 hits on canonical sequences
for K motif and K motif extended position, respectively, localized to intrinsically
disordered regions in the proteome (Table 2.13, Supp. Table 2.11).
Table 2.13. K motif representation on the human proteome using SLiMSearch4; unique
sites on canonical sequences (IUPred disordered cut-off >= 0.4).
Position

K motif

# Sites proteome
(canonical)

K motif, extended

# Sites proteome
(canonical)

p+1

[ST]K[DE][DE]

723 hits in 655 proteins

[ST]K[DE][DE][DE]

127 hits in 124 proteins

p+2

[ST][DE]K[DE]

833 hits in 734 proteins

[ST][DE]K[DE][DE]

146 hits in 143 proteins

p+3

[ST][DE][DE]K

721 hits in 635 proteins

[ST][DE][DE]K[DE]

156 hits in 134 proteins

Several warnings were raised by SLiMSearch4 across all positions. After filtering,
hundreds of hits remained for K motif and K motif extended variants (Table 2.14, Supp.
Table 2.11). The warnings represented instances for example where the sites localized to
a structural domain in the protein, the site has low surface accessibility, the protein
constraining the site is secreted, etc. (Supp. Table 2.11).
Table 2.14. Warnings detected on K motif representation on the human proteome using
SLiMSearch4; unique sites on canonical sequences (IUPred disordered cut-off >= 0.4).
Position

p+1

K motif

# Sites warnings (keep)

[ST]K[DE][DE]

200 (523)
Domain: 166
Localisation: 42
Surface accessibility: 12

K motif, extended

# Sites warnings (keep)

[ST]K[DE][DE][DE]

34 (93)
Domain: 28
Localisation: 4
Surface accessibility: 2
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p+2

p+3

2.5.5.1

Topology: 20

Topology: 4

[ST][DE]K[DE]

216 (617)
Domain: 170
Localisation: 36
Surface accessibility: 21
Topology: 37

[ST][DE]K[DE][DE]

31 (115)
Domain: 26
Localisation: 3
Surface accessibility: 3
Topology: 8

[ST][DE][DE]K

180 (541)
Domain: 151
Localisation: 36
Surface accessibility: 2
Topology: 18

[ST][DE][DE]K[DE]

42 (114)
Domain: 35
Localisation: 9
Surface accessibility: 1
Topology: 3

Conservation and accessibility

The K motif hits returned by SLiMSearch4 (IUPred >= 0.4) are deemed to have less
propensity to be in a globular region of the protein and are considered highly accessible
(Fig. 2.6, Supp. Fig. 2.4, Supp. Table 2.11). The mean disorder score for the hits returned
was between 0.58-0.67 for the K motif and K motif extended hits, higher than the cut-off
of 0.4 (Fig. 2.6, Supp. Fig. 2.4). Additional parameters were also explored, i.e., sequence
conservation, surface accessibility, and propensity of folding upon binding (Fig. 2.6,
Supp. Fig. 2.4). Regarding conservation, the analysis performed by SLiMSearch4
computed the conservation of the hits in metazoans and orthologs (Quest For Orthologs
dataset), values representing conservation over large evolutionary distances [63] (Fig.
2.6, Supp. Fig. 2.4). Some of the hits for which the conservation scores were calculated
were found conserved (low score); however, the mean conservation value was between
0.6-0.74 (Fig. 2.6, Supp. Fig. 2.4) indicating that the majority of these sites are not
conserved over large evolutionary distances. However, for the K motif extended hits +3,
7 low score outliers (outliers coefficient (Tukey’s method) = 1.5.) were found pointing to
their conservation in Metazoan (Supp. Fig. 2.4). The propensity to fold upon binding was
determined by the anchor score, a higher score implies a higher propensity to folding
upon binding i.e., a transition between disorder-to-order upon binding [64]. These
binding events are relevant in cell signaling and regulatory processes since the coupling
of folding and binding can control binding specificity without increasing affinity and
provides flexibility for the binding site to adopt different conformations when faced with
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different interactors [64]. A mean anchor score between 0.17-0.23 was observed across
all variants meaning that most of the hits do not have a propensity to fold upon binding
(Fig. 2.6, Supp. Fig. 2.4). However, several outliers (outliers coefficient = 1.5, Tukey’s
method) were identified with anchor scores ~0.75 across all variants (Fig. 2.6, Supp. Fig.
2.4) suggesting these might localize to disordered binding regions. Finally, not enough
information was available to confidently assess surface accessibility of K motif hits
(Supp. Table 2.11) due to the lack of protein structure information [63].
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Figure 2.6. SLiMSearch4 results for the K motif variant +2 (K motif extended
(ext_SLiMSearch) and all hits (SLiMSearch)) showing the distribution of the disordered,
conservation, and Anchor scores for the hits found. Left-Right: Disorder score (IUPred).
Conservation in Metazoa. Conservation in Quest for Orthologs (QFO), Anchor score
(disorder-order transition upon binding). Outliers coefficient (Tukey’s method) = 1.5.
The conserved counter score, i.e., the number of species in which the motif consensus is
present at the same position as the query species motif, was analyzed for outliers (Fig.
2.7, Supp. Fig. 2.5). As a result, nine hits conserved in more than 75 species in Metazoa
and seven in more than 10 orthologs were identified (Fig. 2.7, Supp. Fig. 2.5). The mean
number of species where the hit position was conserved was 22 and 6 for Metazoan and
orthologs, respectively. In addition, the conservation of the K motif variants relative to
their flanking regions in Metazoa and orthologs was also analyzed (Fig. 2.7, Supp. Fig.
2.5). This is calculated in SLiMSeach by determining the significantly conserved residues
in the defined positions vs the significantly conserved residues in the flanks, +/- 10 amino
acids [63]. The mean motif vs flank conservation score was zero meaning that most of the
hits do not have conserved residues or have the same proportion of conserved residues
between the motif sequence and the flanking region (Fig. 2.7, Supp. Fig. 2.5).
Importantly, several outliers with higher conservation inside the motif vs flanks. Among
them Ser161 of BAZ1B was observed, a K motif extended hit at position +2 (Fig. 2.7),
known to be phosphorylated in cells and neighboring other modified residues.
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Figure 2.7. SLiMSearch4 hits for K motif +2 variant conserved counter (Outliers
coefficient = 1.5) and conservation, motif v flank scores (Outliers coefficient (Tukey’s
method) = 5).

2.5.5.2

Functional features

An array of sequence and boundary properties of the K motif were previously calculated
with SLiMSearch4 suggesting a functional relevance for several of the K motif hits
across all variants. Thus, the next analysis was focused on those sequence features and
properties that provide context on the function of the K motif hits. For this the
SLiMSearch4 output was explored for evidence of occurring PTMs (complementary to
PSP and iPTMnet analyzes), functional domains, motifs, mutagenesis, SNPs, etc. (Table
2.15, Supp. Table 2.11). Of notice was the finding that sequences conforming to the K
motif are targets of SNPs and mutations in the cell (Table 2.15, Supp. Table 2.11).
Table 2.15. SLiMSearch4 functional features on K motif hits.
Position
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PTM type

p+1

p+2

p+3

Acetylation

15

16

12

Methylation

2

3

2

AA modified

K
Sumoylation

-

1

-

Ubiquitination

21

14

14

Phosphorylation

60

83

61

O-glycosylation

-

1

---

Enzyme

1

1

-

Other

1

5

3

Domain

29

31

25

Motif

2

1

1

Structure

7

16

7

SNP

33

40

25

S/T

K, S/T, or D/E
Mutagenesis

2

3

0

Region

24

37

25

Topology

11

13

9

Secondary Structure

4

13

5

Isoform

31

26

24

Switch

0

1

0

The domain, motif, and secondary structure information provided by SLiMSearch4
(Table 2.15) was extended to all the K motif hits found in the human proteome scan using
ScanProsite with information retrieved from UniProtKB and PDB [65] databases. The K
motif hits were found to overlap in three cases with nuclear localization signals and with
> 200 domains (Supp. Table 2.12). Also, several types of secondary structure were also
identified including unordered regions (Supp. Fig. 2.6), as expected from SLiMSearch4
analysis, but also strand, helix, and turn (Supp. Fig. 2.6).
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2.5.5.3

Mutations

Since SLiMSearch4 returned information regarding mutagenesis (UniProt: mutated
residues which alter function) and SNPs (dbSNP, 1000genomes and UniProt: single
nucleotide polymorphism with disease association and genotype information). The hits in
which mutations impact the local charge of the K motif were determined.
Correspondingly, several hits were identified where Lys was substituted by Glu and vice
versa in all K motif variants (Table 2.16, Supp. Table 2.11). Substitutions of Lys by noncharged amino acids like Ile and Gln were also detected.
Table 2.16. Mutations targeting the positions in the K motif returned by SLiMSearch4.
No. hits

Substitution

Protein and site targeted
p +1

7

S->P:3; S->C:2;
S->G:1; S->N:1

FCRL4_510; IRX2_199; NOP56_513; SRCAP_1844; TINF2_305;
TRPM2_663; ZNF638_1528

10

T->A:3; T->I:3;
T->N:2; T->M:1;
T->S:1

ALOX12_568; CHCHD4_16; CMYA5_3027; CWF19L2_278; KDELC1_498;
L3MBTL3_183; NFKB1_489; UBE3A_174; ZCCHC6_666; ZDHHC23_238

11

D->N:4; D->E:3;
D->G:2; D->A:1;
D->V:1

ARHGAP11A_755; DNHD1_620; EPB41L5_578; FAM154A_340;
HERC5_230; MIA3_876; OS9_302; PODXL_546; TCP1_537; VCAN_1351;
ZNF407_828

15

E->K:5;
E->D:3; E->G:3;
E->Q:2; E->*:1;
E->V:1

EIF4ENIF1_31; EML6_488; FBRS_263; HMGN1_70; HNF1B_257;
ICT1_169; KIAA2013_628; LRRFIP1_801; MAP2_763; MYH2_1267;
ORC3_507; OTUD7A_571; RIF1_1879; SLC8A1_690; TCAP_102

15

K->E:8;
K->R:2; K->T:2;
K->M:1; K>N:1; K->Q:1

CCAR2_584; CDC5L_625; CENPC_439; HECW1_482; KIF20B_734;
LAD1_78; MCM3_176; MSH6_269; POLK_724; PSMC2_12; RREB1_59;
SRSF6_265; TTN_16066; WDR49_548; ZNF445_757
p +2

8

S->C:2; S->N:2;
S->G:1; S->L:1;
S->P:1; S->Y:1

ALAS1_65; ANKRD12_1758; DMRT3_171; KTN1_1319; LRRIQ1_1536;
MXRA5_750; SYCP2L_422; TRDN_339

8

T->M:5; T->I:3

CDH3_568; GABPA_450; KAT6B_1397; KCNH2_895; SEC24D_604;
SURF2_195; TMEM209_230; USP35_688

11

D->E:6; D->G:3;
D->Y:2

CDYL2_163; CENPJ_759; EVPLL_70; GAPT_107; IFIT3_393; KIF1A_1555;
PPIG_442; PRRC2A_1765; RABGAP1L_464; SDC2_107; ZBTB41_324
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13

E->K:5;
E->G:4; E->D:2;
E->Q:1; E->V:1

KIAA0101_76; KIF4B_953; LRRD1_2; MYZAP_334; OPTN_10;
RNF113A_124; RSBN1L_21; RSF1_643; SETD1B_1065; SMARCA2_992;
TIAM2_1314; TSHZ2_662; UBE2E1_22

13

K->N:6;
K->E:3;
K->R:3; K->I:1

ARID4A_651; C1orf168_398; C2orf44_550; CARD10_512; CCAR2_285;
DSC3_408; FBXO40_246; FREM3_460; GOLGA4_1335; LDHA_220;
PJA2_447; RMDN3_189; RPL6_235
p+3

8

S->C:2; S->N:2;
S->G:1; S->L:1;
S->P:1; S->Y:1

ALAS1_65; ANKRD12_1758; DMRT3_171; KTN1_1319; LRRIQ1_1536;
MXRA5_750; SYCP2L_422; TRDN_339

8

T->M:5; T->I:3

CDH3_568; GABPA_450; KAT6B_1397; KCNH2_895; SEC24D_604;
SURF2_195; TMEM209_230; USP35_688

11

D->E:6; D->G:3;
D->Y:2

CDYL2_163; CENPJ_759; EVPLL_70; GAPT_107; IFIT3_393; KIF1A_1555;
PPIG_442; PRRC2A_1765; RABGAP1L_464; SDC2_107; ZBTB41_324

13

E->K:5;
E->G:4; E->D:2;
E->Q:1; E->V:1

KIAA0101_76; KIF4B_953; LRRD1_2; MYZAP_334; OPTN_10;
RNF113A_124; RSBN1L_21; RSF1_643; SETD1B_1065; SMARCA2_992;
TIAM2_1314; TSHZ2_662; UBE2E1_22

13

K->N:6;
K->E:3;
K->R:3; K->I:1

ARID4A_651; C1orf168_398; C2orf44_550; CARD10_512; CCAR2_285;
DSC3_408; FBXO40_246; FREM3_460; GOLGA4_1335; LDHA_220;
PJA2_447; RMDN3_189; RPL6_235

To expand our understanding on the substitutions that could occur inside the K motif hits
data from the database COSMIC [66] (the Catalogue Of Somatic Mutations In Cancer)
(September, 2019) was also retrieved and analyzed for hits. More than 100 mutation
instances in cancer were identified targeting all K motif variants (Fig. 2.8A) including
missense substitutions (Fig. 2.8B). According to FATHMM prediction provided by
COSMIC most of such mutations were classified as pathogenic and a lower number as
neutral (Supp. Table 2.12); furthermore, some of the mutations were annotated as
contributing to resistance (Supp. Table 2.12). As with SLiMSearch4 output, the COSMIC
data was searched for mutations affecting the local charge of K motif hits (Fig. 2.8C).
The mutations retrieved represent different tumor origins: primary, secondary, recurrent,
and metastasis; some are non-specified (Supp. Table 2.12). The primary site and
histology of the cancer were diverse (Supp. Table 2.12). Additional mutation data was
gathered (Supp. Table 2.12).
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Figure 2.8. Curated mutations annotated in COSMIC (February 2020) on sites matching
the K motif. A) Number of mutations per K motif variants. B) Mutation description. C)
Missense substitution, unique mutation id.
A total of 3, 2, and 15 missense substitution mutations annotated in COSMIC matching
the K motif variants +1, +2, and +3, respectively, were found to change Lys by Glu.
These results were of special interest for +1 and +3 hits where the presence of Lys
abrogates phosphorylation by CK2. Although there is no direct evidence of the relevance
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of these mutations at the functional molecular level some functional remarks can be
made. For example, regarding position +1 mutations impacting the residue Lys1994 of
ATM were observed in chronic lymphocytic leukemia. ATM is a Ser/Thr kinase that
senses DNA damage, the residue Lys1994 is localized to the FAT domain, a regulatory
domain that binds the kinase domain in the absence of DNA damage and thus inhibiting
its activity [67]. Interestingly, Lys1994 is in the vicinity of main phosphorylation sites
Ser1981 and Thr1989 [67] and has been identified to be ubiquitinated [68]. Another
mutational example of interest retrieved from COSMIC and expanded upon from the
literature are the variants observed for the protein PIK3CA (Phosphoinositide-3-kinase)
generated by the substitution of Gln546 and neighboring residues in the sequence
544TEQE547

to 544TEKE547 and 544TEEE547. These mutations localize to the helical domain

of PIK3CA; as a result, the helical domain is regarded as a “hotspot” for mutations,
which are considered to impact binding to the SH2 domain of PI3KCA resulting in
activation of the kinase [69]. The impact of this substitutions on phosphorylation and if
phosphorylation occurs at Thr544 site (evidence of phosphorylation in the GPMdb
database [70]) is not known. However, since PIK3CA is functionally linked to CK2 as a
regulator of the AKT/mTOR pathway [71] it raises questions about the relevance of such
mutations in the K motif hits and the rewiring of phosphorylation.

2.5.5.4

Regulatory sites

The K motif hits were searched for regulatory sites annotated in the PSP database
(September 2019). A total of 3, 8, and 1 regulatory site were observed for +1, +2, and +3
hits, respectively (Supp. Table 2.13). This is a relevant finding as it implies that they are
among the few highly studied modification sites in the proteome, likely due to their
biological role or the role of the proteins that contain them. The list included 10
phosphosites as well as one sumoylation site and one methylation site. Interestingly, for
+2 hits the regulatory sites observed are involved in regulating the activity of the
corresponding proteins by inducing protein stability, inducing activity, and regulation of
molecular association (Supp. Table 2.13). Their phosphorylation is known to impact
transcription, RNA splicing, endocytosis, and translation processes (Supp. Table 2.13).
Complementary, a total of 88, 90, and 74 genes which contain mutations that have been
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causally implicated in cancer processes and thus driving cancer annotated in the
COSMIC Cancer Gene Census [72] were observed for +1, +2, and +3 variants,
respectively (February 2020).

2.5.5.5

Sites in pathways

Additional important regulatory information retrieved for the K motif hits is their
involvement in pathways as annotated in the database Reactome [73]. Regarding the +2
hits the sites K164 of DDX58 and K788 of NCOA2 were annotated to a total of 24
reactions in 15 pathways linked to innate immune system and the sumoylation of
NCOA2, respectively (Supp. Table 2.13).

2.5.5.6

Relationship to lysine acetylation writers and erasers

The protein-protein interaction data of the proteins containing K motif hits was retrieved
using the PSICQUIC services [74] in R [75] and searched for lysine acetyltransferases
(KAT) and lysine deacetylases (KDAC) interactors. As a result, 411 and 396 unique
instances of gene-KAT and gene-KDAC interactions, respectively, and 199 unique geneKDAC-KAT interaction pairs were observed (Table 2.17, Supp. Table 2.13). This
amounted to a total of 57 combinations of KDACs-KATs represented in the hit proteins
(Table 2.17, Supp. Table 2.13). Importantly, for all three K motif variants interactions
were observed with both KDACs and KATs (Table 2.17, Supp. Table 2.13).
Table 2.17. Enzyme-substrate relationships represented in the positions matched in the K
motif (iPTMnet).
KDAC-KAT

Gene-KDAC-KAT

Gene-KAT

Gene-KDAC

p+1 hits

p+2 hits

p+3 hits

57

199

411

396

KDAC: 77
KAT: 125
Both: 45

KDAC: 76
KAT: 126
Both: 95

KDAC: 104
KAT: 122
Both: 43

KAT: lysine acetyltransferase; KDAC: lysine deacetylase

For position +2 the KDACs identified as interactors were: HDAC1, HDAC2, HDAC3,
HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10, SIRT1, SIRT3,
SIRT4, and SIRT6. The KATs identified were: CLOCK, CREBBP, EP300, GTF3C4,
HAT1, KAT14, KAT2A, KAT2B, KAT5, KAT6A, KAT6B, KAT7, KAT8, MCM3AP,
NCOA1, NCOA2, NCOA3, TAF1. Interestingly the functional association between CK2
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a number of these erasers and writes has been described in the literature (see Chapter 3).
The corresponding relationships were extracted from the literature using Chilibot (Fig.
2.9).

Figure 2.9. Literature relationships between CK2 and lysine deacetylases and
acetyltransferases extracted using Chilibot.

2.5.6 Functional link to CK2
The functional association of the K motif hits to CK2 was assessed according to CK2
substrates, CK2 interactors, CK2 neighborhood, mentions in the CK2 literature, coregulation with CK2, similarity with GO biological processes annotated for CK2,
changes when CK2 is manipulated, and conforming to CK2 motif while localizing to
subcellular compartments where CK2 is found. More than 320 human proteins
conforming to the K motif linear patterns across all variants were found linked to CK2
including 152 known CK2 substrates and more than 170 other closely functionally linked
proteins (outlier.coef = 6, Tukey’s method) (Fig. 2.10). Collectively, these observations
highlight a need for understanding how CK2-dependent signaling integrates at the hit
sites in these proteins.
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Figure 2.10. K motif hits in the human proteome functionally linked to CK2. “SCORE”
(0-1), all resources values are averaged, and “SCORE_SUB”, all resources values are
averaged except for the CK2 targets which is summed to the average score allowing for
direct identification of known CK2 substrates as outliers. Higher ranking proteins, CK2
substrates: SCORE_SUB > 1). Resources: CK2 substrates, CK2 interactors, CK2
neighborhood, mentions in the CK2 literature, co-regulation with CK2, similarity with
GO biological processes annotated for CK2, changes when CK2 is manipulated, and
conforming to CK2 motif while localizing to subcellular compartments where CK2 is
found. Outliers coefficient = 6, determined by Tukey’s method.

2.5.7 Candidate K motif sites for CK2-dependent phosphorylation
Following the described analysis, a list of known and candidate CK2 substrates
conforming to the K motif variant +2 and the K motif extended variants +1 and +3 (with
four or more negative residues) was generated. This list contained sites matching the
criteria from the curated known CK2 substrates retrieved from PSP, the in vitro hits
phosphorylated by CK2, the sites inhibited by CX-4945, the sites annotated
phosphorylated and acetylated in PSP or just phosphorylated (Supp. Table 2.14).
Functional information about the sites can be accessed in the Supplemental Material. A
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total of 113 unique sites was selected (Supp. Table 2.14) with the corresponding 109
proteins displaying diverse molecular activities (Table 2.18, Supp. Table 2.14) including
DNA (cytosine-5-)-methyltransferase, histone acetyltransferase, histone
methyltransferase, kinase, and nuclease activities.
Table 2.18. Summary of GO molecular function, level 5, classification corresponding to
the candidate CK2 substrates conforming to the K motif variant.
ID

Description

Count

GeneRatio

geneID

GO:0001228

DNA-binding transcription activator activity, RNA
polymerase II-specific

4

4/107

TFAP2A/PRDM2/ARNTL/RR
EB1

GO:0016301

kinase activity

4

4/107

RIOK1/PKM/PRKG1/MAST2

GO:0008168

methyltransferase activity

3

3/107

FTSJ3/PRDM2/DNMT1

GO:0001227

DNA-binding transcription repressor activity, RNA
polymerase II-specific

2

2/107

TFAP2A/ZEB1

GO:0004518

nuclease activity

2

2/107

APEX1/EXOSC9

GO:0003755

peptidyl-prolyl cis-trans isomerase activity

2

2/107

PPIG/PPIL4

GO:0030374

nuclear receptor transcription coactivator activity

1

1/107

CCAR1

GO:0016615

malate dehydrogenase activity

1

1/107

MDH1

GO:0016747

transferase activity, transferring acyl groups other
than amino-acyl groups

1

1/107

KAT6A

GO:0042578

phosphoric ester hydrolase activity

1

1/107

APEX1

GO:1990380

Lys48-specific deubiquitinase activity

1

1/107

OTUD7B

GO:0009982

pseudouridine synthase activity

1

1/107

PUS7L

GO:0003909

DNA ligase activity

1

1/107

LIG1

GO:0042054

histone methyltransferase activity

1

1/107

PRDM2

GO:0003886

DNA (cytosine-5-)-methyltransferase activity

1

1/107

DNMT1

GO:0008649

rRNA methyltransferase activity

1

1/107

FTSJ3

GO:0046943

carboxylic acid transmembrane transporter activity

1

1/107

SLC1A5

GO:0005216

ion channel activity

1

1/107

TRPV5

GO:0099516

ion antiporter activity

1

1/107

SLC9A5

GO:0015186

L-glutamine transmembrane transporter activity

1

1/107

SLC1A5

GO:0015103

inorganic anion transmembrane transporter activity

1

1/107

SLC4A7

GO:0015399

primary active transmembrane transporter activity

1

1/107

RALBP1

GO:0035064

methylated histone binding

1

1/107

CDYL2

GO:0005070

SH3/SH2 adaptor activity

1

1/107

SKAP1

GO:0048018

receptor ligand activity

1

1/107

GDF6

GO:0017112

Rab guanyl-nucleotide exchange factor activity

1

1/107

DENND1A

GO:0005246

calcium channel regulator activity

1

1/107

PRKG1

GO:0030414

peptidase inhibitor activity

1

1/107

APLP2

GO:0005096

GTPase activator activity

1

1/107

RALBP1

GO:0005125

cytokine activity

1

1/107

GDF6
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2.6 K motif as a ground for PTM interplay
To study the co-occurrence of phosphorylation and acetylation in sites conforming to the
K motif we performed immunoblotting and phosphoproteomic studies followed by
functional analysis.

2.6.1 Modulation of CK2-dependent signaling by lysine deacetylase
inhibitors
First, an appropriate treatment to increase acetylation in U2OS and HeLa cells was found
by treating cells for 3 to 16h with the lysine deacetylase inhibitors (KDACi)
Nicotinamide (NAM), Trichostatin A (TSA), Bufexamac (Bx), and Tubacin (Fig. 2.11A).
Then the modulation of CK2-dependent signaling was evaluated using immunoblotting
(Fig. 11B-F) and phosphoproteomics (Fig. 2.16-17). Interestingly, a modulation on CK2dependent signaling was observed at 10 and 16 h of treatment by immunoblotting with
the CK2 motif ((pS/pT)DXE) antibody (Fig. 2.11B, Fig. 2.13). No changes were
observed in the total protein levels of CK2alpha and CK2alpha’ (Fig. 2.11C) or in the
phosphorylation by CK2 of the N-terminal of CSNK2B at 16h and 10h of treatment (Fig.
2.11C). No changes were observed in the phosphorylation levels of Ser162 of EEF1D
and Ser2 of EIF2B bonafide substrates of CK2 at 16 h of treatment (Fig. 2.11D-F). An
induction of apoptosis was observed by monitoring PARP1 cleavage at 16 h, which was
more marked in the TSA and Bx treatments (Fig. 2.11G).
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Figure 2.11. Immunoblots of lysine deacetylase inhibitor (KDACi) treatment of U2OS
and HeLa cells at different time points monitoring total protein acetylation status and the
modulation of CK2 subunits and CK2 substrates. A) Increase in acetylation levels in
HeLa cells at 3, 6, 10, and 16 h using pan-AcK antibody (Immunechem). B) Impact on
CK2 substrates in HeLa and U2OS cells at 3, 6, 10, and 16 h using the pan-CK2 motif
((pS/pT)DXE) antibody. C) Impact on CK2 levels in HeLa and U2OS cells at 3, 6, 10,
and 16 h using GST-CK2 antibody. Impact on CSNK2B N-terminal phosphorylation at 3,
6, and 10 h using phosphor-Ser2/3/8 CSNK2B antibody. D) Impact on the bonafide CK2
substrate Ser2 of EIF2B in HeLa cells at 16 h using phosphor-Ser2 and total (Novus)
EIF2S2 antibodies. E) Impact on the phosphorylation of the bona fide CK2 target site
Ser162 of EEF1D and total protein levels of EEF1D in HeLa and U2OS cells at 3, 6, and
10 h. Detected using phospho-Ser162 and total EEF1D (YenZym) antibodies. G) Total
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PARP1 levels in HeLa cells at 16 h using total PARP1 (CST) antibody. Nicotinamide
(NAM), Trichostatin A (TSA), Bufexamac (Bx). All immunoblots were performed in
three biological replicates (BR1-3) and the signal was detected in a LiCor Odyssey
Infrared Imaging System managed by the Odyssey v3.0 software. Quantification of
EIF2S2 and EEF1D signals was performed by using the up-bottom background method
in Odyssey v3.0 software. Lane normalization for quantification was performed using
total GAPDH (Millipore) antibody or REVERT 700 total protein stain (LiCor) as
indicated by LiCor.
Since changes were observed with the anti-pan-CK2 substrate antibody the
phosphoproteome of isotopically-labeled U2OS cells in response to TSA and NAM
treatment at 6 and 16 h was profiled (Fig. 2.12). Overall changes to several sites
corresponding to proteins functionally linked to CK2 were observed which was marked at
16 h (Fig. 2.12).
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Figure 2.12. SILAC workflow of lysine deacetylase (KDAC) inhibitor treatment of
U2OS cells. Increased acetylation levels in HeLa and U2OS cells after 16 h of treatment.
Followed by triple/double-SILAC phosphoproteomic profiling of modified sites and
identification of proteins functionally linked to CK2 whose phosphorylation was
impacted at 16 h of treatment. Nicotinamide (NAM) and Trichostatin A (TSA).
Many known and tentative CK2 sites were quantified in three or more replicates out of
four in U2OS cells treated with 2.5 µM TSA or 20 mM NAM for 6 and 16 h (Fig. 2.13,
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Supp. Table 2.15). As indicated, most of the sites studied belong to known acetylproteins (iPTMnet database) (Fig. 2.13, Supp. Table 2.15). Several of the quantified sites
contain one or more known acetylation sites nearby, +/-20 amino acids (Fig. 2.13, Supp.
Table 2.15).
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Figure 2.13. Known and tentative CK2 target sites and substrates quantified in U2OS
cells treated with the lysine deacetylase inhibitors (KDACi) Trichostatin A (TSA) and
Nicotinamide (NAM) for 6 (top) and 16 h (bottom) across different experiments. 6 h
experiment, 20 mM NAM vs control condition (M/L triple-SILAC) and 2.5 µM TSA vs
control condition (H/L triple-SILAC). 16 h experiments, -1: 20 mM NAM vs control
condition (M/L triple-SILAC) and 2.5 µM TSA vs control condition (H/L triple-SILAC);
-2: 20 mM NAM or 2.5 µM TSA (M/L double-SILAC). The phosphosites and proteins
were quantified if identified in three or more replicates (FDR adjusted p value < 0.05). *:
known CK2 site, a: acetyl-protein, n: nearby acetylation site (+/- 20 aa) to the
phosphorylation site studied, prot: proteins, L: light label, M: medium label, and H:
heavy label.

2.6.2 Co-occurrence of lysine acetylation and phosphorylation in
neighboring residues
Next the acetylated fraction of the phosphoproteome was determined for finding K motif
instances in vivo where both the phosphorylatable and acetylation site are modified. For
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this the same unlabeled HeLa and U2OS protein samples collected after 16 h treatment
with NAM, TSA, or Bx were analyzed using two different strategies: 1) phosphopeptide
enrichment (phosphoproteome) followed by acetyl enrichment (acetyl fraction of the
phosphoproteome); 2) phosphopeptide enrichment followed by dephosphorylation
(dephosphorylated phosphoproteome) and acetyl enrichment (acetyl fraction of the
dephosphorylated phosphoproteome) (Fig. 2.14, Supp. Table 2.16). After
dephosphorylation of the samples we observed a shift towards higher retention times,
which was indicative of a decrease in the polarity of the samples being analyzed by
removal of the phosphate group (Fig. 2.14). Particularly, we observed this change in the
subgroup of ms2 spectra containing the ms2 diagnostic ion for acetyllysine: 126.0913 m/z
[76,77] (Fig. 2.14), indicative that in the samples analyzed these peptides contained both
phosphorylation and acetylation moieties.

Figure 2.14. Label-free workflow to study the acetylated fraction of the
phosphoproteome.

2.6.2.1

Biological processes represented

To assess the validity of our experiments on providing relevant functional information
regarding the acetylation of the phosphoproteome in vivo, the overlap between biological
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processes represented in our study and the Scholz et al. 2015 was determined.
Noticeably, an extensive overlap of many processes found represented in both studies
was observed (Fig. 2.15, Supp. Table 2.17). Furthermore, like in Scholz et al. 2015 study
the acetylation of HIF1A was observed in the Bx treatment. Expressly, acetylation of
Lys251 in concert with phosphorylation of either Ser247 or Ser244 residues was
observed. These sites localize to the second PAS domain of HIF1A, i.e., PAS-B,
necessary for protein heterodimerization [78]. Phosphorylation of Ser247 by CK1 has
been described in the literature and decreases HIF1A binding to HIF1B (ARNT) affecting
HIF1A induced gene expression [78].

Figure 2.15. Functional classification of phosphoproteins containing acetylation sites in
HeLa and USOS cells, biological processes observed in common in Scholz et al. study
and our study. A) Trichostatin A (TSA) treatment. B) Nicotinamide (NAM treatment). C)
Bufexamac (Bx) treatment. D) Modulation of HIF1A modification in Scholz et al. 2015
study [24] and the Bufexamac treatment.
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2.6.2.2

Histone code represented

Since the “histone code” is the most studied example of PTM interplay the sites identified
were search for histone modifications as validation of the experimental method
implemented. As expected, we observed several previously described histone
modifications (Fig. 2.16). What is more, several unannotated acetylation and
phosphorylation sites and their combination were also identified. This consistent with the
increasing number of phosphorylation and acetylation sites reported to date in the
databases and intriguing considering their co-occurrence and the lack of information
available on this subject (Fig. 2.16).

Figure 2.16. Histone code observed. Red: histone modifications annotated in iPTMnet
and PSP databases and Scholz et al. 2015 study [24].

2.6.2.3 Known modification sites, enzyme-substrate relationships,
and functional classification
The known modifications annotated to the identified sites (including ambiguously
localized sites) were retrieved from the iPTMnet and PSP database (Table 2.19) as
validation of the experimental method implemented. Hundreds of known sites including
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phosphorylation and acetylation but also other PTM types such as methylation and
ubiquitination that overlap at the identified sites were also identified (Table 2.19). In
addition, 29 enzyme-substrate relationships (iPTMnet database) and 9 regulatory sites
(PSP database) corresponding to the identified sites were retrieved (Table 2.19, Supp.
Table 2.18). Out of the 29 enzyme-substrate relationships 28 were kinase-substrate (19
kinases) and 1 acetyltransferase-substrate hits. The latter represented the autocatalytic
lysine acetylation of EP300 lysine acetyltransferase at the Lys1560 residue (Supp. Table
2.18). This residue is in one of the most highly acetylated regions of EP300 and is likely
responsive to SIRT2 RNAi-mediated depletion [29,79]. The kinase-substrate relationship
retrieved indicated that three of the sites identified in the context of phosphorylation and
acetylation regulate cell cycle, i.e., Ser1112 of RBL2 phosphorylated by CDK2 [80,81],
S878 of KIF20A phosphorylated by AURKB [82], and S247 of HIF1A phosphorylated
by CSNK1D [83]. Overall, the impact on the function of these regulatory sites on the
corresponding proteins spanned regulation of molecular association, induction/inhibition
of activity, change of protein conformation, alteration of receptor desensitization,
receptor internalization, and protein stabilization (Supp. Table 2.18). What is more,
modification at some of these sites was observed to affect protein-protein interaction
(Supp. Table 2.18). For example, phosphorylation of Ser1112 of RBL2 disrupts the
interaction with E2F4 [80,81]. Phosphorylation of Ser153 of PEBP1disrupts interaction
with RAF1 and induces interaction with GRK2 [84,85]. Phosphorylation of Ser140 of
CHEK2 kinase induces interaction with PLK1 kinase [86]. Finally, as mentioned before,
phosphorylation of HIF1A at Ser247 disrupts the interaction with ARNT [83].
Table 2.19. Known modifications annotated to the identified phospho-acetyl sites
retrieved from iPTMnet (December 2019) and PSP (September 2019) databases.
Cell line

Trichostatin A (2.5 µM)

Nicotinamide (20 mM)

Bufexamac (1mM)

U2OS
(iPTMnet)

Phosphorylation: 70
Ubiquitination: 34
Acetylation: 17
Sumoylation: 5
Methylation: 3
O-Glycosylation: 1

Phosphorylation: 106
Ubiquitination: 27
Acetylation: 26
Methylation: 4
Sumoylation: 4
O-Glycosylation: 1

Phosphorylation: 120
Ubiquitination: 49
Acetylation: 27
Sumoylation: 7
Methylation: 4
O-Glycosylation: 2
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HeLa
(iPTMnet)

Phosphorylation: 141
Ubiquitination: 40
Acetylation: 13
Sumoylation: 4
Methylation: 1
O-Glycosylation: 1

Phosphorylation: 182
Ubiquitination: 70
Acetylation: 42
Methylation: 8
Sumoylation: 5
O-Glycosylation: 3

Acetylation: 141
Phosphorylation: 566
Methylation: 24
O-Glycosylation: 1
Sumoylation: 19
Ubiquitination: 248

Total
(iPTMnet
and PSP)

Enzymes

Phosphorylation: 121
Ubiquitination: 59
Acetylation: 22
Methylation: 6
O-Glycosylation: 3
Sumoylation: 1

Kinases: AURKB, CDK2, CHEK2, NEK9, PRKACA, PRKCA, PRKCB, PRKCD, PRKCG,
PRKCZ, STK4, IKBKE, CDK1, CDK12, CDK2, CHEK2, CSNK1D, MST1, and STK4
Lysine acetyltransferases: EP300

The proteins containing the known sites that were found to co-occur with acetylation or
phosphorylation were classified according to their GO molecular function, level 5 (Table
2.20, Supp. Table 2.17). Of notice, several writers, erasers, and readers associated with
protein modification were observed including 33 Ser/Thr protein kinases and 4 lysineacetylated histone binding. Importantly, all three subgroups of methylation writers,
erasers, and readers were identified with 21 methyltransferases and three histone
demethylases identified (Table 2.20). The latter highlights an important link between
different modifications and their writers for example between acetylation and methylation
which target Lys.
Table 2.20. GO molecular function classification, level 5, associated with writers,
erasers, and readers of containing co-occurring phosphorylation and lysine acetylation
sites.
GO ID

Description

Ratio

Genes

Methylation

GO:0008168

methyltransferase activity

21/1097

ASH1L, CMTR1, KMT2A*, KMT2B, KMT2C*, KMT5C*,
METTL18, METTL25, MRM3*, NSD2*, NSD3, NSUN3*,
PRDM1, PRDM10, PRDM16, SETD1A, SETD2*,
SETDB2, SMYD4*, TRMT1*, ZCCHC4

GO:0032454

histone demethylase
activity (H3-K9 specific)

3/1097

JMJD1C, KDM3A*, PHF2*

GO:0042054

histone methyltransferase
activity

11/1097

ASH1L, KMT2A*, KMT2B, KMT2C*, KMT5C*, NSD2*,
NSD3, PRDM16, SETD1A, SETD2*, SETDB2
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GO:0035064

methylated histone binding

10/1097

ATRX*, CBX8*, CDYL2, CHD1*, CHD5, CHD8*, PHF1,
PHF2*, TDRD3*, ZMYND8*

GO:1990226

histone methyltransferase
binding

1/1097

NOP56*

Acetylation
GO:0070577

lysine-acetylated histone
binding

4/1097

BRD4*, KMT2A*, PHIP*, ZMYND8*

GO:0035035

histone acetyltransferase
binding

3/1097

HIF1A*, MYOCD*, SP1*

GO:0042826

histone deacetylase binding

9/1097

CHD4*, HIF1A*, MYOCD*, NIPBL*, PKN2, SP1*,
TOP2B, UHRF1BP1, WDTC1

Phosphorylation

GO:0004674

protein serine/threonine
kinase activity

33/1097

ACVR1*, AKAP13*, ALPK2*, BMPR2, BRD4*,
CDC42BPB*, CDK12*, CHEK2*, CSNK1A1, CSNK1G1,
CSNK1G2, CSNK1G3, LRRK1, MAP3K10, MAP4K3*,
MAST1*, NEK5, NEK9*, PKN2, PRKAA1*, PRKG1,
PRPF4B*, RPS6KA1*, RPS6KA2, SLK*, SRPK1, STK10*,
STK33*, TAOK1*, TLK1, TOP1*, TTN*, WNK1

GO:0004713

protein tyrosine kinase
activity

7/1097

BAZ1B*, EPHB2, FER, FGFR1, IGF2R, KDR*, TTN*

GO:0035173

histone kinase activity

2/1097

BAZ1B*, PRKAA1*

*: Genes with known modification sites co-occurring with acetylation and phosphorylation.

Along with several enzymes found targeted by acetylation and phosphorylation additional
subunits of protein complexes linked to transcriptional regulation and chromatin
organization were also observed dually modified (Table 2.21, Supp. Table 2.17). A
summary of CK2 regulatory roles on these complexes, and chromatin organization in
general, can be found in Chapter 3.
Table 2.21. Protein complexes represented among the proteins containing the identified
phospho-acetyl sites.
Description

No.

Gene

Keyword

GO:0005667: transcription
factor complex

11

ARNT2, EP300*, ERCC4, GTF3C6,
HIF1A*, NCOA6*, RB1*, SKOR1,
TAF2, TAF3, ZFHX3

Transcriptional regulation

GO:0035097: histone
methyltransferase complex

11

C17orf49, CHD8*, HCFC2, JARID2,
KANSL1*, KMT2A*, KMT2B,

Histone methylation
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KMT2C*, NCOA6*, PHF1, SETD1A
GO:0044798: nuclear
transcription factor
complex

6

ERCC4, GTF3C6, HIF1A*, RB1*,
TAF2, TAF3

Transcriptional regulation

GO:0055029: nuclear
DNA-directed RNA
polymerase complex

6

CDC73, ERCC4, POLR3A*,
POLR3GL*, TAF2, TAF3

Transcription

GO:0000428: DNAdirected RNA polymerase
complex

6

CDC73, ERCC4, POLR3A*,
POLR3GL*, TAF2, TAF3

Transcription

GO:0008278: cohesin
complex

5

CDCA5*, SGO2*, SMC1A*, SMC3*,
STAG1

Chromatin cohesion

GO:0031519: PcG protein
complex

5

CBX8*, JARID2, PHC1*, PHF1, RYBP*

Transcriptional repression

GO:0000123: histone
acetyltransferase complex

5

DMAP1*, EP300*, JADE3, KANSL1*,
TAF2

Histone acetylation

GO:0016581: NuRD
complex

3

CHD4*, CHD5, MTA3

Transcriptional repression

GO:0031391: Elg1 RFClike complex

2

ATAD5*, RFC1

Telomere length regulation

GO:0072357: PTW/PP1
phosphatase complex

1

PPP1R10*

Chromatin structure control,
cell cycle progression

GO:0009330: DNA
topoisomerase complex
(ATP-hydrolyzing)

1

TOP1*

Supercoiling and torsional
tension of DNA release

GO:0034991: nuclear
meiotic cohesin complex

1

SMC3*

Chromatin cohesion

GO:0031011: Ino80
complex

1

INO80*

Chromatin remodeling

GO:0070522: ERCC4ERCC1 complex

1

ERCC4

Nucleotide-excision repair

GO:0005663: DNA
replication factor C
complex

1

RFC1

PCNA to DNA loading

GO:0031390: Ctf18 RFClike complex

1

CHTF18*

PCNA to DNA loading
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GO:0033503: HULC
complex

1

RNF20*

Histone ubiquitination

GO:0000347: THO
complex

1

THOC2*

Transcription to cytoplasmic
mRNA export coupling

GO:0005697: telomerase
holoenzyme complex

1

SMG6*

Telomere elongation

GO:0030870: Mre11
complex

1

SP100

Meiotic recombination, DNA
repair and checkpoint
signaling

GO:0032116: SMC
loading complex

1

NIPBL*

Chromosome (SMC) complex
to DNA loading

GO:0071204: histone premRNA 3'end processing
complex

1

YBX1*

Histone pre-mRNAs
processing

*: Genes with known modification sites co-occurring with acetylation and phosphorylation.

2.6.3 In vivo phospho-acetyl K motif hits
All the bioinformatic analyses conducted pointed to the acetylation and phosphorylation
of the K motif variants in vivo. After performing dual enrichment and functionally
validating the sites identified the corresponding window sequences were scanned against
the CK2 consensus and the K motif variants (Table 2.22) to identify hits that occur in
vivo in HeLa and U2OS treated with NAM, TSA, and Bx. As a result, several phosphoacetyl peptides were observed matching the linear patterns (Table 2.22, Supp. Table
2.19). No sites were found matching the +1 extended variant pattern either
phosphorylated and/or acetylated at the motif (Table 2.22). Conversely, several hits were
observed for +2 and +3 variants both for the K motif and K motif extended patterns
(Table 2.22, Supp. Table 2.19). Besides K motif hits a number of sites matching the CK2
consensus and the CK2 consensus extended were observed targeted by phosphorylation
and in the vicinity of an acetylation site (Table 2.22, Supp. Table 2.19); 13 of these sites
were found annotated as phosphorylated in the PSP and iPTMnet databases (Supp. Table
2.19) and three sites i.e. Ser520 of NOP56 (ribosomal subunit biogenesis), Ser102 of
SLIRP (nuclear receptor corepressor), and Ser381 of CWC22 (component of the
spliceosome), were found phosphorylated in vitro by CK2 [49]. The sites discovered here
are novel candidates for studying the interplay between CK2-dependent phosphorylation
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and lysine acetylation. For example, the ATP-dependent RNA helicase DDX18, has a
role in ESC self-renewal by antagonizing the polycomb repressor complex PRC2
maintaining the integrity at actively transcribed rDNA loci [87]. The residue Ser136 of
DDX18, matches the CK2 consensus (SEEE); the neighboring residue Lys129 was found
acetylated. Another interesting candidate is PPP1R10 (PNUTS) a scaffold protein of the
PTW/PP1 phosphatase complex which functions in chromatin organization. The residue
Ser124 of PPP1R10 matches the extended CK2 consensus (SEDEE) and it is in the
region of interaction with TOX4 a core member of the complex and in the TFIIS Nterminal domain. The neighboring sites K122, K118, and K131 could be targets of
acetylation. Finally, among the hits, three CK2 interactors were found: HDGFL2,
NOP56, and SLIRP; and six proteins that belong to the CK2 neighborhood: BDP1,
ATRX, CHD5, POLR3A, CORIN, and ALPL (Supp. Table 2.19). The proteins identified
mentioned in the literature with CK2 were BDP1, DNMT1, and PPFIBP1 (Supp. Table
2.19).
Table 2.22. Phosphorylated and acetylated sites that conform to CK2 consensus and K
motif hits identified in vivo in peptides with co-occurring phosphorylation and
acetylation; includes canonical and isoform sequences.
Group

Type

Pattern

No. sites

CK2 minimal

^.{7}[ST][^PKR].[DE]

555

CK2 consensus

^.{7}[ST][DE].[DE]

100

CK2 extended

^.{7}[ST][DE][DE][DE]

14

CK2 extended

^.{7}[ST][DE][DE][DE][DE]

4

K: K motif, p+1

^.{6}[ST]K[DE][DE]

14

K: K motif, p+2

^.{5}[ST][DE]K[DE]

25

K: K motif, p+3

^.{4}[ST][DE][DE]K

15

K: K motif extended, p+1

^.{6}[ST]K[DE][DE][DE]

0

K: K motif extended, p+2

^.{5}[ST][DE]K[DE][DE]

3

K: K motif extended, p+3

^.{4}[ST][DE][DE]K[DE]

3

S/T: K motif, p+1

^.{7}[ST]K[DE][DE]

18

S/T: K motif, p+2

^.{7}[ST][DE]K[DE]

24

S/T: K motif, p+3

^.{7}[ST][DE][DE]K

13

CK2

K motif

84

S/T: K motif extended, p+1

^.{7}[ST]K[DE][DE][DE]

0

S/T: K motif extended, p+2

^.{7}[ST][DE]K[DE][DE]

3

S/T: K motif extended, p+3

^.{8}[ST][DE][DE]K[DE]

4

The function of the protein containing phosphorylated and acetylated sites in sequences
matching the K motif variants was investigated (Table 2.23). As well as the functional
features of the corresponding proteins (Table 2.23, Supp. Table 2.19). Interestingly,
several K motif hits were identified containing known modification sites annotated in
PSP and/or iPTMnet databases.
Table 2.23. Co-occurring phosphorylation and acetylation sites in vivo at K motif
variants (the table includes ambiguously localized sites).
Data set

Sites

Function (UniProtKB)
p +2

CYLC2: T213*;K215 (TEKD)
Structural constituent of cytoskeleton
UT

CYLC2: T308;K310* (TEKE)
FAM133A: T167;K169 (TEKE)
ANO1: S235;K237 (SDKD)

HT
AZI2: S55;K57; (SEKE)

UN

SAMSN1: S10;K12 (SEKE)

CHD5: S1460;K1462 (SEKE)
HN

Calcium-activated chloride channel, modified sites are on
cytoplasmic domain (IPR031287)
Activates serine/threonine-protein kinase TBK1 and facilitates
its oligomerization. Enhances the phosphorylation of NFkappa-B p65 subunit RELA by TBK1.
Immune response stimulates HDAC1 activity (20478393).
Chromatin-remodeling protein part of a NuRD-like, complex
composed at least of GATAD2B, HDAC1, HDAC2 and
MTA3.

DOPEY1: S1281;K1283 (SEKE)

Traffic between late Golgi and early endosomes.

PPFIBP1: T547*;K549* (TEKE)

Disassembly of focal adhesions.

UB
LHX5: S162;K164 (SDKE)

DNA-binding transcription factor activity, RNA polymerase IIspecific. Regulation of neuronal differentiation.

NOL8: S1008;K1010 (SEKEE)

Regulation of gene expression at the post-transcriptional level
or in ribosome biogenesis in cancer cells.

EXOSC1: T111;K113* (TEKD)

Exonucleolytic catabolism of deadenylated mRNA and rRNa
biogenesis.

HB
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MAP7D3: T181;K183 (TDKE)
POLR3A: S63;K65* (SEKD)

Promotes the assembly and stability of microtubules.
Largest and catalytic core component of RNA polymerase III
which synthesizes small RNAs, such as 5S rRNA and tRNAs.
p +3

HB

ANKRD36: S1101;K1104 (SDEKD)

Interactor of IKZF1 (Ikaros).

HN

BOD1L1: S1040;K1043 (SDDKD)

Cellular response to DNA damage stimulus.

HT

POLR3GL: T141;K144 (TEDKEE)

DNA-dependent RNA polymerase catalyzes transcription by
RNA polymerase III.

U: U2OS, H: HeLa, T: Trichostatin A, N: Nicotinamide, B: Bufexamac. * known modification sites.

The boundaries and cellular properties of the K motif hits were searched for information
provided in the SLiMSearch4 analysis (Table 24). This revealed that several of the sites
identified are conserved across Metazoa and QFO and that the sites do not have the
propensity to fold upon binding. The rest of the hits identified in vivo were not returned
by SLiMSearch4 possibly due to their IUPred score not meeting the 0.40 cutoff selected
as default to perform the analysis.
Table 2.24. K motif hits boundaries and cellular properties determined by SLiMSearch4.
Sites

Description

CYLC2: T213 (TEKD)

IUPred: 0.579; Anchor: 0.046; SA: -1; QFO: 0.4286048, 0.27975; Metazoa: 0.5391182,
0.30075; Phospho: Yes; Flank vs motif: 0 (Metazoa) and 0 (QFO)

FAM133A: T167 (TEKE)

IUPred: 0.571; Anchor: 0.061; SA: -1; QFO: 0.5975777, 0.22975; Metazoa: 0.7148451,
0.167; Phospho: No; Flank vs motif: -0.05 (Metazoa) and -0.15 (QFO)

SAMSN1: S10 (SEKE)

IUPred: 0.817; Anchor: 0.333; SA: -1; QFO: 0.7115836503, 0.259; Metazoa:
0.9574487466, 0.149; Phospho: No; Flank vs motif: 0 (Metazoa) and 0 (QFO)

DOPEY1: S1281 (SEKE)

IUPred: 0.456; Anchor: 0.217; SA: -1; QFO: 0.218416177, 0.199; Metazoa:
0.9979192631, 0.01325; Phospho: No; Flank vs motif: 0 (Metazoa) and 0 (QFO)

PPFIBP1: T547 (TEKE)

IUPred: 0.62; Anchor: 0.34; SA: -1; QFO: 0.172981865, 0.35475; Metazoa:
0.4867627347, 0.2425; Phospho: Yes; Flank vs motif: 0.2 (Metazoa) and 0 (QFO)

LHX5: S162 (SDKE)

IUPred: 0.788; Anchor: 0.105; SA: -1; QFO: 0.539949871, 0.2535; Metazoa:
0.9918983853, 0.01025; Phospho: No; Flank vs motif: 0 (Metazoa) and -0.1 (QFO)

NOL8: S1008 (SEKEE)

ANKRD36: S1101 (SDEKD)
BOD1L1: S1040 (SDDKD)

IUPred: 0.568; Anchor: 0.093; SA: -1; QFO: 0.7633968875, 0.21808; Metazoa:
0.8420275525, 0.13712; Phospho: No; Flank vs motif: -0.05 (Metazoa) and -0.05
(QFO)
IUPred: 0.446; Anchor: 0.465; SA: -1; QFO: 1, 0; Metazoa: 1, 0; Phospho: No
IUPred: 0.612; Anchor: 0.095; SA: -1; QFO: 0.300831324, 0.316; Metazoa:
0.647191683, 0.326; Phospho: No; Compositionally biased region:Lys-rich (315-1046)
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POLR3GL: T141 (TEDKEE)

IUPred: 0.618; Anchor: 0.057; SA: -1; QFO: 0.9368245236, 0.11975; Metazoa:
0.854150482, 0.201; Phospho: No; Domain: RNA_pol_3_Rpc31 (1-218);
Compositionally biased region: Glu-rich (142-191)

2.7 Methods and Materials
CK2 substrates. The known CK2 substrates were downloaded from the database
PhosphoSitePlus (PSP) [46] (September 2019) by querying substrates of: “CK2a1”,
“CK2a2”, “CK2b”. The CK2 substrates annotated in PSP matching the K motif were
manually curated to remove entries with not enough supporting evidence including sites
identified as substrates in multiply phosphorylated sequences and in vivo sites changing
upon treatment with non-specific CK2 inhibitors. The known CK2 substrates were
downloaded from the database iPTMnet [57] (September 2019) by querying: “csnk2a1”,
“csnk2a2”, “csnk2b”. The data sets were combined to generate a list of unique substrates
(see Appendix C).
PTM interplay. The within protein post-translational modifications (PTM) interplay data
were retrieved from a local copy of the database PTMcode v2 (October 2019), containing
15,988,098 intra-protein PTM associations. The overlap between the known CK2 sites on
PSP and the interplaying sites on the database PTMcode v2 [47] at a distance of +/-4 and
+/-7 amino acids was determined. Potential phospho-acetyl interplaying sites were also
determined by overlapping K motif hits information retrieved from the iPTMnet database
(phospho-Ser/Thr, see PTM data retrieval below) and Scholz et al. 2015 (acetyl-Lys, see
Acetyl-protein dataset below) study on the acetylome. Since the Lys site represented in
the K motif can harbor other modification types, tentative interplay information for these
modifications (e.g., phospho-ubiquitination or phospho-methylation) was also retrieved
(see PTM data retrieval below). All data processing and analysis steps were performed
programmatically using R (see Appendix C).
PTM data, kinase-substrate relationship, and regulatory sites retrieval. I retrieved
the PTM information and kinase-substrate relationships programmatically from the
iPTMnet database using R’s package iptmnetr v0.1.8 [88]. Information was also
downloaded from the PSP database (September 2019) and accessed locally using bash
and R (see Appendix C).
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Protein functional classification. I retrieved the protein functions for the CK2 substrates
and other proteins of interest from the UniProt database [60]. GO
classification/enrichment (GO BP, GO CC, and GO MF) [89] was performed using
Bioconductor’s packages clusterProfiler v3.14.3 [90] and org.Hs.eg.db v3.10.0 [91] using
human genome as background (see Appendix C). GO classification/enrichment (GO BP,
GO CC, and GO MF) was also performed using DAVID v6.8 [92]; the human genome
was set as background.
In solution peptide synthesis. Peptides containing the K motif (Table 2.25) were
synthesized by the group of Dr. Shawn Li as described in St-Denis et al. 2015 [18]. A Trp
residue was added to the N-terminal for peptide quantification at 280 nm. Three Arg
residues were added to the N-terminal for binding to P81 Ion Exchange Cellulose
Chromatography Paper (Reaction Biology Crop., IEP-01; VWR, 21426-202; Fisher
Scientific, 05-717-2B (WHT3698325)). The CK2 peptide substrate RRRDDDSDDD or
DSD (EZBiolabs [21]) was used as control. The quality of the peptides was assessed by
MALDI Mass Spectrometry (London Regional Proteomics Centre).
Table 2.25. K motif in solution peptides.
Sample ID

MW

Sequence

Type

D12

1690.79

WRRRADETSEKEQ

K p+2, SET-iso 2 Thr23/Ser24

E1

1732.79

WRRRADETSExEQ

ac-K p+2, SET-iso 2 Thr23/Ser24

E2

1701.86

WRRRVNDVSEKEQ

K p+2, Ser33 CTTN

E3

1743.86

WRRRVNDVSExEQ

ac-K p+2, Ser33 CTTN

E10

1649.65

WRRRADDDSKDDD

K p+1

E11

1649.65

WRRRADDDSDKDD

K p+2

E12

1649.65

WRRRADDDSDDKD

K p+3

F1

1691.65

WRRRADDDSxDDD

ac-K p+1

F2

1691.65

WRRRADDDSDxDD

ac-K p+2

F3

1691.65

WRRRADDDSDDxD

ac-K p+3

In vitro phosphorylation of in solution peptides. The synthesized K motif peptides
were dissolved in an adequate solvent (DMSO or distilled water) according to the peptide
charge and quantified using a NanoDrop. A 2.5 mM peptide stock was prepared for each
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peptide. The radioactive CK2 kinase assays were carried as indicated in Turowec et al.
2010 [93] for 10 minutes in triplicate for peptides concentrations of 200 and 500 µM. The
reactions were started by adding 1:5,000 final dilution of untagged CK2ɑ (specific
activity: 424.3 nmol/min/mg, 19.15 mg/ml). Reactions were carried out by adding 2 μL
of 5x Kinase Activation Buffer (250 mM Tris, pH 7.5, 750 mM NaCl, 50 mM MgCl2,
500 μM ATP) spiked with 0.2 μCi/μL γ-32P-ATP (3000 Ci/mmol, PerkinElmer
BLU002A250UC), 6 μL of peptide, and 2 μL of kinase in CK2 dilution buffer (1 mg/ml
bovine serum albumin, 5 mM MOPS, pH 7.0, 200 mM NaCl) for a total reaction volume
of 10 μL. Negative control reactions were performed by adding water instead of peptide
substrate, 5x Kinase Activation Buffer, or kinase. Reactions were stopped by spotting 4
μL of the reaction onto a 1 x 1 cm squares of P81 Ion Exchange Cellulose
Chromatography Paper followed by 4 x 5 min washes in a shaker with 1 % phosphoric
acid (at least 10 ml of 1% phosphoric acid/paper) and 1 x 5 min in a shake with 95 %
ethanol. The papers were dried for 15 min under a heat lamp and exposed for 20 min to a
PhosphorImager screen followed by scanning in a STORM Phosphorimager (Molecular
Dynamics) and quantification using ImageQuant TL software (Amersham Biosciences).
Quantification of incorporation of γ-32P was enabled by spotting a serial dilution of the 5x
Kinase Activation Buffer as standards.
K motif linear patterns. Several linear patterns were deduced from the peptide
phosphorylation data, represented as regular expressions or ScanProsite patterns, and
used for scanning PTM data, phosphoproteome and acetylome sequence window
information, and the human proteome, for finding relevant hits. Example of regular
expressions: [ST][DE]K[DE] or [ST][^PRK]K[DE]; example of ScanProSite:
[ST]{^PRK}K[DE].
Cell culture. U2OS (human osteosarcoma) and HeLa (cervix adenocarcinoma) cells
were cultured in 10 or 15 cm dishes (TPP, FroggaBio) at 5 % CO2 in Dulbecco’s
modified eagle medium (DMEM), supplemented with 10 % Fetal Bovine Serum (FBS,
HyClone), 100 U/ml Penicillin, and 0.1 mg/mL Streptomycin. Cells were maintained
with 2.5 mg/mL plasmocin (InvivoGen, ant-mpp) to prevent mycoplasma contamination
and tested for mycoplasma using the MycoAlert™ Assay Control Set (Lonza).
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Cell treatment and lysis. For immunoblotting and immunoprecipitation assays the cells
were grown up to 80-90% confluency and treated with lysine deacetylase inhibitors for
different periods of time as indicated. After treatment, the culture media was removed,
and the culture dishes were washed twice with ice-cold Phosphate Buffered Saline (PBS).
Cells were harvested in 300 μL-1 mL RIPA (radioimmunoprecipitation assay buffer)
lysis buffer (150 mM NaCl, 1.0 % NP-40, 0.5 % sodium deoxycholate, 0.1 % SDS, 50
mM Tris pH 7.5) supplemented with protease (1 mM PMSF, 7 μg/mL PepA, 20 μg/mL
Leupeptin, 2.9 μg/mL Aprotinin) and phosphatase (1 μM Okadaic acid, 1 μM
Microcystin, 5 mM NaF, 1 mM Sodium orthovanadate) inhibitors. The cells were scraped
from the culture plate or lifted using (PBS)-EDTA. The cell suspension was incubated on
ice for 30 min vortexing every 5 min. Samples were spun at 15,000 g for 15 or at 3,500
for 30 min at 4 oC. Protein concentration was determined by BCA. For immunoblotting
10 μg was loaded onto a 10% SDS-PAGE gel for separation and transfer to a PVDF
membrane. For detections with pan-antibodies between 25-50 μg of protein lysate was
loaded into the gel. Unused lysates were frozen at -80 oC until further use. At least three
biological replicates were obtained for each experiment.
Lysine deacetylase inhibitors. Nicotinamide (Sigma, N0636), Trichostatin A (Sigma,
T8552), Tubacin (Sigma, SML0065), Bufexamac (Sigma, B0760), Tubastatin A
(Selleckchem, S8049). The inhibitors were used at concentrations: 20 mM Nicotinamide
(NAM) in distilled water, 2 μM Trichostatin A (TSA) in DMSO, 10 μM Tubacin in
DMSO, 1 mM Bufexamac DMSO, and 10 μM Tubastatin A in distilled water.
Antibodies. The antibodies used and the corresponding experimental details are shown in
Table 2.26.
Table 2.26. Antibodies used.
Antibody

Description

Experimental details

pSer2 EIF2S2

Rabbit polyclonal.

1:10,000 dilution in 3 % BSA-TBST. Immunogen: ac-pSGDEMIFDPTMSKC-amide peptide

Total EIF2S2

Mouse monoclonal (clone 2F3,
Novus).

1:500 dilution in 3 % BSA-PBST

Primary antibodies
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pSer2/3/8 CSNK2B

Rabbit polyclonal.

1:10,000 dilution in 3 % BSA-TBST. Immunogen: ac-pS–
pS–pS–EEVSMISWFC-amide and ac-pS–pS–pS–EEV-pSMISWFC-amide peptides, 1:1.

pSer162 EEF1D

Rabbit polyclonal (YenZym
Antibodies, LLC, San Francisco,
CA).

1:20,000 dilution in 3 % BSA-TBST. Fraction R1p1.

Total EEF1D

Rabbit polyclonal (YenZym
Antibodies, LLC, San Francisco,
CA).

1:6,000 dilution in 3 % BSA-TBST. Cross-reactive fraction
from pSer162 EEF1D immunization. Fraction R2p2.

Total CK2 (CSNK2A1
and CSNK2A2)

Rabbit polyclonal (BAbCO,
7592773)

1:2,000 dilution in 3 % BSA-TBST. Immunogen: GSTFusion CK2a

Total GAPDH

Mouse monoclonal (clone 6C5,
Millipore)

1:1,000 dilution in 1 % BSA-PBST.

Total PARP (full length:
116 kDa; large
fragment: 89 kDa)

Rabbit polyclonal (#9542, CST)

1:1,000 dilution in 3 % BSA-TBST.

Total CTTN

Mouse monoclonal (clone H-5, sc5579)

1:200 dilution in 3% BSA-PBST, immunoprecipitation [1-2
μg per 100-500 μg of total protein (1 ml of cell lysate)]

Primary antibodies, pan-specific
Phospho-CK2 Substrate
(pS/pT)DXE.

Rabbit polyclonal mix
(MultiMab™ #8738, CST)

1:1,000 dilution in 3 % BSA-TBST.

Acetylated-Lysine
Antibody

Rabbit polyclonal (#9441, CST)

1:1,000 dilution in 3 % BSA-TBST. Immunogen: synthetic
acetylated lysine-containing peptide.

Acetyl Lysine Antibody

Rabbit polyclonal (ICP0380,
immunechem)

1:1,000 dilution in 3 % BSA-TBST. Immunogen:
Acetylated KLH conjugates.

IRDye® 800CW Goat
anti-Rabbit

Goat (926-32210, LICOR).

1:10,000 dilution in 3 % BSA-TBST or LICOR blocking
buffer. Immunogen: Rabbit IgG.

IRDye® 680RD Goat
anti-Mouse IgG (H + L)

Goat (926-68070, LICOR)

1:40,000 dilution in 1% BSA-PBST or LICOR blocking
buffer. Immunogen: Mouse IgG paraproteins

Secondary antibodies

Immunoblotting. After SDS-PAGE separation the cassette(s) was assembled, and the
transfer performed at 0.4 mA for 1 h. The run was stopped, and the membrane(s) airdried, and then re-wetted in methanol for 1 min. Blocking was performed using the
LICOR blocking buffer or BSA-TBS/PBS for 1 h at room temperature. After 3 washes
with TBST/PBST five minutes each, the primary antibody was added in the correct
dilution on the blocking buffer and incubated for 1 h at room temperature or overnight at
4 oC. After incubation with the primary antibody, the washes were repeated, and the
corresponding secondary antibody was added in the blocking buffer and incubated for 1
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h. After incubation with the secondary antibody, the washes were repeated with a final
wash with TBS/PBS. The membranes were scanned using a LiCor Odyssey Infrared
Imaging System managed by the Odyssey v3.0 software. Quantification was performed
by using the up-bottom background method in Odyssey v3.0 software. Lane
normalization was assessed either by detection with the total GAPDH antibody or by
staining with Revert 700 Total Protein Stain for Western Blot Normalization (LiCor).
Lane normalization was performed as indicated by LiCor in the REVERT protocol.
Src substrate cortactin (CTTN) immunoprecipitation. U2OS cell lysates were
prepared in a RIPA buffer supplemented with protease and phosphatase inhibitors. Then
increasing amounts (2, 4, 8, 16 μg) of the mouse monoclonal H-5 antibody (see antibody
table) were tested against 1 mg of total U2OS protein lysate. The lysates were mixed with
the corresponding amount of H-5 antibody and incubated overnight at 4 oC to allow for
CTTN-H-5 complex formation. Next the CTTN-H-5 complex was precipitated by
incubation with 30 μl of A/G UltraLink beads (Thermo. Prod #53132, Lot # NH174763)
for 1 h at 4 oC followed by centrifugation at 3,000 x g for 2 min at 4 oC. For this step, the
beads were pre-conditioned in PBS overnight and washed 2 x in PBS with centrifugation
at 3,000 x g for 2 min at 4 oC in between. Next, the beads were precipitated by
centrifugation at 3,000 x g for 2 min at 4 oC, the supernatant (unbound fraction) was
discarded and the precipitate was washed four times in 1 mL lysis buffer, with
centrifugation in between each wash. After the final wash step for protein elution the
beads were resuspended in 15 µL of lysis buffer and 15 μL of 2x concentrated Laemmli
sample buffer to a total of 30 μL and heated at 95 oC for 5 min. 25% of the samples were
loaded onto a 10 % SDS-PAGE gel and separated. The gel was stained with Gelcode
Blue 1.5 h after fixing it with 50:10:40 MetOH:AceticAcid:MilliQ-H2O (30 min). The
gel was stored in 5 % Acetic acid at 4 oC until processing for in-gel digestion. After
optimization of the amount of protein lysate required, U2OS cell lysates expressing CK2WT (24 h of induction and 16 h of treatment with 1 mg/ml of tetracycline) treated or not
for 16 h with 20 mM NAM were subjected to CTTN immunoprecipitation. The lysates
were pooled together to achieve 2.4 mg of total protein and the resulting sample was
immunoprecipitated with 38 μg of H-5. The immunoprecipitation was performed as
described above except that the bound CTTN was eluted in 60 μL of buffer.
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In-gel digestion. Sample picking and processing was performed at the Functional
Proteomics Facility (London Regional Proteomics Centre). As a note, in-gel protein
digestion was performed both with chymotrypsin and trypsin to increase peptide
coverage.
CK2 manipulation datasets. Several phosphoproteomic data sets relevant to CK2
manipulation were reused from the literature and from our group. 1) Global screening of
in vitro CK2 substrates by an integrated phosphoproteomic workflow by Bian et al. 2013
[49] (see their Supp. Table 1). Control reaction: light dimethyl label; CK2 reaction: heavy
dimethyl label. CK2 substrates: fold change >= 1.5. 2) SILAC (Stable Isotope Labeling
by/with Amino acids in Cell culture) phosphoproteomic study by Rusin et al. 2017 [51].
Light cells: HeLa cells arrested in mitosis and treated with 10 μM MG132 for 30 min
then treated with DMSO for 45 min. Heavy cells: same as light cells but treated with 5
μM CX-4945 for 45 min instead of DMSO [51]. Site localization was selected for
phosphoRS score >= 0.75. Differentially modulated sites were selected with a log2 fold
change cut-off <= -1. 3) SILAC time course phosphoproteomic study by Rabalski [52].
Light: HeLa cells treated for 1, 2, 3, and 4 h with DMSO, respectively. Heavy: HeLa
cells treated for 1, 2, 3, and 4 h with 20 μM CX-4945, respectively. Site localization was
selected Localization prob >= 0.75. Differentially modulated sites were selected with a
log2 fold change cut-off <= -1. 4) SILAC phosphoproteomic study by Cruise
(https://ir.lib.uwo.ca/etd/5164). Light: U2OS cells over-expressing CSNK2A1-WT
treated for 4 h with DMSO. Medium: U2OS cells over-expressing CSNK2A1-WT treated
for 4 h with 30 μM CX-4945. Heavy: U2OS cells over-expressing CSNK2A1-TM
(V66A/H160D/I174A) treated for 4 h with 30 μM CX-4945. Site localization was
selected Localization prob >= 0.75. Differentially modulated sites were selected from
with a log2 Medium/Light fold change cut-off <= -1.
The data sets 1, 3 and 4 were generated with MaxQuant thus all the phosphopeptides of
the same multiplicity (mono-, di-, and tri-phosphorylated) that provide quantitative
information on a given site were aggregated to produce phosphosite quantification data.
For the dataset 2, only phosphopeptide quantification is available. 5)
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Acetylome dataset. A large-scale SILAC acetylome study by Scholz et al. 2015 [24]
(see their Supp. Table 2) profiling the acetylation sites increased in HeLa cells treated
with: 19 different lysine deacetylase inhibitors (targeting all 18 human lysine
deacetylases), Heavy condition, or vehicle, Light condition. The upregulated sites upon
lysine deacetylase inhibitor treatment were selected with a fold change >= 1.5.
Algorithm for the functional prioritization of protein datasets to CK2. The functional
link between CK2 and different sets of proteins (e.g., the acetyl-proteins reported by
Scholz et al. 2015 or human proteins matching the K motif) was determined by
summarizing available biological information from different sources into a score between
0-1, low-high (see Appendix C). The summarized information is as follows: 1) Known
CK2 substrates (Yes: 1, No: 0): kinase-substrate relationships retrieved from IPTMnet
and PSP databases using the Bioconductor’s package iptmnetr v0.1.8 [88] and manual
download, respectively. 2) Known CK2 interactors (Yes: 1, No: 0): direct interaction
evidence retrieved from IMEx consortium [94] using the Bioconductor’s package
PSICQUIC v1.24.0 [75]. 3) Mention in the CK2 literature (Yes: 1, No: 0): genes
mentioned in papers retrieved by querying PubMed with '"Casein Kinase II"[Mesh]' as
input using the Bioconductor’s package reutils v0.2.3 [95]. 4) Neighborhood of CK2
(Yes: 1, No: 0): proteins that “interact” with CK2 in STRING v10 database using
Bioconductor’s package STRINGdb v1.26.0 [96]; STRING score_threshold = 0.7. 5)
Semantic similarity between GO biological processes annotations of CK2 and a given
protein (GO BP, measure=Wang, combine=BMA) (0-1) calculated using Bioconductor’s
package GoSemSim v2.12.1 [97]. Wang method measures the semantic similarity of two
GO terms based on both the locations of these terms in the GO graph and their relations
with their ancestor terms. The combined Best-Match Average (BMA) strategy calculates
the average of all maximum similarities on each row and column between GO terms
associated with two genes [97]. 6) CK2 motif hit, using the ScanProsite pattern
[ST][DE]X[DE] or the regex [ST][DE].[DE] (Yes: 1, No: 0) and semantic similarity for
GO cellular components; the values are averaged to control for proteins containing the
CK2 motif but that don’t colocalize with CK2 (0-1). For the retrieval of protein
sequences for scanning against the CK2 motif the Bioconductor’s package UniProt.ws
v2.26.0 [98] and/or R’s package curl v4.3 [99] were used. 7) Co-regulation with CK2:
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annotations retrieved from ProteomeHD [100], the cutoff was selected to retrieve
approximately the top 150 co-regulated proteins for each of the CK2 subunits (Yes: 1,
No: 0). 8) Differentially modulated by CK2 manipulation (Yes: 1, No: 0): proteins
containing sites differentially modulated by short treatment with the CK2 inhibitor CX4945 in mitotic HeLa cells identified by Rusin et al. 2017 [51].
A “similarity” score to CK2 was calculated for each protein of interest by dividing the
sum of the values observed across the different resources by the total number of resources
i.e., 8 (see Appendix C). Two different scores were calculated: “score” (0-1), all
resources values are averaged and “score_sub”, all resources values are averaged except
for the CK2 targets which is summed to the average score allowing for direct
identification of known CK2 substrates as outliers. To prioritize the list of proteins these
were ranked based on each of the similarity scores using the R base v3.6.3 function rank
and the ties.method=”random”. The latter was chosen to indicate that for certain proteins
there is no information to prioritize them above others while maintaining the original
number of proteins to rank. The scores were represented as boxplots using R’s package
ggstatsplot v0.4.0 [101] and the outlier.coef (Tukey’s method) was chosen in accordance
with the data set of interest to identify a potential list of candidates (see Fig. 5 for an
example). The scores were also clustered using one-dimensional k-means using R base
v3.6.3 package kmeans with a k parameter = 5, selected by the elbow method i.e.,
plotting k (1-20) vs Total within-cluster sum of squares. The clustering allowed for the
identification of five clusters and three main sets: 1) known CK2 substrates, 2) proteins
functionally linked to CK2 that are not CK2 substrates, 3-4) proteins non-related to CK2
or with missing information on the resources used (see Fig. 5 for an example).
Motif discovery. The set of 8,103 unique 13 mer sequences centered at the acetylation
site identified by Scholz et al. 2015 was analyzed for motif discovery using MoMo v5.0.5
[54] command-line tool from MEME suite. The parameters used were motif-x algorithm,
width=13, min-occurrences=15, control peptides from shuffled input peptides, adjusted P
value > 0.01. The motifs discovered with MoMo v5.0.5 were searched against the human
proteome (UniProt reviewed human sequences (canonical and isoforms) downloaded in
April 2019) using the FIMO v5.0.5 [58] command-line tool from MEME suite. The
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FIMO hits (q-value < 0.05) were scanned for K motif occurrences (see Motif scan
above).
Motif scan. The linear patterns or motifs of interest were represented as regular
expressions and searched using R base v3.6.3 functions gregexpr and regexpr against
unique sequence windows provided, for example, in the MaxQuant [102] output for site
identification or unique sequences retrieved from UniProt using R’s package curl v4.3 or
Bioconductor’s package UniProt.ws v2.26.0. For proteome-wide scans several tools were
used. Motif scan against the human proteome was performed using ScanProsite and the
patmatdb tool of EMBOSS v6.6.0 suite using the reviewed human proteome annotated in
UniProt (December 2019). To determine the number of matches by chance of the motif a
random database was generated using the fasta-shuffle-letters command line tool of
MEME v5.1.0 suite [56]; k-mer=1/2/20, shuffle the sequences so that the frequencies of
all words of length 1/2/20 are preserved. Motif scan against the human proteome was also
performed using the FIMO v5.0.5 and MoMo v5.0.5 motifs as input (see Motif discovery
below).
Probability score of finding hits matching a given pattern. The probability of finding
a given pattern by chance in any given protein sequence was determined as indicated in
the database ELM [59] (see ELM help: probability filter). For each position of a given
pattern specifying one or more amino acids the corresponding amino acid probabilities
(derived from UniProt and using an IUPred cutoff of >= 0.4) are summed. Then the sum
of the amino acid probabilities calculated for each position is multiplied. This score was
used to predict degenerate pattern/motif instances.
Motif boundary and cellular context. The K motif incidence in the human proteome
was studied using the SLiMSearch4 framework [63], which allows the proteome-wide
discovery of functional modules with an expected number of instances returned (E) <
10,000 and localized to intrinsically disordered regions, IUPred disordered score >= 0.4
[63]. The results obtained for each K motif were downloaded and processed in R (see
Appendix C). The SLiMSearch4 scores were visualized using R’s package ggstatsplot
v0.4.0. Additional information about domain (UniProt), motif (UniProt), secondary
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structure (PDB), interaction with acetyllysine writers and erasers (PSICQUIC services),
and mutations (COSMIC curated [66]) was also retrieved and overlapped to the positions
matching the K motif (see Appendix C). This information is more specific than
SLiMSearch4 domain analysis because it doesn’t include domain information
corresponding to the flank sequences and is not limited to the K motifs hits outputted by
SLiMSearch4 since the information was retrieved for all hits in the proteome retrieved by
ScanProsite. The consensus matrix for PDB structure was generated using the
Bioconductor’s package Biostrings v2.42.1 [103]. The heatmap was generated using the
Bioconductor’s package CrispRVariants v1.8.0 [104].
SILAC cell culture. U2OS cells were adapted to light (Arg0/Lys0), medium
(Arg6/Lys4) and heavy (Arg10/Lys8) SILAC-dropout DMEM (Wisent) lacking Larginine and L-lysine, supplemented with 10 % dialyzed-FBS (Wisent), 100 U/ml
Penicillin, 0.1 mg/mL Streptomycin, and 400 mg/mL Pro, and the corresponding
isotopically-labeled amino acid (Silantes) (Table 2.27). Total incorporation of U2OS
labeled cells was determined to be > 95% achieved after 5 passages; cells continued to be
passed in SILAC media for future experiments. SILAC media was filtered-sterilized
using 0.2 µm filters (Nalgene).
Table 2.27. Isotopically-labelled amino acids.
Label

Formula

Concentration

L-arginine (Arg-0)

non-labelled

83.9 mg/mL

L-lysine (Lys-0)

non-labelled

60.04 mg/mL

L-arginine (Arg-6)

13C6

86.2 mg/L (0.398 mM)

L-lysine (Lys-4)

4,4,5,5-D4

61.16 mg/L (0.274 mM)

L-arginine (Arg-10)

13C6, 15N4

87.7 mg/L (0.397 mM)

L-lysine (Lys-8)

13C6, 15N2

52.4 mg/L (0.274 mM)

Cell treatment for mass spectrometry. For mass spectrometry analysis, label-free
U2OS and HeLa cells or isotopically-labeled U2OS cells (light, medium, and/or heavy)
were grown up to 80-90% confluency and treated with DMSO (light) or a variety of
inhibitors for 6-16 h (label-free, medium, heavy). For CX-4945 inhibition followed by
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protein digestion with Asp-N, light and medium isotopically-labeled U2OS cells were
treated with DMSO and 30 μM CX-4945 for 6 h, respectively. One phosphoproteome
sample was run in triplicate in the LC-MS. For the study of modulation of CK2dependent signaling by deacetylase inhibitors, labelled-U2OS cells were treated with 2.5
μM TSA and 20 mM NAM in 6 and 16 h experiments. 6 h triple-SILAC experiment:
NAM vs control condition (M/L condition) and TSA vs control condition (H/L
condition). 16 h experiments, triple-SILAC experiment: NAM vs control condition (M/L
condition) and TSA vs control condition (H/L condition); double-SILAC experiment:
NAM (M/L condition) or TSA (M/L condition). At least three phosphoproteomes and
total proteomes from independent biological replicates were measured for each of these
experiments. For determining the acetylation part of the phosphoproteome in a label-free
experiment both unlabelled HeLa and U2OS cells were treated either with 20 mM NAM,
2.5 μM TSA, or 1 mM Bx.
Cell lysis for mass spectrometry. The culture plates were washed in PBS and harvested
in 300 μL-1 mL Guanidinium chloride lysis buffer (6 M Guanidinium chloride (GdmCl),
100 mM Tris pH 8.5, 10 mM tris(2-carboxyethyl)phosphine (TCEP), 40 mM 2chloroacetamide (CAA)). The cells were scraped from the culture plates using GdmCl
lysis buffer, the cell lysates were heated to 95 oC for 5 min, then kept in ice for 15 min,
sonicated with a probe sonifier output 3 for 4 x 30 sec, and heated to 95 oC for 5 min
again. Samples were spun at 3,500 x g for 30 min. The cell lysates were quantified using
a NanoDrop and frozen at -80 oC until further use.
Sample preparation for mass spectrometry. Sample preparation for phosphoproteome
(and total proteome) was performed using the EasyPhos platform as described by
Humphrey SJ et al. 2015 [105] except for protein precipitation. For SILAC experiments
in U2OS the samples belonging to each label were mixed 1:1 before protein precipitation.
For label-free experiments, no mixing was required. Whenever possible the procedures
were carried using low binding 1, 2, and 5-mL tubes.
Protein precipitation. Lysates for mass spectrometry were diluted < 2 M GdmCl.
Proteins were precipitated using methanol-chloroform extraction. For each 100 μL of
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sample, the precipitation was performed as follows: add 400 μL of methanol, vortex well,
add 100 μL of chloroform, vortex well, add 300 µL of Mass Spectrometry grade water,
and vortex well (sample should look cloudy). Next, centrifuge the samples at 14,000 x g
for 2 min and remove the top aqueous layer (protein is visible in the interface). Add a
total of 400 μL of methanol per sample, vortex well, and centrifuge the samples at 14,000
x g for 3 min. After centrifugation, as much methanol as possible was removed without
letting the pellet dry completely.
Protein digestion. Protein precipitates were resuspended in ABC buffer (50 mM
ammonium bicarbonate (ABC), 10 % 2,2,2-Trifluoroethanol) to a maximum of 1.25
mg/mL. Digestion was initiated by the addition of 1:100 Trypsin/Lys-C Mix (Promega,
V5073) resuspended in the ABC buffer for 30 min. After 30 min 1:100 Trypsin
(Promega, V511A) resuspended in the ABC buffer was added to the samples. Samples
were incubated in a shaker for 18 hours at 37°C, 2,000 rpm.
Phosphopeptide enrichment. Phosphopeptide enrichment was performed as described
in Humphrey SJ et al. 2015 [105] using Empore SPE Disks-SDB (styrene
divinylbenzene) 47 mm (66886-U) and 3M™ Empore™ SDB-RPS Extraction Disks (14386-8).
Phosphopeptide dephosphorylation. The eluate from phosphopeptide enrichment was
dephosphorylated in a 50 μL reaction as indicated by NEB protocol: 40 μl of the sample
(~ 40 μg of peptides) in water, 5 μl of 10X of protein metallo-phosphatase buffer (500
mM Tris-HCl, 1 M NaCl), 5 μL of MnCl2, and 1 μL of 1:20 Lambda phosphatase
dilution (1:1,000 final dilution, purified in our lab). The dephosphorylation reactions
were carried out at 37 oC for 4 h.
Acetyl-peptide enrichment. Eluates from the phosphopeptide enrichment step were used
for acetyl-peptide enrichment. The anti-acetyllysine antibody beads (Acetyl Lysine
Antibody, Agarose 5mg, ICP0388-5MG) were washed in immunoprecipitation buffer (50
mM MOPS pH 7.2, 10 mM Sodium phosphate, 50 mM Sodium chloride) 3 x 5 min,
centrifugation in between at 2,000 x g for 1 min. Next, a bead slurry was prepared with
the immunoprecipitation buffer at the appropriate concentration. The phosphopeptides
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were diluted in the immunoprecipitation buffer and 20 μL of the bead slurry was added to
a total of 500 μL. Samples were incubated for 12 hrs at 4 oC on a rotation wheel. Next,
the beads were washed on a rotation wheel 4 times for 2 min with 1 mL
immunoprecipitation buffer, centrifugation in between at 1,000 x g, followed by two
washes with 1 mL distilled water, centrifugation in between at 1,000 x g. All the steps
were performed at 4 oC. Residual water was removed, and the phospho-acetyl peptides
bound to the beads were eluted by adding 50 μl of 0.1% TFA in water, mixing with the
pipette, and incubating for 5 min. The elution was repeated 3 x with centrifugation in
between at 2,000 x g for 2 min, the eluate was collected in a clean low retention vial
using a DNA gel loading tip. The final eluate (150 μL) was filtered using a Microcon10kDa Centrifugal Filter Unit with Ultracel-10 membrane (MRCPRT010) to eliminate
any polymer contamination from the beads. The filters were pre-conditioned by adding
50 μL of 30% ACN and centrifugation at 15,000 x g for 15’. After filtering the eluate at
15,000 x g for 30 min, the filter was washed with 50 μL of 30 % ACN by centrifugation
at 15,000 x g for 15 min. The filtered samples (250 μL) were concentrated in a Speed Vac
vacuum centrifuge at 45 °C under vacuum until ~ 5 μL remained after which ~ 7 μL of
0.1 % FA solution was added to ensure the acidification of the solution.
Total protein clean-up. For total protein analysis clean-up, C18 stage-tips were
assembled in the laboratory using pipette tips and 3 cores of 2 layers of C18 (Empore
SPE Disks C18 47mm diameter, 66883-U) for each tip assembled. Samples were diluted
to 0.1 μg/μL (20 μg in 200 μL) with Buffer A’ (2% ACN, 0.1% TFA). The pH was
checked to be < 3.0 and adjusted if necessary, with 5% or 10% TFA. The tips were
activated with Buffer B’ (80% ACN, 0.1% TFA) 3 x 200 μL, centrifuged at 3,000 x g, 2
min. Next the tips were equilibrated with Buffer A’ (2% ACN, 0.1% TFA) 3 x 200 μL,
centrifuged at 3,000 x g, 2 min. After equilibration 20 μg of the sample in 200 μL was
loaded and centrifuged at 750 x g, 5 min. The flow-through was reloaded and centrifuges
again. The bound samples were washed with Buffer A (2% ACN, 0.2% FA) 3 x 200 µL,
centrifuged at 3,000 x g, 2 min. After washing the samples were eluted with Buffer B
(80% ACN, 0.2% FA), 100 μL, centrifuged at 2,000 x g, 3 min. The elution step was
repeated with 50 µL of Buffer B. The eluates were concentrated in a Speed Vac vacuum
centrifuge at 45 °C under vacuum until 10-20 μL remained after which 1-2 μL of 1% FA
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solution was added to ensure the acidification of the solution.

The final peptide

concentration was determined by measuring A280 using a Nanodrop. For an LC-MS/MS
analysis the samples were diluted to ~ 0.1 g/L (a final load volume of 3-7 μL should
contain 0.5-0.9 μg) and ~ 15 μL were transferred into glass LC-MS vials. Alternatively,
clean-up for total protein was performed using 100 μl bed Pierce™ C18 Tips (87784) as
indicated by the manufacturer.
LC-MS run. Phosphoproteome and proteome samples were analyzed using an Orbitrap
Elite Hybrid Ion Trap-Orbitrap mass spectrometer (Thermo Scientific) or a Q Exactive
Plus mass spectrometer (Thermo Scientific).
Orbitrap Elite Hybrid Ion Trap-Orbitrap mass spectrometer was connected to a NanoFlex
(Thermo Electron Corp., Waltham, MA) nanospray ionization source with a source
voltage of 2.4 KV. Mass spectrometer was operated by Thermo XCalibur software
(version 2.7.0) in a data-dependent mode using an FT/IT/CID Top 10 scheme for
phosphoproteome and Top 20 scheme for proteome samples. MS1 scans were performed
at 120,000 resolution scanning from 400 – 1450 m/z with Automatic Gain Control (AGC)
set to 5 x 102 ions and an isolation window of 1.0 m/z. The top 20 most abundant ions
were selected for MS2. A lock mass ion was enabled for 445.120025 m/z. Peptide ions
were fragmented using a CID (Collision-Induced Dissociation) with Normalized
Collision Energy set to 35%, an activation time of 10 ms, and a Q value of 0.25. Datadependent MS2 scans were acquired in the linear ion trap using rapid scan selection, with
a dynamic exclusion window of 60 seconds.
Q Exactive Plus mass spectrometer was connected to a NanoFlex (Thermo Electron
Corp., Waltham, MA) nanospray ionization source with a source voltage of 2.4 kV. The
mass spectrometer was controlled by Xcalibur software (Thermo, v. 4.0). Discovery data
were acquired in a data-dependent mode (DDA) using an FT/FT/HCD Top 10 scheme for
phosphoproteome and Top 20 scheme for proteome samples. MS1 scans were performed
at 70,000 resolution scanning from 375 – 1500 m/z with Automatic Gain Control (AGC)
set to 3e6 ions and a maximum IT of 250. A lock mass ion was enabled for 445.120025
m/z. Peptide ions were fragmented using an HCD (Higher-Energy Collision Dissociation)
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with Normalized Collision Energy set to 25%. Data-dependent MS2 scans were acquired
at 35,000 resolution, with an Automatic Gain Control (AGC) set to 2e5 ions and a
maximum IT of 108. Dynamic exclusion was 30 seconds.
Both mass spectrometers were connected to an M-class nanoAquity UHPLC system
(Waters). Samples were first injected onto a Symmetry C18 trapping column (5 mm, 20
mm x 180 mm, 100 Å) at a flow rate of 5 μL/min in 99 % mobile phase A (0.1 % FA
(v/v), 1 % mobile phase B (0.1 % FA (v/v) in ACN) for 5 minutes. Peptides were then
separated on an ACQUITY UPLC M-Class Peptide BEH C18 Column, 130 Å, 1.7 mm,
75 mm × 250 mm, operating at a flow rate of 300 nL/min at 35°C. Phosphoproteome
peptides were separated using non-linear gradients: 130 min (initial condition was 1 % B,
which increased to 7.5 % B over 1 min, to 25 % B at 60 min, to 32.5 % B at 74 min, to 60
% B at 80 min, to 98 % B at 85 min and held for 5 min, then decreased to 2 % B over 5
min and held at 2 % for 5 minutes, increased to 98 % B over 5 minutes and held at 98 %
for 5 min, and finally decreased to 2 % B over 5 minutes and held at 2 % for 15 min) or
160 min (initial condition was 1 % B, which increased to 4%B over 1 min, to 25 % B at
120 min, to 50 % B at 130 min, to 95 % B at 135 min and held at 95% for 5 min, then
decreased to 5%B over 5 min and held at 5% for 15 minutes). Proteome peptides were
separated using a 290 min non-linear gradient: initial condition was 5 % B, which
increased to 7.5 % B over 1 min, to 25 % B at 180 min, to 32.5 % B at 220 min, to 60 %
B at 240 min, to 98 % B at 245 min and held for 5 min, then decreased to 2 % B over 5
min and held at 2 % for 5 minutes, increased to 98%B over 5 minutes and held at 98 %
for 5 min, and finally decreased to 5 % B over 5 minutes and held at 5 % for 15 min.
Computational proteomics. For SILAC experiments protein and phosphopeptide
identification was performed using the open software MaxQuant v1.6 [102]. For labelfree experiments, both PEAKS v.9 [106] and SearchGUI v3.3.17 [107] were used. Unless
specified the default, parameters were used for the tools. Protein and peptide searches
were performed using the human proteome containing reviewed canonical and isoforms
sequences only (April 2019).
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MaxQuant analysis. Trypsin/P was set as the protease, a maximum of two missed
cleavages was allowed unless specified, and specific search was selected. For CK2
inhibition SILAC experiment, Asp-N was selected as the protease and a maximum of
three missed cleavages was set. Cysteine carbamidomethylation was set up as fixed
modification for all searches. N-terminal protein acetylation, Met oxidation, and Asn/Gln
deamidation were used as variable modifications for all searches. A maximum number of
4 modifications was accepted per peptide. Protein quantification was performed using
only the unmodified peptides or peptides containing carbamidomethyl cysteine and/or
oxidized methionine. Protein and peptide identification were controlled at 1 % FDR. To
increase identification coverage Match between runs was selected. Phosphorylation and
acetylation site localization probability was filtered by sites with localization probabilities
>= 0.75. The significantly modulated proteins and modified sites (phosphosites and
acetylation sites) were found using a one-sample t-test; the obtained P values were FDR
adjusted 1 %. These and other common processing steps for MaxQuant output were
performed in R (see Appendix C) following a typical Perseus [108] analysis workflow.
SearchGUI analysis. For double enrichment experiments with and without
dephosphorylation, SearchGUI 3.3.17 (October 29, 2019) was used in Windows for
peptide identification and a maximum of four missed cleavages was allowed. All
identification search engines available from within SearchGUI were used. Same variable
modifications and proteome database was set as in the MaxQuant search. The
identification results were visualized and exported using PeptideShaker v1.16.42 (July
10, 2019) [109].
PEAKS analysis. For double enrichment experiments with dephosphorylation PEAKS
v.9 was also used for peptide identification, a maximum of four missed cleavages was
allowed. The other parameters were set as above.

2.8 Discussion
CK2 target sites occur in the vicinity of other modified residues including lysine
acetylation sites. Since lysine is regarded as a negative determinant of CK2-dependent
phosphorylation and lysine acetylation removes the positive charge on this residue the
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breath of our work addresses if these residues are tolerated in the context of the CK2
motif and the extent of the occurrence in the human proteome. To achieve this, we
performed kinase assay, immunoblotting, and phosphoproteomic experiments along with
the processing and analysis of PTM and phosphoproteomic data available in the
databases and the literature. As a result, we identified in vitro a link between CK2dependent phosphorylation and lysine acetylation at the substrate level and determined in
vivo candidates of this regulatory association.

2.8.1 PTM interplay at CK2 target sites
As indicated by our global analysis of CK2 networks, the neighboring residues of CK2
target sites (e.g., +/-7 amino acids) are modified by other constituents of regulatory
networks and are likely involved in interplay. By studying the cis-acting interplay
predicted for the CK2 targets annotated in the PhosphoSitePlus database (PSP),
interplaying lysine acetylation sites were identified based on evolutionary history and
closeness in the protein 3D structure. Although the number of tentative interplaying
acetylation sites observed was not comparable to phosphorylation, likely due to the
prevalence of phosphorylation data, the in silico evidence pointed to the co-evolution of
these two PTM types. An interplay between lysine acetylation and phosphorylation sites
has been previously reported in the H3 histone tail where phosphorylation of Ser10
residue is enhanced by the acetylation of either Lys9 or Lys14 residues [110].

2.8.2 CK2 specificity against peptides containing lysine or
acetyllysine as determinants
Considering that lysine acetylation changes the local properties of the modified sequence
by removing a positive charge and that CK2 is an acidophilic kinase, in solution peptides
resembling the CK2 peptide substrate DSD but containing either lysine or acetyllysine at
positions +1, +2, or +3 from the phosphorylation site were subjected to phosphorylation
by CK2 in vitro. Peptide phosphorylation data indicates that CK2 phosphorylation occurs
in the presence of a lysine residue at position +2 (24.19 %) and, more importantly, that
acetylation at this position promotes phosphorylation to 71.13 % of DSD signal.
Phosphorylation by CK2 does not occur in the presence of lysine or acetyllysine at
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position +1 and +3, with acetyllysine at position +3 being the most tolerated (~ 6.26 %
rescue) among them. These results are in accordance with the working model for CK2
substrate specificity where positions +1 to +3 are deemed the most relevant for
phosphorylation [111,112]. They are also in accordance with a model of the
phosphoacceptor substrate binding region bound to the peptide substrate
RRRADDSDDDDD and with CK2 mutants defective in determinants recognition [113].
In the model and mutational analysis, the Asp determinant at position +2 is only directly
implicated with the Lys49 residue in the phosphoacceptor binding region, whereas the
Asp determinants at positions +1 and +3 are implicated directly/indirectly with a network
of positive residues including Lys198/Arg191/Arg195 and Lys74-77/Arg80/Lys83,
respectively [113]. The latter could suggest a higher tolerance to the chemical nature of
the residue at position +2 due to a decreased necessity for accommodating positive
charges in the phosphoacceptor binding site if position +2 on the peptide substrate were
to be compromised by the substitution of the negative charge. In addition, a web logo
analysis of 433 known CK2 substrates annotated in the database phosphoELM also
pointed to higher variability of determinants at position + 2 with 53 % of the residues
being different than Asp or Glu, compared to 43 % and 25 % for positions +1 and +3,
respectively [114]. In this regard, lysine was demonstrated to be tolerated for CK2dependent phosphorylation at position +2. Furthermore, for the first time acetyllysine was
identified as promoting phosphorylation to a higher extent than lysine further reinforcing
the relationship between acetylation and CK2.
To examine the phosphorylation of endogenous sites containing lysine/acetyllysine at
position +2 by CK2, two peptides conforming to Ser33 of CTTN and Thr24 of SET-iso 2
sites were phosphorylated in vitro. Although the unmodified lysine peptides were not
phosphorylated a modest increase was observed for the acetylated endogenous sequences
compared to DSD. The lower phosphorylation observed for these sequences could be due
to the fact that the control peptide assessed was designed to mimic an ideal CK2 peptide
substrate, whereas endogenous sequences are obviously more complex and other
mechanisms are at play in favoring phosphorylation in the cellular context [115]. We also
performed immunoprecipitation of candidates to perform LC-MS analysis for
identification of modifications on these proteins. However, we were unable to achieve
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immunoprecipitation of sufficient amounts of endogenous protein to enable identification
of PTMs. Thus, the analysis was moved forward to the identification of candidates by
mining the information in PTM databases like PhosphoSitePlus, iPTMnet, and PTMcode
v2 and in the literature.

2.8.3 Identification of K motif candidates
Several linear patterns were derived from the peptide phosphorylation data, referred to as
K motifs variants that conformed to the minimal or extended CK2 consensus motif in the
context of Lys at position +1, +2, or +3. The known CK2 substrates found to contain Lys
at position +2 are Ser429 of TFAP2A (transcriptional regulator), Ser53 of RNPS1
(mRNA splicing), Ser236 of MAPRE2 (microtubule polymerization), and Ser123 of
APEX1 (DNA repair). The number of hits found among the curated CK2 substrates in
PSP was significantly different between the three positions in the K motifs with more hits
found for +2 as might be expected from our studies with peptides. Similar results were
obtained from a global study for the identification of CK2 substrates by using in vitro
CK2 assay followed by phosphoproteomics [49]. In addition, it was observed that the K
motif hits retrieved for position +1 and +3 contain four or more negatively charged
residues, with a total among variants of 10 in vitro phosphorylated hits containing four or
more negative residues towards the C-terminal of the phosphorylatable site. This finding
indicates that a highly negative environment is preferred by CK2 in the context of Lys.
Moving away from in vitro analysis, phosphoproteomic studies where CK2 activity was
manipulated in U2OS and HeLa cells by inhibition with the ATP-competitive inhibitor
CX-4945 were also analyzed. As before, similar results were obtained when analyzing
the matches among the significantly inhibited in vivo sites with most of the site matching
position +2. Interestingly, inhibition of a CK2 site containing Arg in the position +2 was
also observed in vivo. This observation brings up the question of how translatable is the
information obtained for Lys as a determinant at position +2 is to Arg. Overall, a role of
lysine as a positive determinant in the appropriate negative environment was observed
both in vitro and in vivo in sites responding to CK2 activity manipulation. Likely many
other potential sites are yet still to be identified for which the adoption of a
phosphoproteomic strategy where the phosphopeptides are generated using Asp-N may
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contribute to report complementary information to that obtained with conventional
trypsin digestion.

2.8.4 CK2 and lysine acetylation networks
The connection between CK2 and lysine acetylation networks was also explored in silico
to help understand the potential regulatory role of this modification as determinant of
CK2-dependent phosphorylation. As a result, hundreds of proteins known to be
acetylated in the cell identified by Scholz et al. 2015 [24], including 124 CK2 substrates,
ranked high in an algorithm that we developed to predict functional association to CK2
based on protein interaction, GO similarity, CK2 motif scan, literature mentions, CK2
activity manipulation, etc. Among these proteins, we found the histone deacetylase
HDAC1, a CK2 substrate directly linked to the maintenance of acetylation in the cells
[35], and COPS2, a protein encoded by a gene whose expression is regulated by the
lysine deacetylase SIRT7 [116]. COPS2 functions as a component of the COP9
signalosome complex, a regulator of the ubiquitin conjugation pathway with associated
CK2 activity [117]. Taken together, these findings demonstrate the existence of direct
and indirect links between CK2-dependent signaling and the acetylation networks in the
cell. Furthermore, quantitative information gathered on the acetyl-proteins functionally
linked to CK2 pointed to the lysine deacetylase inhibitors Nicotinamide (NAM),
Trichostatin A (TSA), and Bufexamac (Bx) as chemical tools important to study these
links. Moreover, motif discovery analysis revealed that sites known to be acetylated in
the cell occur in negative sequences (adjusted P value < 0.01) indicating a representation
of acidic acetylation motifs in the cell. Interestingly, from several PTM sources it was
confirmed that many sites matching the K motif linear patterns in the human proteome
are targets of acetylation and phosphorylation in the cell, with no distinction among
variants. Instances of phosphorylation and acetylation targeting the same K motif hits
were observed, including the CK2 target sites Ser123 of APEX1 and Ser236 of
MAPRE2. However, although no experimental information is available to establish the
co-occurrence of these modifications at these sites, a small number of these were
predicted to interplay in cis.
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The kinase-substrate relationships retrieved indicate that kinases other than CK2
including the basophilic kinases AKT1, PRKACA (PKA), and PRKCA (PKC)
phosphorylate the K motif hits. This was somewhat expected as the presence of upstream
motifs provide the determinants required for these and other kinases; also, the Lys residue
in the K motifs serves as a positive determinant of phosphorylation by PRKACA and
PRKCA kinases. Furthermore, protein-protein interaction information corresponding to
the proteome-wide K motif hits revealed 411 gene-lysine acetyltransferase (KAT) and
396 gene-lysine deacetylase (KDAC) tentative underlying enzyme-substrate associations,
with > 190 unique proteins hits-KAT-KDAC interaction pairs. The wealth of writers and
erasers acting upon the K motif hits is also expanded by the fact that the Lys matching
the K motif were also found to be targets of methylation, sumoylation, and ubiquitination.
This brings new regulatory players into consideration and makes us ponder on the
intricacy of the regulation and signal integration that could be occurring at the sequences
conforming to the K motifs in cell.
Overall, a list of K motif candidate sites for CK2 phosphorylation was generated from the
integrated information which can serve as a base for future validation experiments.
Among these, three relevant activities that regulate Lys residues modifications in the cell
were identified, i.e., the lysine acetyltransferase KAT6A, the histone methyltransferase
PRDM2, and the deubiquitinase OTUD7B. The site Ser1104 (sKDEEEDE) of the
oncoprotein KAT6A (MYST3) is a CK2 candidate target site. This acetyltransferase is
capable of acetylating H3 and H4 residues in vitro and H3 as part of the MOZ/MORF
complex (source UniProtKB). Furthermore, KAT6A controls the activation of TP53 by
PML via acetylation of 'Lys-120' and 'Lys-382' residues of TP53 (source UniProtKB).
The site Ser1256 (SKEEEE) of PRDM2 is also a candidate for CK2 phosphorylation.
PRDM2 methylates Lys9 of H3 (source UniProtKB), a repressive mark [118]. Finally, it
is important to add that the number of hits found in the human proteome scan equaled the
number of hits found by chance in a shuffled version of the human proteome. This is
because the K motif variants are short linear motifs, however, the probability of finding
them by chance in a protein is still considerably lower than the accepted CK2 consensus
sequence [ST]XXE. According to a study of false occurrences of functional motifs in the
human proteome by Allegra et al. [119], false motif occurrences do not tend to compete
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with true positive hits since there are other boundary conditions required by motifs for
their functionality. For instance, the discrimination of true positive hits by interactors of
similar sites [119]. This differentiation can also be observed, at least in part, in
phosphoproteomic experiments where not all proteins matching the CK2 consensus or
known CK2 substrates are differentially modulated upon manipulation of CK2 activity
[51].

2.8.5 Boundary and cellular conditions of the K motif hits
The analysis of the boundary and cellular conditions of the K motif hits in the human
proteome showed that hundreds of hits for all variants are localized to disordered regions
and that several hits have a propensity to fold upon binding. The latter is an important
property of functional regulatory motifs that provides conformational flexibility and
affinity control [64]. A significant number of hits were also found localized to protein
domains, this should not raise a warning as known modification sites also localize to
functional domains; the latter can be due to the fact that annotated domains may describe
sequences with accessible loops or represent conserved disordered regions [63].
Conservation of the residues matching the motif vs that of the flanks is another important
aspect of the K motif hits. An assessment of the proportion of conserved hit sequences
compared to their direct flanks (5 amino acids up/downstream) showed strong
conservation for ~20 of the hits for K motif position +2. The list includes Ser161 of
BAZ1B, a neighbor of Ser160 which was found inhibited by treatment with CX-4945;
phosphorylation at both sites was confirmed in the proteome database GPMdb. Several
hits were also found present at the same position as the query species motif in more than
10 species. The conservation of K motif hits matches the view that functional motifs in
rapidly evolving intrinsically disordered regions are likely to be more conserved than the
neighboring regions [63].
Another interesting finding regarding the K motif hits is that they are targets of SNPs and
mutations. Notably, several instances where the Lys residue in the K motif was replaced
by Glu, or vice versa, were observed. These changes were recorded for all the three
variants of the K motif, but they could be playing a bigger role at positions +1 and +3
where Lys is not tolerated and Glu is a positive determinant. For example, the Lys1994 to
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Asp substitution in the protein ATM detected in hematopoietic and lymphoid tissue
occurs in a sequence that matches the K motif variant +1, which could potentially impact
the phosphorylation of the known phosphosite Ser1993 and create a target sequence for
CK2. The mutational analysis highlights how proteoform dynamics could change the
primary sequence at K motifs. A functional association between CK2 and ATM pathways
has been discussed elsewhere [120,121].

2.8.6 Integration of phosphorylation and lysine acetylation networks
The evidence gathered both experimentally and in silico for the K motif hits paves the
way for investigating the co-occurrence of phosphorylation-acetylation in vivo and at the
K motif variants. To achieve this, U2OS and HeLa cells were treated with three different
lysine deacetylase inhibitors known to target acetylation sites matching the K motif. After
assessing the treatment for different periods of time, increased lysine acetylation in both
cell lines was observed along with the modulation of the CK2-dependent
phosphoproteome at 6 and 16 h of treatment with both 2.5 µM trichostatin A (pan-HDAC
inhibitor) and 20mM nicotinamide (pan-SIRT inhibitor). The modulation occurs at
phosphosites matching the CK2 consensus or by potentially targeting acetylation sites in
their vicinity. After observation of a direct/indirect impact on the CK2-dependent
phosphoproteome, a double enrichment strategy was applied exploring the acetylated
fraction of the phosphoproteome in U2OS and HeLa cells. To estimate the effectiveness
of the double enrichment, the ms2 spectra identified were searched for the acetyllysine
diagnostic fragment ion at 126.0913 m/z [76,77] at 10 ppm. After comparing the
retention time of the spectra containing the diagnostic fragment between the double
enriched samples and their dephosphorylated counterparts a displacement of the m/z hits
from early to later time points was observed. This is consistent with a decrease in polarity
due to the removal of the phosphorylation group suggesting that the corresponding
acetylated peptides indeed carried phosphorylation and identifying them as phosphoacetyl peptides. This is an exciting discovery using a high-throughput method considering
the assumptions often made in the literature regarding different PTMs types as mutually
exclusive. However, as mentioned before the presence in vivo of phosphorylationacetylation pairs and their interplay in cis has been previously described in the histone
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code [122,123]. To assess the validity of the double enrichment approach, GO biological
process classification was performed and compared to the processes represented in a
large-scale study of the acetylome by Scholz et al. 2015. Overlapping processes were
observed including gene expression, RNA metabolism, chromosome organization,
cytoskeleton organization, apoptosis, and mitosis. Notably, acetylation of HIF1A upon
treatment with the deacetylase inhibitor Bx was also observed as described in Scholz et
al. 2015. However, different modification sites were uncovered in the protein this time,
namely, acetylation of Lys251 in concert with phosphorylation of either Ser247 or
Ser244 residues. These sites localize to the second PAS domain of HIF1A, i.e., PAS-B,
which is necessary for heterodimerization [78]. Interestingly, Ser247 has been previously
identified as a target of CK1; phosphorylation by CK1 impacts HIF1A binding to ARNT
affecting HIF1A induced gene expression [83]. Additionally, several known
phosphorylation and acetylation sites were identified for histones and other proteins, a
direct validation of our findings. Interestingly, many of the co-occurring histone
phosphorylation and acetylation sites identified localize to the C-terminal of H1 histone
variants. This region is a long unstructured domain that functions in maintaining the
binding of H1 to the nucleosome and in chromatin condensation [124]. Functional
classification and enrichment analysis of this set of proteins indicate that they function on
biological processes linked to lysine acetylation, such as histone modification, protein
acetylation/deacetylation, and regulation of chromatin organization. Several kinasesubstrate relationships and one acetyltransferase-substrate relationship were found
highlighting potential enzymes that could be used in follow-up experiments to understand
phosphorylation-acetylation interplay. Among the kinases found are: CDK2, NEK9,
AURKB, and CHEK2, which function in cell cycle regulation; STK4, pro-apoptosis;
IKBKE, inflammation and DNA damage-induced cell death; and PRKCA, positive and
negative regulation of cell proliferation, apoptosis, differentiation, migration, and
adhesion, etc. The acetyltransferase observed was EP300 corresponding to an
autocatalytic site [79]. Importantly, several regulatory functions associated with the
phosphorylation sites in phosphorylation-acetylation pairs were observed regarding
regulation of molecular association, induction/inhibition of activity, change of protein
conformation, alteration of receptor desensitization, receptor internalization, and protein
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stabilization. Given the functional relevance of these phosphorylation sites, we could
speculate that the co-occurring acetylation sites could also display regulatory functions.
In this regard, including all proteins with co-occurring phosphorylation and acetylation
sites, three main relevant groups of writers, erasers, and/or readers were observed:
methylation, acetylation, and phosphorylation. Indicating that co-occurring
phosphorylation and acetylation sites target essential regulators and mediators of cell
signaling.
Finally, and more importantly, several hits for CK2 consensus sites were observed for
phosphopeptides co-occurring with acetylation and more in particular for the K motif +2
variant. Of interest is the PPFIBP1 protein which functions in the disassembly of focal
adhesions. In this case, both the Ser and Lys residues matching the K motif have been
previously found phosphorylated and acetylated, respectively. Furthermore, this protein
was found acetylated in the Bx treatment which inhibits deacetylation by HDAC6 an
enzyme with an important role in microtubule-dependent cell motility by deacetylating
tubulin. It has been shown that HDAC6 inhibition results in a decrease in microtubule
dynamics which in turn results in decreased focal adhesion turnover [125]. Among other
candidates for studying the interplay between CK2-dependent phosphorylation and lysine
acetylation are DDX18, PPP1R10 (PNUTS), HDGFL2, NOP56, SLIRP, BDP1, ATRX,
CHD5, POLR3A, CORIN, ALPL, and DNMT1 (Supp. Table 19).
Overall, our results further extend understanding of the complexity of kinase specificity
and more specifically on CK2 specificity and the role of lysine acetylation. We provide in
silico, in vitro, and in vivo evidence supporting acetylation of lysine as a positive
determinant of CK2-dependent phosphorylation at position +2. We also provide
experimental evidence on the presence of phosphorylation sites, some of which are
known to be regulatory, and neighboring acetylation. This was accompanied by the
identification of several kinases including CK2 that target such phosphorylation sites and
are potential candidates in the search for the interplay between phosphorylation and
acetylation. Thus, our studies lay the groundwork for further low and high-throughput
exploratory and validation experiments.
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2.9 Concluding remarks and implications
Here we combined proteomic, bioinformatic, and molecular biology strategies for
understanding the interplay between phosphorylation and acetylation networks in the cell
(Fig. 2.17). As such, we provide a framework for studying experimentally and in silico
how phosphorylation by protein kinases can be regulated by the addition of a nearby
modification through the exploration of the impact of lysine acetylation on CK2dependent phosphorylation. Applying this framework brought us one step closer to
deciphering the phosphoproteome and its dynamic integration with regulatory PTM
networks. This was possible by generating our own context-dependent datasets and by reusing data available in the literature and databases and thus analyzing it outside the
original context in which they were generated. It was also possible using the R
programming language extended by Bioconductor packages. The development of a datadriven application that summarizes all the main analytical steps that allows the reanalysis
and reuse of the data is recommended (see Chapter 4). In addition, exploring the
functional association of CK2 and biological processes regulated by acetylation such as
chromatin organization is recommended to provide groundwork on the relevance of such
connections (see Chapter 3).
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Figure 2.17. Established framework. Round boxes: main results; orange border: main
experiments.
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Chilibot query: “ck2” AND “acetylation”.
PubMed query: “ck2” AND “acetylation”; STRING representation 0.7 confidence, top 100.
GO biological process enrichment of PubMed query: “ck2” AND “acetylation”; STRING
representation 0.7 confidence, top 100.
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Supp. Table 2.2. Known CK2 target sites annotated in PhosphoSitePlus (PSP) and
iPTMnet databases matching the K motif variants and their function (UniProt).
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Known CK2 target sites annotated in PhosphoSitePlus (PSP) and iPTMnet databases
matching the K motif variants and their function (UniProt). P: position; -p: phosphorylation.
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Supp. Table 2.3. K motif hits from in silico analysis of in vitro high-throughput CK2
kinase assay.
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Sites identified by Bian et al. 2013 [49] that match the K motif variants before and after
filtering of phosphorylation vs control ratio > 1.5.
K motif hits (not including K motif, minimal hits).
Workflow evaluation.
Jurkat cells.
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Supp. Table 2.4. Differentially inhibited phosphosites identified in three different
phosphoproteomic studies of CX-4945 inhibition that match the K motif variants.
Sheet

Name

1

Table 4

Appendix A

Content
Percent of phosphosites identified in three different phosphoproteomics studies that match
the K motif variants.
All identified sites.
Differentially inhibited phosphosites identified in three different phosphoproteomics studies
of CX-4945 inhibition that match the K motif variants.
HeLa cells 20 µM CX-4945 for 1-4 h.
U2OS cells, 30 µM CX-4945 for 4 h.
HeLa mitosis, 5 µM CX-4945 for 45 min.
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Supp. Table 2.5. Motif discovery on acetylation sites identified in Scholz et al. 2015
using MoMo v5.0.5.
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Motif discovery on acetylation sites identified in Scholz et al. 2015 using MoMo v5.0.5.
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Supp. Table 2.6. K motif hits annotated phosphorylated and acetylated in PSP database
(September 2019); does not imply co-occurrence of phosphorylation and acetylation
(September 2019).
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K motif hits annotated phosphorylated and acetylated in PSP database (September 2019);
does not imply co-occurrence of phosphorylation and acetylation.
K motif extended hits targeted by acetylation and phosphorylation (co-occurrence not
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Supp. Table 2.7. K motif hits annotated phosphorylated in PSP database (September
2019).
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K motif hits annotated phosphorylated in PSP database (September 2019).
K motif extended hits targeted phosphorylation.
K motif hits targeted by phosphorylation.
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Supp. Table 2.8. K motif hits annotated phosphorylated in the iPTMnet database
(September 2019) reported acetylated in iPTMnet and/or the Scholz et al. 2015 data and
corresponding PTM interplay from PTMcode v2 (October 2019).
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K motif hits annotated phosphorylated in the iPTMnet database (September 2019) reported
acetylated in iPTMnet and/or the Scholz et al. 2015 data and corresponding PTM interplay
from PTMcode v2.
Phosphorylation (iPTMnet) and acetylation (iPTMnet).
Phosphorylation (iPTMnet) and acetylation (Scholz et al. 2015).
PTM interplay retrieved from PTMcode v2 (October 2019).
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Supp. Table 2.9. Kinase-substrate relationships corresponding to K motif hits annotated
phosphorylated in the PSP and iPTMnet databases (September 2019).
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Kinase-substrate relationships corresponding to K motif hits annotated phosphorylated in the
iPTMnet database (September 2019).
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Appendix A

Kinase-substrate relationships corresponding to K motif hits annotated phosphorylated in
PSP database (September 2019).
Supplemental Material – Chapter 2

Supp. Table 2.10. K motif representation on the human proteome (September 2019) with
FIMO v5.0.5 by using the MoMo v5.0.5 motifs discovered in the acetylation sites
identified in Scholz et al. 2015 as input; unique sequences. UniProtKB human sequences
reviewed and isoforms April 26, 2019.
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Content
K motif representation on the human proteome with FIMO v5.0.5 by using the MoMo v5.0.5
motifs discovered in the acetylation sites identified in Scholz et al. 2015 as input; unique
sequences. UniProtKB human sequences reviewed and isoforms April 26, 2019.
All K motif hits.
K motif extended.
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Supp. Table 2.11. K motif representation on the human proteome using SLiMSearch4;
unique sites on canonical sequences (IUPred disordered cut-off >= 0.4).
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K motif representation on the human proteome using SLiMSearch4; unique sites on
canonical sequences (IUPred disordered cut-off >= 0.4).
All K motif hits.
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Supp. Table 2.12. UniProtKB domain and COSMIC mutations (February 2020)
functional features of K motif hits.
Sheet

Name

1

Table 12

Appendix A

Content
Domain and COSMIC mutations functional features of K motif hits.
Functional domains that contain K motif hits (UniProtKB).
COSMIC mutations, February 2020.
K to E mutations.
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Supp. Table 2.13. Functional features of sequences conforming to K motif hits:
Regulatory Sites, CGS, KDAC-KAT, and Sites in Pathways.
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Functional features of sequences conforming to K motif hits: Regulatory Sites, CGS,
KDAC-KAT, Sites in Pathways.
Regulatory role for K motif hits retrieved from PSP (September 2019).
KDAC and KAT interactors of K motif hits.
K motif hits in Cancer Gene Census (February 2020).
PTM in Reactome pathways.
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Supp. Table 2.14. Summary of CK2 candidate sites matching the K motif.
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Summary of CK2 candidate sites matching the K motif.
Known CK2 substrates curated from PSP and iPTMnet databases.
Human in vitro K motif hits for p+2 and K motif extended p+1 and p+3 variants.
Differentially inhibited phosphosites identified in three different phosphoproteomics studies
of CX-4945 inhibition that match the K motif variants.
PSP K motif extended hits targeted by acetylation and phosphorylation (co-occurrence not
implied).
PSP K motif extended hits targeted phosphorylation.
All candidates.
GO molecular function, level 5: activity, histone, and chromatin.

125

Appendix A

Supplemental Material – Chapter 2

Supp. Table 2.15. CK2 candidate sites modulated by lysine deacetylase treatment in
U2OS cells.
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CK2 candidate sites modulated by lysine deacetylase treatment in U2OS cells.
Supplemental Material – Chapter 2
MS identification and quantification data

Supp. Table 2.16. Peptides with acetylation and phosphorylation sites co-occurrences.
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Peptides with acetylation and phosphorylation sites co-occurrences.
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MS identification data

Supp. Table 2.17. GO level 5 classification of proteins with co-occurring
phosphorylation and acetylation sites.
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Content
GO level 5 classification of proteins with co-occurring phosphorylation and acetylation sites.
GO biological process, level 5, represented in the phosphorylated and acetylated proteins.
GO cellular compartments, level 5, represented in the phosphorylated and acetylated
proteins.
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Supp. Table 2.18. Known sites (iPTMnet and PSP), known kinase-substrate
relationships (iPTMnet), and known regulatory sites (PSP) corresponding to the
identified sites in acetylated and phosphorylated peptides (September and December
2019).
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Content
Known sites (iPTMnet and PSP), known kinase-substrate relationships (iPTMnet), and
known regulatory sites (PSP) corresponding to the identified sites in acetylated and
phosphorylated peptides (September and December 2019).
Known kinase-substrate relationships corresponding to the identified sites iPTMnet,
December 2019.
Regulatory sites annotate in PSP corresponding to the identified sites, December 2019.
Known sites iPTMnet.
Known sites PSP.
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Supp. Table 2.19. CK2 consensus and K motif hits found in vivo and their corresponding
protein function and site modification information.
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Figures

Content
CK2 consensus and K motif hits found in vivo and their corresponding protein function and
site modification information.
K motif hits acetylated and phosphorylated and corresponding functional information.
CK2 consensus hits phosphorylated located nearby acetylation sites.
UniProtKB function.
Functional link to CK2 for [ST][DE].[DE] and extended hits.
Known modification sites for [ST][DE].[DE] and extended hits.
Supplemental Material – Chapter 2
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Supp. Figure 2.1. Functional association STRING network corresponding to the
PubMed query: “ck2” AND “acetylation” represented with Cytoscape v3.8.0; confidence
cut-off score: 0.7, and a maximum number of proteins: 100. A) Histone deacetylation
subnetwork, 17 proteins (FDR < 0.001), B) Chromatin organization subnetwork, 59
proteins (FDR < 0.001), C) Chromatin silencing subnetwork, 25 proteins (FDR < 0.001).
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Supp. Figure 2.2. MALDI quality analysis of in-solution peptides, > 1000 m/z with >
3% intensity. 1 Dalton difference amide C-terminal. P/p: position, ac: acetylation.
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Supp. Figure 2.3. CTTN modification status in U2OS cells. A) Antibody optimization
using U2OS lysate. B) Quantification of antibody optimization. C) PEAKS coverage and
CTTN modifications after in-gel digestion and LC-MS/MS analysis.
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Supp. Figure 2.4. SLiMSearch4 scores for K motif variants A) +1 and B) +3; K motif
extended (ext_SLiMSearch) and all hits (SLiMSearch). Left-Right: Disorder score
(IUPred). Conservation in Metazoa. Conservation in Quest for Orthologs (QFO), Anchor
score (disorder-order transition upon binding). Outliers coefficient (Tukey’s method) =
1.5.
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Supp. Figure 2.5. K motif variants A) +1 and B) +3; K motif extended
(ext_SLiMSearch) and all hits (SLiMSearch). Top-Bottom: Conserved counter (Outliers
coefficient = 1.5), Conservation motif vs flank (Outliers coefficient (Tukey’s method) =
5).

Supp. Figure 2.6. PDB secondary structure information for K motif hits found in the
human proteome scan. H = alpha helix; B = residue in isolated beta-bridge; E = extended
strand, participates in beta ladder; G = 3-helix (3/10 helix); I = 5 helix (pi helix); T =
hydrogen bonded turn; S = bend; “space” = unordered.
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Chapter 3

3

Protein kinase CK2: Regulatory Role in Cellular
Signaling and its Impact on Chromatin Organization

An intricate ensemble of biological networks orchestrates cellular events. These
networks, which include metabolic, cell signaling, protein-protein interaction, genetic
interaction, and gene/transcriptional regulatory networks are precisely regulated in cells
and undergo significant rewiring to promote cancer progression [1,2]. High-throughput
technologies and system analyses continue to expand our understanding of these
networks and how they are modified in cancer. Interestingly, many of the
networks/subnetworks converge, demonstrating the emergent properties and robustness
of biological systems [3]. For instance, attention has recently been drawn to how distinct
signaling pathways that are deregulated in cancer target histones through posttranslational modifications (histone code), which could ultimately change the cell's
epigenetic marks; the latter refers to chemical modifications of histone proteins and DNA
that dictate gene expression without affecting the gene sequence [2]. Epigenetic changes
are known to be key players in cancer by mediating, among other effects, the silencing of
tumor suppressor genes [4,5]. However, when considering the hereditary aspect of
epigenetics it is unclear how histone modifications could transmit the information of the
chromatin structure from mother to daughter cells, how widespread are the mechanisms
involved, and if other mediators are required for the transmission of information [6].
Nevertheless, by changing the modification status of histones the deregulated signaling
pathways in cancer directly impact processes like transcription and DNA repair through
chromatin (DNA and histones) remodeling i.e., local changes in the structure of the
chromatin [7].
Histones represent major structural components within the nucleus, where they
coordinate the assembly of DNA into chromatin. In the cell, histone proteins are modified
by the addition of post-translational modifications (PTMs) such as phosphorylation,
acetylation, methylation, and ubiquitination [5]. The DNA can also be modified through
methylation. The addition, removal, and recognition of these chemical modifications of
histones and DNA are mediated by several catalytic or binding activities often referred to
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as writers (e.g., acetyltransferases and methyltransferases), erasers (e.g., deacetylases and
demethylases), and readers (e.g., ADD, Chromodomain, Bromodomain, 14-3-3, MDB,
and BIR), respectively [8,9]. Similar to histones, the histone-modifying enzymes, and
more generally the chromatin-modifying enzymes (which include DNA-modifying
catalytic activities in addition to histone-modifying activities) can also be the targets of
aberrant signaling pathways in cancer [10], adding another layer of complexity. The
combined action of these enzymes mediates chromatin remodeling, characterized by
dynamic structural changes to the eukaryotic chromatin which are critical for both
transcriptional regulation and chromosome segregation. Consequently, a comprehensive
understanding of the regulatory relationships that modulate chromatin structure and
dynamics is a prerequisite for devising novel and effective therapies in cancer. Towards
this goal, systematic phosphoproteomic and acetylome studies profiling the effect of
kinase and lysine deacetylase inhibitors can provide us with proteome-wide information
regarding the modification status of chromatin-modifying enzymes and their interaction
partners. A detailed review of how signaling pathways modulate histone phosphorylation
upon upstream kinase activation can be found elsewhere [2]. In contrast, the information
pertaining to chromatin-modifying enzymes and their regulation through various
signaling pathways and post-translational modifications spans a functionally more
diverse set of proteins [6,11,12] and has not yet been comprehensively summarized.
One protein kinase that has been linked to chromatin remodeling and transcriptional
regulation is protein kinase CK2 [13,14], a constitutively expressed and ubiquitous
protein Ser/Thr kinase that targets acidophilic motifs (pS/T-[DE]-X-[DE]) found in many
nuclear and cytoplasmic proteins [15]. CK2 also displays Tyr kinase activity evidenced
by phosphorylation of H2A in yeast and mammals [16]. CK2 typically forms a tetrameric
holoenzyme composed of two catalytic (encoded by CSNK2A1 and CSNK2A2 genes,
respectively) and two regulatory (encoded by CSNK2B) subunits [17]. The upregulation
of CK2 catalytic subunits has been described in cancer where it displays pro-survival and
antiapoptotic roles [18]. Both low and high-throughput experiments have corroborated
the extensive network of phosphoproteins modulated by CK2 which includes histonemodifying enzymes such as lysine deacetylases and demethylases [19,20]. In addition, a
regulatory link was established between CK2-dependent phosphorylation and lysine
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acetylation. To extend these observations, we sought to illustrate and summarize the
connections of CK2-dependent signaling with chromatin remodeling (i.e., dynamic
structural changes to eukaryotic chromatin occurring throughout the cell division cycle;
definition as in GO:0006338). Since inhibitors of both CK2 and chromatin-modifying
enzymes are being assessed in the clinic [21,22], of interest are relationships between
CK2 and these proteins that may be useful from the perspective of therapeutic potential
or translational research.

3.1 Exploring the link between CK2 and chromatin
organization
In order to approach this challenge, the functional link between CK2 and proteins
involved in chromatin organization and epigenetics, processes tightly regulated by the
balance of acetylation-deacetylation of histone/non-histone proteins in the cell, was
investigated. For this, several bioinformatic tools and/or their output were applied to
implement a workflow in R that integrates information retrieved from the literature and
databases (Fig. 3.1). First, an automated literature search [23] was performed for finding
the co-occurrence of relevant terms with CK2 using Pubmed and PMC (provides full-text
information) (Supp. Table 3.1). Complementarily, the text mining tool Chilibot [24] was
used to extract relationships between two specific terms e.g., “ck2” and “histone” (Supp.
Table 3.1). Given that Google is a powerful search engine it was also included as a tool
for literature search. Next, lists of proteins involved in chromatin organization and
epigenetics were retrieved from AmiGO [25] and Reactome [26] databases. If necessary,
the protein mentions extracted from the databases were mapped [27] to the common
database identifiers UniProt accession numbers and identifiers, HUGO gene symbols, and
Entrez GeneID. As a result, lists of proteins involved in chromatin organization and
epigenetics were generated. These lists were searched for CK2 substrates, CK2
interactors, literature co-occurrence with CK2, members of relevant protein complexes,
presence of CK2 consensus motif, and proteins changed in phosphoproteome studies as a
result of CK2 manipulation (Fig. 3.1, see Chapter 2). Since database information may not
be regularly updated depending on the source, the information retrieved from the
literature in the first step was essential to expand the analysis and not to overlook relevant
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proteins and their association with CK2. If appropriate, the results were represented as
networks such as the involvement of CK2 in the regulation of chromatin-remodeling
complexes.

Figure 3.1. Bioinformatics workflow implemented for finding chromatin organization
proteins functionally linked to CK2. Left: examples of what to expect from literature and
ranking analysis.
All the proteins in the chromatin organization data sets (Supp. Table 3.2) were scored and
ranked using the functional link to CK2 using the algorithm described in Chapter 2 (Fig.
3.2A). High scoring proteins that are known CK2 substrates involved in chromatin
organization were observed (Fig. 3.2B-D, Supp. Table 3.3) along with a few high scoring
chromatin organization proteins that are not known CK2 substrates but are strongly
linked to CK2 (Fig. 3.2B-D, Supp. Table 3.3). Overall, several proteins functionally
linked to CK2 were identified using the designed workflow, serving as a motivation to
further summarize and investigate these findings.
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Figure 3.2. Chromatin organization proteins functionally linked to CK2. A) Annotations
included and score calculation B) AmiGO chromatin remodeling. C) Reactome
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chromatin-modifying enzymes. D) Reactome epigenetics. Outlier coefficient (Tukey’s
method) = 1.5.

3.2 CK2-dependent signaling and histones
Histone proteins form the nucleosomes along with DNA. The nucleosome is the basic
organizational unit of genomic DNA in the cell, which assembles into a higher proteinDNA structure known as chromatin. Many events regulate the organization of
nucleosomes (i.e., assembly, arrangement, and disassembly) and thus the access to the
DNA, including the modification of histones and chromatin-associated proteins, the
incorporation of histone variants, histone replacement, histone folding, and ATPdependent nucleosome remodeling. Such events confer dynamism to the chromatin
throughout the cell cycle allowing and/or resulting from transcription regulation, DNA
replication, DNA repair, cell cycle progression, etc. [28–30].
Histone modification by phosphorylation profoundly affects histone-DNA interaction by
masking the positive charge of histones and it also provides a recognition site for
chromatin-associated proteins [31]. Consequently, there has been considerable focus on
investigating the interplay between kinases and histones and its impact on chromatin
organization, i.e., chromatin specification, formation, and maintenance. To gain an
appreciation of the extent of this regulation, the phosphorylation of histones is mediated
by at least 20 different kinases including CK2 (Supp. Table 3.1), PRKCD, JNK, and
AURKB [2]. Collectively, phosphorylation of histones has been linked to transcription,
DNA damage response, apoptotic chromatin condensation, and mitosis [2]; all these
processes require a certain degree of accessibility to the DNA.
In particular, the CK2-dependent phosphorylation of histones plays a role in DNA
damage, transcriptional elongation, and in the regulation of transcription [31]. CK2
targets Ser1 residue of H4 in yeast in response to double-strand break DNA damage as
part of the DNA-repair histone code playing a role in non-homologous end joining;
phosphorylation of Ser1 by CK2 occurs independently of the cell cycle [32]. In yeast,
phosphorylation of Ser1 negatively impacts H4K5, H4K8, and H4K12 acetylation by the
acetyltransferase NuA4 [33]. The proposed mechanism is that the deacetylase complex
Sin3/Rpd3 mediates deacetylation of H4 tails while the associated CK2 activity
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phosphorylates Ser1 blocking further acetylation [33]. The impact of decreased H4 tail
acetylation is not well understood but it could constitute a stable epigenetic mark based
on a study in early murine development [34] and that along with phosphorylation of H2A
at Ser129 promotes genome stability upon DNA damage [33]. CK2 also phosphorylates
Tyr57 residue of H2A; the modification of this residue is thought to regulate the activity
of the SAGA complex and thus transcriptional elongation [35]. The SAGA complex
localizes to the basal transcriptional machinery recruited to gene loci, where it mediates
histone acetylation of promoters and facilitates transcriptional elongation by
deubiquitinating and acetylating histones [36]. In yeast and humans, both Tyr57Phe H2A
mutant (non-phospho mimic) and CK2 inhibition were shown to enhance SAGA’s H2B
deubiquitinase activity [35]. In cancer, the enzymatic activities of the SAGA complex
have been linked to tumorigenesis and poor prognosis [36]. Thus CK2-dependent
phosphorylation of H2A, a direct target of the complex, points to a potential strategy to
modulate SAGA’s role in cancer. Additionally, a recent study showed in vitro evidence
of phosphorylation of Thr11 residue of H3 by CK2 in response to nutritional stress in
yeast [37]. As summarized here, beyond phosphorylation, CK2 has an overall impact in
the histone code (Table 3.1), highlighting a crucial regulatory role of this kinase on
chromatin dynamics.
Table 3.1. Histone modification functionally linked to CK2.
Histone

Modification

CK2

Proposed functional relevance

H4 (yeast)

Ser1-p

Phosphorylation by

Role in DNA damage repair. Possibly inhibitory of acetylation
at H4K5, H4K8, and H4K12 [33].

H2A (yeast,
human)

Tyr57-p

Phosphorylation by

Regulation of transcriptional elongation. Impact on H2B
ubiquitination levels [35].

H3 (yeast)

Thr11-p

Phosphorylation by

Response to nutritional stress in yeast [37].

H3 (human)

Lys9-me3

Downregulation of

Senescence and DNA damage response [38-40].

H3 (yeast)

Lys56-ac

Downregulation of

H3/H4 turnover [43].

Furthermore, CK2 regulates histone methylation and acetylation with an impact on gene
expression and histone recognition, folding, and turnover (Table 3.1). A link between
CK2 and H3K9me has been described in cellular senescence and DNA damage response.
Specifically, the histone methyltransferase EHMT2 (G9a) which catalyzes H3K9me1 and
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H3K9me2 was recently found to be a target of CK2 at Ser211 in the DNA damage
response [38]. On the other hand, CK2 downregulation in MCF-7 and HCT116 cells
resulted in increased H3K9me3 due to an increased expression of the H3K9
trimethyltransferase SUV39H1 (KMT1A) and a decrease in EHMT1 and EHMT2 (GLP)
[39,40]. H3K9me3 is a repressive histone-mark, localized to constitutive heterochromatin
and tissue-specific genes, that prevents transcription factor binding [39].
Correspondingly, the CK2-driven increase of H3K9me3 was shown to promote the
binding of CBX3 (HP1γ) to H3K9me3, a marker of senescence-associated
heterochromatin foci, resulting in the repression of cell cycle progression genes [40].
Similarly, CK2 phosphorylation of Ser11/14 in human and mouse cell lines enhanced
CBX5 (HP1ɑ) binding to nucleosomes containing H3K9me3 [41,42]. CBX5 is a
component of heterochromatin that functions in repression. In yeast, CK2 depletion was
shown to promote H3K56ac in transcribed genes (permissive mark) product of H3/H4
turnover, resulting in antisense and cryptic transcription [43]. Interestingly, the histone
chaperone Spt6 required for H3/H4 turnover was shown to be a target of CK2. Mutants
mimicking Spt6 N-terminal phosphorylation by CK2 decreased H3/H4 exchange
favoring proper chromatin refolding after transcription [43].
Finally, CK2 could potentially impact histone acetylation through the phosphorylation of
ANP32A (PP32) a component of the INHAT (inhibitor of histone acetyltransferases)
complex [44]. The INHAT complex binds and protects histones tails from the
acetyltransferases CREBBP, EP300, and PCAF [44,45]. INHAT is composed of two
highly acidic proteins SET (isoform 1: TAFIA, isoform 2: TAF1A), and ANP32A [46],
which contain low-complexity acidic regions (LCAR). Multiple acetylation and single
phosphorylation of H3 tails have been shown to inhibit the binding of the INHAT
complex [45]. ANP32A is a moonlighting protein, which functions as a regulator of
transcription, apoptosis, PP2A activity, etc. [47]. CK2 phosphorylates the C-terminal
residues Ser158 and Ser204 of ANP32A located at a region necessary for its tumor
suppressor function and at the LCAR, respectively. In the context of transcriptional
regulation, the deletion of the LCAR region did not have an impact on the binding to
histones, but deletion of both LCAR and the tumor suppression region resulted in
impaired binding [44]. In correspondence, CK2-dependent phosphorylation of Ser158
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alone or in combination with the phosphorylation of Ser204 could increase the negative
charge of the LCAR and its adjacent region enhancing INHAT activity; however, the
implications of phosphorylation by CK2 are unknown.

3.3 CK2-dependent signaling and chromatin-modifying
enzymes
The covalent modification of chromatin is dependent on a diverse group of molecular
functions referred to as chromatin-modifying enzymes. This group contains “writer” and
“eraser” proteins, which catalyze the addition and removal of the modifications,
respectively. Examples of writers are kinases (as previously discussed for histones),
acetyltransferases, and methyltransferases whereas their opposing erasers are
phosphatases, deacetylases, and demethylases, respectively. These enzymes [6] are also
subjected to covalent modifications themselves, acting as proxies for signal integration
and storage in the chromatin [2]. The latter connects diverse stimuli such as metabolic
changes, hypoxia, growth factors, etc., with changes to chromatin organization. Changes
introduced to the chromatin can be sensed by a group of proteins called “readers” and/or
acted upon by other chromatin-modifying proteins or associated molecular complexes
[10]. For example, phosphorylation of the DNA methyltransferase DNMT1 by AKT
increases its resistance to proteasome-dependent degradation, which could in part explain
the aberrant DNA methylation observed in cancers with abnormal levels of AKT pathway
activation [48]. In addition to writers and erasers, the chromatin-modifying group also
includes proteins that mediate ATP-dependent nucleosome remodeling or “remodelers”.
Modification of these remodelers can regulate their function in protein-DNA interaction
disruption, nucleosome sliding, and deposition of histone variants [10]. For instance, the
SAGA complex, mentioned before for its role in histone acetylation, can also acetylate
the remodeler complex RSC in yeast [49].
To further investigate the extent to which proteins involved in chromatin organization
(Reactome: R-HSA-3247509 and R-HSA-212165, AmiGO: GO:0006338) are modified
and the signaling pathways involved the corresponding kinase-substrate relationships and
the regulatory roles of such modifications were retrieved from the databases iPTMnet and
PhosphoSitePlus (Supp Fig. 3.1). As a result, it was found that the chromatin

141

organization proteins display several PTM types, with more information available on
phosphorylation (> 600 sites) (Fig. 3.3A). In this regard, around 160 chromatin
organization proteins were found phosphorylated by approximately 170 kinases involving
more than 1000 kinase-substrate relationships (Fig. 3.3A). Among the top kinases for
which information is available, CK2 appeared with more than 90 phosphosites reported
(Fig. 3.3B).

Figure 3.3. Merged kinase-substrate relationships found in PhosphoSitePlus (PSP) and
iPTMnet databases. A) Summary of available information. B) Top kinases with
information available. C) Merged kinase-substrate relationships found for proteins with
EC numbers. D) Top kinases with information available evidencing from C. E) CK2 and
HDAC-containing complexes; complex functions.
Next, information on chromatin organization proteins that display enzymatic activity was
retrieved by selecting those with EC numbers. As a result, 50 enzymes were found to be
modified by 92 kinases (Fig. 3.3C). Among the top kinases (sites >= 20) for which
information is available CK2 could be found (Fig. 3.3D). CK2 was shown to
phosphorylate not only the lysine deacetylases HDAC1, HDAC2, HDAC3, and SIRT1,
but also the lysine demethylase KDM1A, and the lysine methyltransferase EHMT2 (Fig.
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3.3C). These activities are critical in modulating chromatin organization by
erasing/writing acetyl or methyl groups from histones and non-histone proteins. Histone
acetylation affects nucleosome assembly in concert with histone chaperones and makes
chromatin more permissive by disrupting histone-DNA binding, deacetylation and
methylation oppose this effect [50]. Maintaining the balance between acetylationdeacetylation and methylation-demethylation is essential for transcription regulation as it
dictates the accessibility to the DNA. Correspondingly, loss of histone acetylation and
methylation have been identified as common hallmarks in cancer [5].
The observation of CK2-dependent phosphorylation of several chromatin-modifying
enzymes reinforces the view of a global impact of CK2 signaling on chromatin dynamics
under normal and abnormal conditions (Fig. 3.3D). However, additional information is
still necessary to fully comprehend the impact of the CK2-dependent phosphorylation
events in chromatin organization. Briefly, CK2 phosphorylates HDAC1, HDAC2, and
HDAC3 at several sites, which increases their deacetylase activity and regulates their
binding to members of transcriptional repressor complexes [51–54] (see next subsection),
potentially modulating a plethora of biological processes and pathways that require
HDAC activity. In fact, CK2 can have important regulatory roles in HDAC1/2 containing
complexes that function as corepressors or activators depending on the signaling context
and are essential in maintaining transcriptional silencing, suppressing cryptic
transcription, and priming for a transcriptional response [55] (Fig. 3.3E). SIRT1
phosphorylation by CK2 modulates its enzymatic activity [56,57]. Phosphorylation of
EHMT2 by CK2 has only been studied in DNA repair thus the role of phosphorylation in
histone methylation is unknown [38] (see the previous section). ERCC3 (XPB) is an
ATP-dependent DNA helicase that functions in general transcription and DNA repair;
phosphorylation of Ser94, Ser751, and Ser892 by CK2 impacts its role in nucleotide
excision repair by modulating DNA damage recognition [58,59]. Finally, CK2 also
phosphorylates Ser10 and Ser506 residues of TOP1, a chromatin remodeling protein that
releases the supercoiling and torsional tension of DNA. Phosphorylation by CK2 may
enhance TOP1–DNA binding and relaxation of plasmid supercoils, but this has been
tested in vitro only [60].
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3.3.1 CK2-dependent phosphorylation of HDAC lysine deacetylases
CK2 regulates the activity of several lysine deacetylases, main regulators of transcription
by mediating the deacetylation of both histones and non-histones proteins [61].
Acetylation of histones is thought to induce transcriptional activation by allowing the
access of transcription factors to the chromatin [62]; conversely, deacetylation, in
general, is regarded as an event that induces transcriptional repression of gene expression
[63]. The HDAC superfamily of lysine deacetylases is composed of four classes (class IIV) distributed across two structurally distinct protein families: the HDAC (histone
deacetylase) and SIRT (SIR2 regulator) families. The classes are defined by their
structural and sequence homology to yeast proteins as follows: class I (HDAC1, HDAC2,
HDAC3, and HDAC8) shares homology with Rpd3-like proteins, class II (IIa: HDAC4,
HDAC5, HDAC7, and HDAC9; IIb: HDAC6, HDAC10) with Hda1-like proteins, and
class III (SIRT1-7) with SIR2-like proteins; class IV (HDAC11) shares homology with
classes I and II [61]. The discussion on the regulatory role of CK2 on the HDAC family
follows; the discussion of SIRT family regulation is covered later.
CK2 has been shown to phosphorylate HDAC1, HDAC2, HDAC3, and HDAC6 proteins.
The functional implications of CK2 phosphorylation of HDAC1-3 have been well
documented [19,51–54,64–68] whereas phosphorylation of HDAC6 was only described
recently [69]. The CK2-dependent phosphorylation of HDAC1, HDAC2, and HDAC3 is
of interest since these form corepressor complexes with ligand-free nuclear receptors and
with chromatin remodelers [63,70]. In the early 2000s, mass spectrometry analysis of
HDAC1 allowed the identification of Ser421 and Ser423 residues as main
phosphorylation sites conforming to the CK2 motif. Furthermore, Ser to Ala substitutions
of these residues led to a decrease in the deacetylase activity and impaired complex
formation of HDAC with transcriptional regulators [65]. Around the same time, the
phosphorylation of the C-terminal domain of HDAC2 by CK2 at Ser394, Ser422, and
Ser424 sites was described with Ala substitution showing the same detrimental effects on
the enzymatic activity and complex formation [66]. The phosphorylated form of HDAC2
was found to have low abundance in estrogen receptor-positive human breast cancer T5
cells and was bound to chromatin in a complex with HDAC1, and the transcriptional
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regulator SP3 [67]. Regulation of HDAC1/2 by CK2 also extends to mitosis where
phosphorylation promotes the dissociation of complexes containing both HDAC1 and
HDAC2, possibly to allow the formation of mitotic-specific complexes [52]. Moreover,
under hypoxia, phosphorylation of HDAC1/2 by CK2 was found to promote HDAC1/2mediated inactivation of the tumor suppressor gene VHL and subsequent HIF1A protein
stabilization in HeLa cells [19]. Since CK2 directly activates HDAC1/2, exploring the
effect of CK2 inhibitors, alone or in combination with other drugs, on HDAC1/2
mediated transcriptional repression will help to further reveal the functional context for
the association between CK2 association and the HDAC family. In this regard, a recent
experiment combining the clinical CK2 inhibitor CX-4945 and the proteasome inhibitor
bortezomib showed synergistic effects in B-cell acute lymphoblastic leukemia by
inducing the association between the RELA subunit of NFκB and HDAC1 and the
subsequent repression of the anti-apoptotic genes BCL-xL and XIAP [71].
Early studies also showed HDAC3 phosphorylation by CK2 at the Ser424 site not found
in HDAC1 and HDAC2 [66]. Phosphorylation of HDAC3 by CK2 is also critical for its
deacetylase activity and may be counteracted in cells by the action of a complex
containing Ser/Thr phosphatase-4 activity [68]. Recently, a mitotic complex containing
CK2, HDAC3 phosphorylated at Ser424, and the linker histone H1.3 was identified in
HeLa cells suggesting a role of CK2-dependent phosphorylation in chromatin compaction
and microtubule stability [72]. CK2 also regulates HDAC3 function by an indirect
mechanism, which involves CK2-dependent phosphorylation of PDCD5 at Ser119.
PDCD5 is a novel protein found downregulated in cancer patients where overexpression
facilitates genotoxic stress-induced apoptosis mediated by TP53 [73]. Phosphorylation of
PDCD5 by CK2 enhances its stability and facilitates its nuclear import. In the nucleus,
PDCD5 promotes the dissociation of HDAC3 from TP53 in response to genotoxic stress
which leads to HDAC3 proteasomal degradation and the stability of TP53 by increased
acetylation [73]. Thus, CK2-dependent phosphorylation not only regulates HDAC3
deacetylase activity directly but also its stability.
HDACs have been implicated in cancer both as members of HDAC-containing
transcriptional repressor complexes and as deacetylases of non-histone proteins [74,75].
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For instance, differential expression patterns of HDACs have been reported in gastric
cancer for HDAC1 and HDAC2, and in colon and breast cancer for HDAC3 and HDAC6
[63]. Hence, it is not surprising that HDAC inhibitors are either FDA approved (e.g.,
SAHA) or being tested in the clinics as chemotherapeutic agents [76]. Given, that CK2
can enhance the activity and/or the stability of these deacetylases combined therapies of
HDAC and CK2 inhibitors could be beneficial for cancer treatment. In fact, a recent
study described the synthesis and evaluation of dual inhibitors derived from the SAHA
and TBB compounds, which are inhibitors of HDAC1 and CK2, respectively. The study
showed enhanced pro-apoptotic effect for the dual compounds compared to their parental
counterparts [77]. These dual compounds constitute a starting point and further
experiments are needed to understand if synergistic/additive effects can be achieved
when combining HDAC and CK2 inhibitors.

3.4 CK2-dependent signaling and regulation of gene
expression
Regulation of gene expression is necessary to respond and adapt to stimuli and stressors
in cells. Such regulation involves coordinated events by chromatin-modifying enzymes to
open or restrict the accessibility of transcription factors and the transcriptional machinery
to the DNA. In the cell, three large HDAC1 and HDAC2 containing transcriptional
repressor complexes can be found: SIN3 (SIN3A/B), NuRD (nucleosome remodeling and
histone deacetylase), and CoREST (corepressor of RE1-silencing transcription factor)
complexes (subunits of each complex listed in Supp. Table 3.4). SIN3 and NuRD share
HDAC1, HDAC2, RBBP4, and RBBP7 proteins suggesting the existence of an HDAC
complex that matures into these repressor complexes; CoREST and NuRD contain
KDM1A as an auxiliary subunit (Figure 3.3E). These complexes regulate the balance of
histone deacetylation/acetylation and act as scaffolds for context-specific recruitment of
other chromatin-modifying enzymes facilitating chromatin compaction and thus
repressing transcription [78]. Recent studies also indicate the role of these complexes in
transcriptional activation [55]. This may be a functional dichotomy but may serve a role
in transcription priming. A balance between acetylation and deacetylation is essential in
priming transcription by maintaining promoters in a more responsive state that can be
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switched between repression and activation (see [55] for a comprehensive review). Since
CK2-dependent phosphorylation directly enhances the deacetylase activity of these
complexes a potential role of CK2 in transcription priming may be considered,
particularly shifting the balance towards a repressive state. However, CK2 has also been
shown to phosphorylate and/or interact with other core and auxiliary members of these
complexes, suggesting a more intricate and context-dependent role for CK2-dependent
regulation in maintaining such balance. The multiple functions and auxiliary subunits of
these complexes have been discussed elsewhere [79,80] here we focus on presenting
evidence that supports a regulatory role by CK2.
The SIN3 complex functions as a scaffold that recruits lysine deacetylases, methylases,
demethylases, methylated-DNA binding proteins, and transcription factors to regulate
gene expression; a role in DNA repair, transcription elongation stalling, and proteins
stability has also been proposed [79]. CK2 has been shown to phosphorylate BMRS1 [81]
an auxiliary subunit of SIN3. BRMS1 is a nuclear transcriptional repressor related to
SUDS3 adapter protein (a core component of SIN3 complex), that facilitates the
recruitment of SIN3 to promoter regions and down-regulates the expression of antiapoptotic NFκB responsive genes [82]. BRMS1 has been shown to inhibit metastasis in
breast cancer and melanoma with the region coding for BRMS1 often lost in late-stage
breast cancer [83]. CK2 phosphorylation of BRMS1 at Ser30 residue promotes BRMS1
nuclear export by YWHAE and its ubiquitin-dependent proteasomal degradation in
response to TNF treatment. In correspondence, Ser30Ala mutants display a reduced level
of metastases in orthotopic xenograft lung cancer models [81]. CK2 also phosphorylates
components of the NFkB signaling pathway extending its regulatory role both upstream
and downstream of BRMS1 function in metastasis [84].
The NuRD complex is formed by the shared HDAC complex and MTA1/2/3 (chromatin
and deacetylase binding), MBD2/3 (methylated-DNA binding), CHD3/4 (DNA helicase,
nucleosome remodeling), and GATAD2A/B (protein bridging and DNA binding)
proteins [78]. A literature search showed that CK2 could be phosphorylating GATAD2A
and GATAD2B in mitotically arrested HeLa cells as decreased phosphorylation at
Ser107 and Ser129, respectively, was observed upon treatment the CK2 inhibitor CX-
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4945 [85]. Interestingly, the phosphorylation of GATAD2B at Ser129 was somewhat
rescued by the expression of an inhibitor tolerant CK2 mutant variant in U2OS cells
treated with CX-4945 (https://ir.lib.uwo.ca/etd/5164).
As a member of the CoREST complex KDM1A has been linked to breast cancer
metastasis, negative regulation of differentiation in neuroblastoma, and acute myeloid
leukemia [86]. Overexpression of KDM1A has been described in glioblastoma, bladder,
and breast cancer, among others [87]. Recently, KDM1A inhibition in glioblastoma stem
cells was shown to induce apoptosis and differentiation [88]. In addition, KDM1A
demethylates both TP53 and DNMT1 (DNA cytosine-5-methyltransferase).
Demethylation of TP53 affects interaction with its repressor positively regulating
apoptosis while demethylation of DNMT1 (DNA methyltransferase) stabilizes the
proteins contributing to the maintenance of the DNA methylation pattern [86,89,90].
Phosphorylation of KDM1A by CK2 occurs at several sites (Ser131, Ser137, and Ser166)
on the N-terminal region [91] and modulates KDM1A function in DNA damage [90].
Phosphorylation at Ser131 and Ser137 promotes KDM1A interaction with the E3
ubiquitin ligase RNF168 and its recruitment to DNA damage sites where KDM1A can
demethylate H3 and RNF168 ubiquitinates H2A. KDM1A phosphorylation also promotes
RNF168 interaction with TP53BP1 and its subsequent ubiquitination; TP53BP1
ubiquitination is essential for the non-homologous end joining pathway. Furthermore,
phosphorylation of Ser131 and Ser137 has been linked to cell proliferation and survival
after treatment with bleomycin or etoposide [90].
CK2 also has the potential to modulate the corepressor complexes NCOR and SMRT
[92] (Supp. Table 4). These complexes function by repressing unliganded nuclear
receptor signals [93]. The NCOR complex contains NCOR1, GPS2, CORO2A, and
TBL1XR1 while SMRT complex contains NCOR2 (SMRT) instead of NCOR1 and lacks
CORO2A. Two more general complexes have also been described: the NCOR1 and the
NCOR2 complexes, which mediate gene silencing by several transcriptional factors. The
NCOR1 complex is formed by HDAC3, NCOR1, SMARCA4, SMARCB1, TRIM28,
SF3B3, SF3A1, SRCAP, and SMARCC1/2 [94]. The NCOR2 complex is composed of
HDAC1/2/3, NCOR1/2, SAP30, and SIN3A thus sharing proteins with the SIN3 complex
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[94]. CK2 phosphorylates both NCOR1 and NCOR2 at Ser2436 and Ser2522 residues,
respectively. NCOR1 promotes histone deacetylation and repression of the chromatin and
phosphorylation of the C-terminal by CK2 stabilizes NCOR1 from ubiquitin-dependent
proteasomal degradation [95]. Phosphorylated NCOR1 binds to the AP1 binding site of
the metastasis-related gene CXCL10, which along with phosphorylated HDAC3 and JUN
promotes transcriptional repression and prevents the recruitment of coactivators [95].
Another study showed that the balance between NCOR1 complex and the H3K4
methyltransferase KMT2D coactivator complex at Notch target genes changes upon
mutation of Ser2436 site of NCOR1 and CK2 inhibition [96]. Similarly, NCOR2
promotes chromatin condensation mediated by nuclear receptors. Phosphorylation in
vitro using CK2 stabilized to some extent NCOR2 interaction with the thyroid hormone
receptor [97]. NCOR2 phosphorylation by CK2 is sensed by the corepressor SPEN
(SHARP) [98].

3.4.1 CK2 regulatory role in PRC-mediated gene repression
In addition to the complexes described above, HDAC1 and HDAC2 have been linked to
the Polycomb repressive complex PRC1.6 [99], however, the functions of PCR1.6 are
unknown. In general, PRC1 complexes mono-ubiquitinate H2A providing a marker of
transcriptional repression and promoting ubiquitination-independent chromatin
compaction [100] (Supp. Table 3.4). The PRC1 complex nomenclature groups a set of
complexes that contain RNF2 (also known as RING1B or RING2) and PCGF1-6 as core
subunits and several other accessory subunits. Based on the composition of PCGF
proteins six groups of PRC1 have been proposed [99]. Interestingly, CK2 has been shown
to phosphorylate Ser168 residue of RNF2, the core E3 ubiquitin ligase of PRC1
complexes, inhibiting its enzymatic activity. However, phosphorylation of this residue
has only been reported for an AUTS2-PRC1 like complex (PRC1.5) in neuronal diseases.
In the context of the PRC1.5 complex (PCGF5, RNF2, CK2 holoenzyme, RYBP, and
AUTS2) the protein AUTS2 is needed to maintain the repression of neuronal
developmental genes [101]. Phosphorylation of RNF2 by CK2 is believed to be a
mechanism that changes the repressive role of this PRC1.5 complex variant into a
transcriptional activator [101]. Beyond PRC1.5 and PRC1.6 complexes, CK2 could also
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be a regulator of PRC1.4 complex, which contains BMI1 (PCGF4) a CK2 substrate, and
the core PCGF protein. BMI1 is heavily phosphorylated in cancer showing contextspecific phosphorylation patterns but the role of CK2-dependent phosphorylation in the
context of the PRC1.4 complex is unknown. CK2 phosphorylates BMI1 at Ser110, which
increases protein stability and may contribute to exacerbate BMI1 role in conferring
clonal self-renewal property to ovarian cancer cells [102]. What is more, CK2
phosphorylates CBX2, a core member of PRC1.4 and PRC1.2 complexes, at a poly-Ser
region, residues 464–469, next to an acidic region [103]. CBX proteins are necessary for
the recruitment of PRC1 to the chromatin by binding to methylated lysine residues;
CBX2 preferentially binds H3K27me3 but it also contains a DNA binding motif [99].
Phosphorylation by CK2 increases CBX2 affinity for H3K27me3-containing
nucleosomes and decreases its DNA-binding activity. The deletion of either the poly-Ser
domain, where phosphorylation by CK2 occurs, or the acidic domain negatively impacts
the repression of PRC1 target genes [103]. All the evidence shown here point to a key
regulatory role of PRC1-mediated repression by CK2.

3.4.2 CK2 regulatory role in DNA methylation
DNA methylation is catalyzed by DNMTs (DNA methyltransferases) and is counteracted
by TET (Ten-eleven Translocation) proteins. DNA methylation is directly linked to the
modification of histones to maintain proper gene expression after DNA replication. DNA
methylation has been associated with a repressive state of chromatin and transcription
inhibition [104]. A literature search revealed that CK2 phosphorylates DNMT3A, a de
novo DNMT that modifies unmethylated CpG dinucleotides. CK2 targets two conserved
residues, Ser386 and Ser389, located in the vicinity of the PWWP (Pro-Trp-Trp-Pro)
motif and negatively regulates its ability to methylate the DNA [105]. The PWWP
domain is required for binding the H3K36me3 mark and thus for the localization of
DNMT3A to heterochromatin [104]. CK2-dependent phosphorylation promotes
DNMT3A localization to heterochromatin and has an overall impact on the methylation
patterns with a most notable decrease in methylation of the SINE (short interspersed
nuclear element) CpGs [104]. A study of fetal globin gene silencing described the
importance of the H4 methylation mark H4R3me2s generated by the arginine
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methyltransferase PRMT5 as a factor required for the recruitment of DNMT3A and for
the assembly and recruitment of multiprotein repressor complex containing CK2 and
HDAC1, among other proteins [106]. The latter suggests a context-dependent role of
CK2 in transcription repression as a direct regulator of DNMT3A or a component of
HDAC-containing repressor complexes as documented before.
The text mining analysis also indicated that CK2 phosphorylates the epigenetic regulator
UHRF1 (ICBP90), potentially at the Ser165 and Ser354 residues [107]. Researchers
propose that CK2-dependent phosphorylation regulates UHRF1 transcriptional activity
and thus its antiapoptotic properties [107]. Interestingly, UHRF1 is a multidomain protein
that promotes the propagation of DNA methylation during DNA replication by recruiting
DNMT1 to hemimethylated DNA sites at replication forks [108]. In this regard, the
Ser165 and Ser354 sites, the suggested targets of CK2, are in the Tudor-like 1 and the
Histone H3R2me0 binding domains, respectively. Both these regions of the protein are
involved in binding of H3R2me0 (un-methylated) thus CK2-dependent phosphorylation
could be essential for regulating the epigenetic role of UHRF1. What is more, UHRF1 is
overexpressed in several cancers and its downregulation blocks the cell cycle in G1
[109]. In correspondence, additional information could expand on CK2 as a regulator of
UHRF1 function in normal cells and cancer and provide further evidence on the
regulatory role of CK2 on the DNA methylation landscape.

3.4.3 CK2 regulatory role in ribosomal RNA expression
The expression of ribosomal RNA (rRNA) is epigenetically regulated by the eNoSC
(energy-dependent nucleolar silencing complex) and the NoRC (nucleolar remodeling
complex) complexes (Fig. 3.4, Supp. Table 3.4). The lysine deacetylase SIRT1 is a CK2
substrate and functions as a metabolic sensor in the cell. As a core component of the
eNoSC complex, along with HDAC1 and HDAC2, also known CK2 substrates, and the
DNA methyltransferases DNMT1 and DNMT3B, it promotes a repressive state of the
chromatin at the rRNA genes [110–112]. In this context SIRT1 mediates H3
deacetylation, which can then be subsequently modified to H3K9me2 by the
methyltransferase SUV39H1, thus inhibiting the transcription of rRNA [113] (Fig. 3.4).
The concerted action of SIRT1 and SUV39H1 is also important for the formation of
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facultative heterochromatin and SIRT1 has been shown to regulate the activity of
SUV39H1 by acetylation [114]. SIRT1 also deacetylates the subunit TFA1B of SL1
complex (RNA polymerase I core factor complex), which recruits polymerase I to the
ribosomal DNA (rDNA) promoters thus inhibiting transcription of the rRNA genes [115].

Figure 3.4. Epigenetic regulation of gene expression in Homo sapiens (Reactome
identifier: R-HSA-212165). * Examples of CK2 substrates in the pathway.
CK2 phosphorylates SIRT1 at Ser162 (corresponding to S154 in mice), Ser659, Ser661,
and S683 residues [56,57] but the regulatory role of these phosphorylation events is not
well understood. In mice, phosphorylation of SIRT1 by CK2 was shown to increase the
deacetylation rate and to protect cells against DNA damage-induced apoptosis by
promoting the deacetylation and binding of TP53 [57]. Since CK2-dependent
phosphorylation was found to increase SIRT1 deacetylase activity it could be of interest
to understand the impact of phosphorylation in the context of rRNA expression. The
NoRC complex binds to HDAC1 and HDAC2 to facilitate the deacetylation of H4 which
allows for DNA methylation and silencing [116]. In both cases, CK2 could be
modulating the deacetylase activity at the rRNA genes thus enhancing rDNA repression
mediated by both these pathways. CK2 also phosphorylates TAF1C (TAFI110) a
component of the SL1 complex and UBTF, which recognizes the rRNA gene promoter
and activates transcription. CK2 phosphorylation of TAF1C prevents SL1 from binding
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to rDNA impeding the formation of the preinitiation complex (PIC) [117,118].
Conversely, phosphorylation of the UBTF C-terminal stabilizes and activates the protein
promoting transcription of rDNA [117,118].
Besides its potential role in the negative regulation of rRNA expression, CK2 has also
been shown to phosphorylate protein DEK [119]. DEK is a component of the B-WICH
complex, a multi-subunit complex that recruits histone acetyltransferases positively
regulating the expression of rRNA [120,121] (Fig. 3.4). This protein is a pleiotropic
oncoprotein [122] that was first identified as the fusion protein DEK-CAN (NUP214) in
AML (acute myeloid leukemia) [123] and is the target of autoantibodies in several
diseases including lupus and arthritis [119]. The function of DEK is not well understood
but CK2 has been identified as the main kinase that phosphorylates it. Phosphorylation by
CK2 occurs at Ser32 and at the C-terminal residues Ser243, Ser244, Ser251, Ser301,
Ser303, Ser306, and Ser307 [119]. The knockdown of DEK leads to genomic instability
due to a global loss of chromatin integrity manifested in the loss of heterochromatin
(increase in histone acetylation and a decrease in histone methylation) [124]. DEK is
regarded as an architectural protein and phosphorylation of CK2 regulates the binding to
DNA. Thus, through modulation of DEK binding affinity CK2 could be an important
regulator of DEK functions in rRNA expression but also in the maintenance of a global
chromatin structure [119].
The B-WICH complex is an extension of the WICH complex, a member of the ISWI
(Imitation SWItch) family of chromatin remodeling complexes composed of seven
different complexes containing either the helicase SMARCA5 or SMARCA1 [125].
Specifically, the WICH complex is composed of SMARCA5 and BAZ1B (WSTF)
proteins [126]. During replication, BAZ1B interacts with PCNA promoting an open
chromatin structure along with SMARCA5 [127]. Interestingly, BAZ1B, an atypical
tyrosine-protein kinase and a core member of WICH, that recruits the complex to the site
of DNA replication was described to be a substrate of CK2 at Thr945 and Ser947
residues in a phosphoproteomic study of mitotically arrested HeLa cells treated with CX4945 [85]. The inhibition by CX-4945 of BAZ1B at the Ser1468 residue which conforms
to the CK2 motif was also observed when expressing an exogenous inhibitor tolerant
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CSNK2A1 mutant variant (https://ir.lib.uwo.ca/etd/5164) in U2OS cells. The
phosphorylation of Ser1468 by CK2 was also confirmed in an in vitro dephosphorylationphosphorylation assay followed by phosphoproteomic analysis and peptide synthesis and
in vitro CK2 phosphorylation assay [128]. The tentative CK2 target sites on BAZ1B are
not located in critical domains, however, without further studies is impossible to define
the relevance of CK2-dependent phosphorylation of BAZ1B and the subsequent impact
on the function of the WICH complex in chromatin remodeling.

3.4.4 CK2 regulation of transcription factors
CK2 phosphorylates the transcriptional corepressor DAXX [129] which interacts with the
CK2 substrates: DEK, HDAC1, and HDAC2. As a transcriptional corepressor DAXX
binds sumoylated (small ubiquitin-like modification) transcription factors (e.g., AR,
SMAD4, and CBP) through its SUMO-interacting motif (SIM) negatively regulating
basal and activated transcription [130]. The presence of a SIM motif on DAXX also
mediates its sumoylation [130,131]. Interestingly, CK2 phosphorylates DAXX at Ser737
and Ser739 within the SIM motif (I733IVLSDSD740) and changes its preference to
SUMO1 compared with SUMO2 and SUMO3 [131]. Evidence indicates that
phosphorylation of the SIM motif of DAXX sensitizes cells to apoptosis by repressing
the expression of anti-apoptotic genes [131]. DAXX function is also regulated by its
binding to PML nuclear bodies through interaction with MCSR1 and the SUMOmodified protein PML [132]. Of importance, CK2 also phosphorylates PML at three
residues, Ser560-Ser562, localized to the SIM (V556VVISSS562) domain, which is
necessary for recruitment of sumoylated transcription factors to the PML-bodies [133].
CK2-dependent phosphorylation of PML at Ser517 residue has also been described and
regulates the levels of PML by promoting its ubiquitin-dependent degradation [134].
Overall, experimental data points to CK2 as an important regulator of DAXX corepressor activity not only by directly changing its affinity towards SUMOs but also by
modulating PML levels. An overlap between CK2 phosphorylation and SIM motifs has
also been described for the transcriptional regulator PIAS1 [135].
IKZF1 is a lymphoid lineage transcriptional regulator that acts as a repressor in the
context of SIN3-HDAC, NuRD, and CtBP (C-terminal binding protein) complexes.
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IKZF1 is also an activator when bound to the SWI/SNF complex (PYR complex) [136–
138]. The presence of dominant-negative IKZF1 isoforms (while retaining a wild-type
copy) has been linked to the development of hematological malignancies (e.g., ALL,
AML, and myelodysplastic syndrome) with evidence supporting a tumor suppressor role
of the full-length protein [139]. CK2 phosphorylates IKZF1 at Ser13 and Ser294
affecting its binding to the DNA and its localization to pericentromeric heterochromatin;
the latter results in a diffuse pattern of the protein across the nucleus [140,141].
Phosphorylation by CK2 inhibits IKZF1-HDAC1 complex-mediated repression of the
histone H3K4 demethylase KDM5B (JARID1B), resulting in KDM5B overexpression
and in turn the expression of leukemia-associated genes [20]. CK2 is overexpressed in
leukemia and CK2 inhibition promotes the transcriptional repressor activity of the wildtype IKZF1 allele by inhibiting the expression of genes involved in cell cycle and the
PI3K pathway [139,142]. In addition, CK2 inhibition promotes IKZF1-dependent
expression of the lysine demethylase PHF2 a tumor suppressor whose expression is low
in ALL [143]. The data presented provide a rationale for CK2 inhibition in leukemia
dependent on changes in the chromatin modification status.
CK2 also phosphorylates the transcriptional regulator MAX at Ser2 and Ser11 residues
[144]. MAX is a component of the MXD1-MAX (MAD-MAX) heterodimer that
associates with a complex containing SIN3A and HDAC1/2 and mediates repression of
MYC-MAX target genes during differentiation and enhancing cell growth inhibition by
MXD1 [145,146]. Phosphorylation by CK2 results in enhanced DNA binding of both
MAX-MAX homodimer and MYC-MAX heterodimers [144]; thus, antagonizing MXD1MAX heterodimer function and inducing expression of MYC-target genes. Interestingly,
the Ser11 site is adjacent to a CASP5 cleavage site at E10, and phosphorylation of this
residue has been described to block CASP5-mediated cleavage [147]. Furthermore, CK2
phosphorylates MYC at several phosphosites (Ser249, Ser250, Ser252, Ser347, Ser348)
which are thought to promote MYC stability and regulate the DNA binding properties of
MYC-MAX dimers [148–150].
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3.5 Chromatin dynamics intersect with the CK2 proteinprotein interaction network
Three major groups of proteins are involved in chromatin organization, those that
methylate DNA, those that modify histones, and those that regulate DNA-histone
interactions in an ATP-dependent manner [7]. Several of these proteins have been
mentioned here as bonafide CK2 substrates but many others have been identified as CK2
interactors with no phosphorylation link provided to the kinase. To further explore the
CK2 regulatory role, I retrieved the interactors of the CK2 subunits using the
Bioconductor package resource PSICQUIC v1.24.0 [151] without filtering by detection
method. Next, I filtered the interactors to find the chromatin organization proteins
represented. As a result, 57, 23, and 22 unique hits for CSNK2A1, CSNK2A2, and
CSNK2B, were found respectively (Suppl. Table 3.5). The merged interactors for all
subunits represented 69 proteins of the chromatin organization proteins included in the
data sets. This analysis is a snapshot and can change with new protein-protein interaction
data added to the PSICQUIC participating databases. As a summary, Table 3.2 shows the
GO cellular compartments functional classification of all the CSNK2A1 interactors
(Suppl. Table 3.6) retrieved from PSICQUIC filtered by complexes relevant to chromatin
organization.
Table 3.2. CSNK2A1 subunit interactors members of chromatin organization complexes
(GO cellular compartment, level 5).
Description

Count

Genes

transcription factor complex (GO:0005667)

38

SIN3A, ATF1, FOS, JUN, DDIT3, TAF1, TAF1D, SOX2,
WWOX, TP53, KDM1A, MED23, HDAC1, PRKDC, BRF1,
RELA, SPI1, GTF2F1, HCLS1, SFPQ, HMGA1, SUB1,
HSP90AB1, AIP, XRCC6, NFYA, ASCC1, LHX3, HIF1A,
HES6, GTF2A1, TCF7L2, MAX, MYF5, TAF7, PROP1,
NKX2-5, REL

PcG protein complex (GO:0031519)

19

HDAC2, SIRT1, RYBP, CBX2, CBX4, CBX7, CBX8,
RNF2, PCGF5, PCGF3, PCGF6, PHC1, RBBP4, RING1,
PHF19, BMI1

methyltransferase complex (GO:0034708)

18

HDAC2, TAF1, SIRT1, PAXIP1, RNF2, RBBP4, CLNS1A,
ZC3H13, KMT2A, WDR5, PRMT1, PHF19, MCRS1,
RBBP5, DPY30, KMT2B, MAX, TAF7

histone methyltransferase complex
(GO:0035097)

15

HDAC2, TAF1, SIRT1, PAXIP1, RNF2, RBBP4, KMT2A,
WDR5, PHF19, MCRS1, RBBP5, DPY30, KMT2B, MAX,
TAF7
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nuclear DNA-directed RNA polymerase complex
(GO:0055029)

13

TAF1, TP53, POLR2E, GTF2F1, CTR9, RTF1, PAF1,
LEO1, RPRD2, MCM3, POLR2A, GTF2A1, TAF7

SWI/SNF superfamily-type complex
(GO:0070603)

10

HDAC2, CHD3, HDAC1, DPF3, RBBP4, CHD4,
SMARCC2, RSF1, MCRS1

Sin3-type complex (GO:0070822)

7

HDAC2, SIN3A, NCOR1, HDAC1, RBBP4, SUDS3

protein acetyltransferase complex (GO:0031248)

6

CREBBP, OGT, WDR5, MCRS1, TAF7, JADE2

NuRD complex (GO:0016581)

6

HDAC2, CHD3, HDAC1, RBBP4, CHD4

nBAF complex (GO:0071565)

2

DPF3, SMARCC2

DNA topoisomerase complex (ATPhydrolyzing) (GO:0009330)

2

TOP2A, TOP1

protein N-acetylglucosaminyltransferase
complex (GO:0017122)

1

OGT

DNA helicase complex (GO:0033202)

1

MCRS1

npBAF complex (GO:0071564)

1

SMARCC2

Ino80 complex (GO:0031011)

1

MCRS1

chromatin silencing complex (GO:0005677)

1

SIRT1

Furthermore, I identified several chromatin-modifying enzymes as CK2 interactors of the
CSNK2A1 subunit, i.e., the lysine-specific demethylase KDM5C, the lysine
methyltransferases KMT2A and KMT2B, the arginine N-methyltransferase PRMT1, and
the histone deacetylase HDAC5. Other CK2 interactors found linked to chromatin
organization are CHD3, a helicase incorporated to the NuRD complex [152];
SMARCAD1, an SWI/SNF-like protein that mediates ATP-dependent nucleosomeremodeling [153,154]; JADE2, an E3 ubiquitin-protein ligase component of the histone
acetyltransferase complex HBO1 involved in KDM1A degradation during neurogenesis
[155,156].
Regarding repressor complexes, CSNK2A1 directly interacts with SUDS3 and CHD4
proteins, which are members of the SIN3 and NuRD complexes, respectively. SUDS3 is
a regulatory protein known to enhance HDAC1 activity in the context of the SIN3
complex [157]. CHD4 provides ATP-dependent DNA helicase activity to the NuRD
complex and functions by combining ATP-dependent nucleosome remodeling activity
with “reader” domains that bind histone tails [158]. Interestingly, in the lymphoid system
CHD4-NuRD complex interact with IKZF1 (IKAROS), a CK2 substrate, which provides
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sequence recognition specificity resulting in nucleosome mobilization, histone
deacetylation, and promoter decommissioning [158]. This highlights once again the
relevance of CK2-dependent signaling in transcriptional regulation of the lymphoid
system.
Coactivator complexes were also represented with two members of the SWI/SNF
superfamily-type complex: SMARCC2 and RSF1 identified as CSNK2A1 interactors
[93]. The SWI/SNF chromatin remodeling complexes change DNA-histone interaction to
allow gene expression. SMARCC2 (BAF170) functions as a scaffolding protein for the
SWI/SN family with domains important in chromatin targeting and DNA specificity
[159]. RSF1 (HBXAP) is a histone chaperone for the ISWI complex family that along
with SMARCA5 forms the RSF complex (Remodeling and spacing factor). RSF1 is
frequently overexpressed in cancer, which impacts genome stability by inducing DNA
strand breaks [125]. Another CSNK2A1 interactor involved in chromatin activation is the
lysine acetyltransferase CREBBP (CBP).

3.6 CK2-dependent phosphoproteome and chromatin
dynamics
Although several functional associations have been exposed here, the phosphorylation of
HDAC1-3 by CK2 remains the best characterized in the context of chromatin
organization. To further explore the involvement of CK2-dependent phosphorylation we
performed a motif scan of the proteins in the merged datasets followed by search in two
orthogonal phosphoproteomic datasets describing a global in vitro screening of CK2
substrates [128] and the treatment of mitotic HeLa cells with the CK2 inhibitor CX-4945
[85], respectively. As a result, 21 proteins involved in chromatin organization that
contains at least one CK2 consensus sequence hit were found to be phosphorylated in
vitro by CK2 and/or its phosphorylation was inhibited by CX-4945 treatment (Table 3.3).
The functional classification pointed to a tentative regulatory role of CK2 in histone (and
other proteins) methylation and demethylation, which reinforces the notion that the CK2
roles in chromatin organization extend beyond modulation of HDAC activity. It also
expands the CK2 role in transcriptional repression by exposing candidate CK2 targets
including GATAD2A, GATAD2B, and CHD4, core components of the NuRD complex;
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SUDS3 and ARID4B, components of SIN3A complex (Table 3.3). It also ratifies
potential CK2 roles in chromatin remodeling by revealing tentative targets like
SMARCA4, a core component of SWI/SNF chromatin remodeling complexes; and
CHD1, a component of the histone acetylation complex SAGA (Table 3.3). In fact, a
recent study suggests a regulatory role of CK2-dependent phosphorylation in the
subcellular compartmentalization of SMARCA4 as the hyperphosphorylated protein was
found to localize to the soluble chromatin [160]. It also pointed to the possibility of
interactors of CK2 like RSF1 and CDH4 as targets of CK2-dependent phosphorylation
(Table 3.3).
Table 3.3. Proteins involved in chromatin organization that contains at least one hit for
CK2 consensus sequence with changed phosphorylation when CK2 is manipulated.
Protein
Function
Histone-modifying enzymes

CK2 motif (-7/+7)

CK2 manipulation
Thr487 (APAEDVDTPPRKKK)*,**

EZH2

Histone methyltransferase

Ser87 (TRECSVTSDLDFPTQ)
Thr378 (NVLESKDTDSDREAG)

NSD1

Histone methyltransferase

More than 10 hits

SETD2

Histone methyltransferase

KDM2A

Histone demethylase

More than 10 hits
Ser28 (RYEDDGISDDEIEGK)
Ser692 (QKRKMEESDEEAVQA)
Ser787 (PSGKKELSEVEKAKI)

Transcriptional modulator
AEBP2
Repressor
ATF7IP

Activator/Repressor

GATAD2A

Repressor

GATAD2B

Repressor

SAP30BP

Corepressor

CBX3

Repressor

SMARCA4
(BRG1)
ARID4B
SUDS3

Activator/Repressor
Repressor
Repressor

Ser211 (RGSLEMSSDGEPLSR)
Ser445 (ILEKLAPSEDELTCF)
Ser496 (KEAFLVLSDEEDISG)
Thr20 (RALERDPTEDDVESK)
Thr42 (LLASDLNTDGDMRVT)
Ser107 (SPDVIVLSDNEQPSS)
Ser112 (VDMSARRSEPERGRL)
Ser129 (SPDIIVLSDNEASSP)
Ser18 (LAVYAEDSEPESDG)
Ser22 (AEDSEPESDGEAGIE)
Ser72 (EDENSRQSEDDDSET)
Ser77 (RQSEDDDSETEKPEA)
Thr91 (ADDPKDNTEAEKRDP)
Thr55 (FLKWKGFTDADNTWE)
Ser95 (GTKRKSLSDSESDDS)
Ser97 (KRKSLSDSESDDSKS)
Ser1627 (SRAKPVVSDDDSEEE)
Ser1631 (PVVSDDDSEEEQEED)
More than 10 hits
Ser45 (RSCRGRESDEDTEDA)
Ser53 (DEDTEDASETDLAKH)

Ser483 and Ser486
(CLKSLAFDSEHSADEK)**
Ser323 (GIFLGSESDEDSVRT)**
Ser28**

Ser515 (KVFNLYLSKQ_____)**
Thr677 (PPVSPGKTVNDVNSN)**
Ser107**
Ser129**

Ser43 (EEKGGLVSDAYGEDD)**

Ser95 and Ser97*

Ser1627 and Ser1631*
Thr793 (IEVLSEDTDYEEDEV)*
Ser45*

Chromatin remodeling
BAZ1A

Accessory unit. Nucleosome
spacing

Ser164 (DGETIIISDSDDSET)
Thr498 (EVAKEQLTDADTKDL)
Thr731 (ELDQDMVTEDEDDPG)
Ser1214 (RQRPSLESDEDVEDS)

Thr731**
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Ser1238 (GDEEEGQSEEEEYEV)
BPTF

Nucleosome sliding

More than 10 hits

ATRX

Helicase

More than 10 hits

CHD1
CHD4

Helicase
Helicase

More than 10 hits
More than 5 hits

RSF1

Histone chaperone

More than 10 hits

SUPT6H

Transcription elongation factor

More than 10 hits

Thr300 (VVLREEDTSNTTFGP)*
Thr301 (VLREEDTSNTTFGPA)*
Ser303 (REEDTSNTTFGPADL)*
Thr1763 (TTVTKLSTPSTGGSV)**
Ser677 (RMSHSSSSDTDINEI)*
Ser1156 (IQSGSSSSDAEESSE)*
Ser850 (NTKDFDSSEDEKHSK)*
Ser1061 (SKKKDELSDYAEKST)**
Ser216 (KKRQIDSSEEDDDEE)*
Ser103 (EEEVALRSDSEGSDY)*
Thr1305 (KRLHRIETDEEESCD)*
Thr1332 (SQPRVLPSEQESTKK)*
Ser1345 (KKPYRIESDEEEDFE)*
Ser78 (EGSDSGDSEDDVGHK)*

Thr803 (KEDVLWCTELERIFG)

Thr136 (GRNHVDESPVEFPAT)**

DNA methylation
DNMT3B

DNA methyltransferase

*phosphorylated by CK2 in vitro (Bian et al. 2013 [128])
**responsive to CX-4945 treatment (Rusin et al. 2017 [85])

After gathering information on CK2 modulation and CK2 interactors we looked beyond
repressive complexes and HDACs focusing on ATP-dependent chromatin-remodeling
complexes. These complexes contain an “ATP motor” that breaks the DNA-protein
contacts to allow nucleosome assembly (ISWI and CHD subfamily), access (SWI/SNF
subfamily), or editing (INO80 subfamily, SRCAP) through different mechanisms of
action [161]. The diverse composition of these complexes determines their interaction
with transcription activators, repressors, and histone modifications, and thus chromatin
targeting [161]. Interestingly, regulatory links between CK2 and a number of core and
auxiliary components of the SNF/SWI [162], ISWI [125], CHD [163,164], and INO80
[165,166] remodeling complexes (Supp. Fig. 2) were identified. Notice that some of these
complexes can contain enzymatic activities that function in gene repression [167,168].
For instance, the CHD complex NuRD contains the histone deacetylases HDAC1 and
HDAC2, both CK2 substrates as discussed before. The NuRD “ATP motor” and
deacetylase activities promote heterochromatin formation and rapid termination of gene
expression [168]. Given that, CK2 phosphorylation enhances HDAC1 and HDAC2 (and
HDAC3) deacetylase activity and regulates their binding to repressor complexes, CK2
stands at the junction of this chromatin remodeling-deacetylase link.
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3.6.1 Asp-N phosphoproteome
Trypsin is widely used for phosphoproteome generation. To uncover other possible sites
modulated by CK2 manipulation we performed a SILAC phosphoproteomic study in
U2OS treated for 6h with 30 µM CX-4945 using Asp-N as the protein digestion enzyme
[169] (three technical replicates) (Supp. Table 3.7). Interestingly we identified changes in
several chromatin organization proteins. Importantly, we observed a potential regulatory
role of CK2 in the regulation of the PRC2 complex through the modulation of
phosphorylation of EED and EZH2 core proteins (Supp. Table 3.7). This is in addition to
the regulatory role described for PRC1. Thus, pointing to a global role of CK2 in
regulating the function of the Polycomb group (PcG) proteins, chromatin-associated
proteins that assemble into diverse complexes that maintain transcriptional repression
[170,171]. The modulation of KAT7 phosphorylation was also observed (Supp. Table
3.7).
PRC2 complex mediates H3K27me1, H3K27me2, and H3K27me3, through the action of
the methyltransferases EZH2 and EZH1; H3K27me3, is a repressive histone mark
[170,171]. The core subunits of PRC2 are the adaptor protein SUZ12, EED, and the
lysine methyltransferase EZH2. Both SUZ12 and EED are required for binding to
chromatin and for catalytic activity [170]. The residues Ser378 and Ser380 of EZH2, the
catalytic subunit of PRC2, were found inhibited ~ -3 fold. These sites localize to the
region 329–522 where interaction with the chromatin reader CDYL has been mapped
[172]. Importantly, phosphorylation at Thr350 by CDK1, a residue in this region,
modulates the recruitment of PRC2 enhancing its binding to ncRNA, which directs the
complex to defined target genes [173,174]. Increased phosphorylation of Ser43 and Ser46
residues of EED at ~ 1.54 fold was also observed. EED is required for the catalytic
activity by allosteric activation of the PRC2 complex via binding of H3K27me3and
potentially JARID2 K116me3 [170]. The N-terminal region of EED is required for
interaction with H3 [175], thus increased phosphorylation of this region could directly
impact EED function in PRC2.
The change of several phospho-proteins directly or indirectly involved in histone
modification was recorded (UniProt source), such as HUWE1, histone deubiquitination;

161

ISWI, part of the SUPT6H-IWS1-CTD complex with recruits histone methyltransferases
and function in elongation-coupled H3K36 methylation; KAT7, H4-specific
acetyltransferase activity, which also mediates H3K14 acetylation; LEO1, a member of
the PAF1 complex which mediates the formation of H2BK120ub1 and H3K4me3;
MPHOSPH8, a member of the HUSH complex that recognizes the H3K9me3 and
mediates transcriptional silencing by promoting H3K9me3 deposition through recruiting
of the histone methyltransferase SETDB1 also promotes DNA methylation through
DNMT3A; SART3, recruitment of USP15 for histone deubiquitination.

3.7 Methods and Materials
Data sets. Chromatin organization data sets were retrieved from Reactome [26] (R-HSA3247509, R-HSA-212165) and AmiGO [25] (GO:0006338) portals to perform functional
association to CK2.
Protein function. Protein function was retrieved from the UniProt database [176] to
determine the role of proteins of interest in chromatin remodeling and CK-dependent
signaling.
Literature search. Automated literature retrieval and extraction were performed with
Chilibot text mining tool [24] and the reutils Bioconductor R package [23] to discover
known associations between proteins of interest and CK2.
Database search. Automated database searches were performed using the Bioconductor
R packages UniProt.ws v2.26.0 (UniProt) [177], curl v4.3 (UniProt) [178], iptmnetr
v0.1.8 (PTM and kinase-substrate relationships) [179], and PSICQUIC v1.24.0
(molecular interaction) [151]. CORUM (protein complexes) database [180] search was
performed on data downloaded in August 2019. This allowed for retrieval of the protein
sequence, modification, kinase-substrate, and protein interaction data used in the
experiments described in the chapter.
Phosphoproteomic data. Phosphoproteomic data for CK2 manipulation was obtained
from: 1) Bian et al. 2013 ([128], all sites previously reported in databases); 2) Rusin et al.
2017 [85] supplementary materials; 3) SILAC phosphoproteomic study by Edward
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Cruise et al. (https://ir.lib.uwo.ca/etd/5164). Light: U2OS cells over-expressing
CSNK2A1-WT treated for 4 h with DMSO. Medium: U2OS cells over-expressing
CSNK2A1-WT treated for 4 h with 30 μM CX-4945. Heavy: U2OS cells over-expressing
CSNK2A1-TM (V66A/H160D/I174A) treated for 4 h with 30 μM CX-4945. Site
localization was selected Localization prob >= 0.75. Differentially modulated sites were
selected from with a log2 Medium/Light fold change cut-off <= -1. 4) 30 μM CX-4945
treatment of U2OS cells for 6 h followed by sample preparation and protein digestion
with the endoproteinase Asp-N [169] (see Chapter 2).
Protein complex representation. Protein complex data retrieved from CORUM was
overlapped with CK2-specific information and plotted using the RCy3 Bioconductor R
package [181]. Nodes style scheme: yellow circle (protein), white square (complex), dark
red (CK2 substrate), medium red (Bian et al. 2013, fold change >= 2), light red (Bian et
al. 2013), blue (Rusin et al. 2017), green (PPI). This analysis was performed to find core
complexes proteins functionally linked to CK2 such as interactors and substrates.

3.8 Concluding remarks
The genomic DNA, histone proteins, and other associated proteins assemble into the
chromatin structure formed by the nucleosome as its basic unit. The composition and
conformation of the chromatin structure, i.e., chromatin organization, is decided by
events like the modification of histones and DNA and by transcription, which dictate its
specification, formation, and/or maintenance. The information relating to the regulatory
role of protein kinase CK2 in chromatin organization remains sparse. As shown here,
there is little information describing the direct relevance of CK2-dependent
phosphorylation events in this context. However, considering the wide distribution in the
proteome of the CK2 consensus motif, several target sites are likely yet to be discovered
among proteins involved in chromatin organization. In addition, evidence obtained in
Chapter 2 indicates a functional association between CK2 and lysine acetylation
networks in the cell involving chromatin remodeling proteins among other activities.
Briefly, here we discussed the role of CK2 as a histone H4 and histone H3 kinase
impacting DNA repair and the function of the SAGA transcriptional co-activator,
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respectively. We also summarized lesser understood roles of CK2 as a modulator of
heterochromatin methylation patterns, chromatin-remodeling, and transcriptional
repression. Regarding the latter, we gathered novel evidence supporting a regulatory role
of CK2 on the function of the repressor complex PRC2 as treatment with CX-4945
inhibited the phosphorylation of its core subunits EZH2 and EED at sites matching the
CK2 consensus. Finally, we also observed that inhibition of CK2-dependent signaling
could result in the modulation of the phosphorylation of the lysine acetyltransferase
KAT7. Overall, these novel observations require further validation using other chemical
probes targeting CK2, but they expand the breadth of potential regulatory roles to
consider when studying CK2.
All in all, our analysis highlights the importance of conducting/mining both low and
high-throughput experiments for finding and validating new connections between
associated biological processes and CK2-dependent signaling. Of special interest should
be the phosphoproteomic profiling of existing and novel CK2 inhibitors. But also, the
necessity of novel studies profiling the changes in the phosphoproteome resulting from
CK2 protein level manipulation either by over-expressing or knocking-down CK2
subunits. Regardless, here we were able to summarize and identify essential aspects of
the regulatory role of CK2 in chromatin organization.
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Supp. Figure 3.1. Summary of enzyme-substrate relationships and site information
retrieved from iPTMnet and PhosphoSitePlus (PSP) databases. Annotation ID: Reactome
(R-HSA-3247509, R-HSA-212165) and AmiGO (GO:0006338). NA: not available.
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Supp. Figure 3.2. Chromatin-remodeling complexes and CK2 highlighting core subunits
that are CK2 substrates and/or are modulated upon CK2 inhibition. A) CHD complexes.
B) ISWI complexes. C) SNF/SWI complexes. D) INO80 complex. E) SRCAP complex.
Nodes style scheme: yellow circle (protein), white square (complex), dark red (CK2
substrate), medium red (Bian et al. 2013, fold change >= 2), light red (Bian et al. 2013),
blue (Rusin et al. 2017), green (PPI).
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Chapter 4

4

Strategies for the functional analysis of lists of
modification sites

Several bioinformatics tools are available to functionally contextualize long lists of
proteins by focusing, for instance, on the representation of annotations of interest such as
GO ontologies and pathways [1,2]. However, fewer tools are available for the
contextualization of lists of post-translational modifications (PTMs) sites, for example,
those identified or found differentially modulated in phosphoproteome [3] and acetylome
experiments [4]. In such cases, the tools for analyzing protein lists are of use but the
specificity decreases since information on the modified sites are disregarded [2]. Only
downstream analysis pipelines that incorporate site-specific functional and quantitative
data can assist in uncovering the patterns and dynamics of protein modifications. Thus,
providing insights into signal integration and the regulation of biological processes and
pathways in the cell; potentiating the development of novel molecular-targeted therapies.
Here we describe strategies that implement and interconnect existing bioinformatic tools
for the functional analysis of lists of modification sites. We cover the topics: pattern
matching and discovery [5,6]; retrieval and/or extraction of information from databases
and the literature concerning known PTM information [7], kinase-substrate relationships
and molecular interactions [8–10]; prediction of kinase-substrate relationships [11];
prediction of PTM functional relevance [12]; functional association to PTM writing
enzymes [13]; motif and domain representation [14]. We also remark on the advantages
of designing and executing the analysis strategies in R for which Bioconductor [15] is
available. Bioconductor is an open software initiative that provides a suite of packages
for the analysis of high-throughput genomic data [15]. A notable example of analysis
implementation in R is the INKA (Integrative Inferred Kinase Activity) pipeline [16],
which integrates kinase-centric and substrate-centric information for inferring kinase
activity data from lists of phosphosites and other phosphoproteomic data. In order to do
so, INKA brings together experimental information on phosphopeptides; data from
UniProt (protein identifiers), PhosphoSitePlus (phosphorylation data), KinBase (protein
kinases) and HGNC (gene symbols) databases; and the tools Phomics (kinase activation
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loops) and NetworKIN (prediction of kinase-substrate relationships). Another example is
the web service SELPHI [17], which performs GO term enrichment on clusters of
phosphopeptides, motif enrichment, and phosphosite-phosphatase correlation, etc.
SELPHI integrates information from more than 10 different tools and databases. Here,
capitalizing on our group’s practical experience studying signaling by protein kinase
CK2, we provide examples that illustrate the use of analysis pipelines complementary to
INKA and SELPHI for uncovering biologically relevant information for this and kinase
substrates. More importantly, we describe the implementation in R of a report and
functional analysis tool, visualRepo, that features strategies for exploring PTM interplay
and for the functional association of PTM lists to writer enzymes.

4.1 Functional analysis strategies
4.1.1 Pattern scan and discovery
High-throughput studies, such as phosphoproteome studies, identify hundreds of
modified peptides that change in the cell in response to perturbations. These lists of
peptides are frequently represented as sequences centered at the modified residue with a
range of flanking residues anywhere from 6 to 30. The centered sequences are frequently
visualized as sequence logos and analyzed for pattern discovery. This allows making
inferences regarding the writer enzyme(s) modulated in the system of interest. Examples
of available sequence logo generators are PhosphoSitePlus (PSP) sequence Logo
Analysis [9,18], WebLogo 3 [19], and Two Sample Logo [20]. Tools that can be used for
pattern (motif) discovery in PTM data are MoMo [6] from the Meme suite [21]
(implements motif-x algorithm) and PSP Motif Analysis Generator [9,18]. Additionally,
if a previous hypothesis exists, such as inhibition of a given enzyme with a chemical
probe, scanning the sequences for specific consensus motifs is usually performed. Tools
that can be used to scan a protein database or specific sequences with user-defined motifs
are ScanProsite [22], EMBOSS’ patmatdb [23], and FIMO [5] from the MeMe suite. A
distinctive feature of ScanProsite search is that pattern matches can not only be
performed against the UniProt Knowledgebase (protein sequence database) [24] but also
against the PDB (protein structure database) [25]; this way researchers can also retrieve
structural information on the observed hits. Another useful functionality is provided by
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PSP Site Search which retrieves a list of modified sites matching a given pattern and the
output can be filtered by molecular weight, cell type, cell line, tissue, treatment, GO
ontologies, etc. [9,18]. Finally, using R the linear patterns of interest can be defined as
regular expressions and the search performed using the grep function, and its variants
regexpr and gregexpr, on a list of protein/peptide sequences. The sequences can be
uploaded for processing from a local copy of UniProt database in fasta format using
Bioconductor’s package Biostrings [26] or directly from UniProt database using
Bioconductor’s package UniProt.ws [27]. The package Biostrings also provides the
functions (v)matchPattern and (v)countPattern for pattern scan. Sequence information
from PDB about secondary structure [25] can also be uploaded into R. The sequences can
be searched and based on the position of the hits inside the sequence, the corresponding
secondary structure information of the hits can be obtained.

4.1.1.1 Pattern scan and motif discovery strategies applied to CK2
datasets
The list of CK2 target sites was downloaded from the PSP database and the
corresponding +/- 7 centered sequences (Fig. 4.1A, Supp. Table 4.1) were analyzed using
pattern scan and motif discovery strategies. The sequences were represented in a
sequence logo (Fig. 4.1A). As expected of an acidophilic kinase, the input sequences
were found enriched on negatively charged residues when using all the annotated Ser/Thr
phosphosites in PSP as background (Fig. 4.1A). However, when using the input
sequences as background we further determined that the positions downstream of the
phosphosite (C-terminal) were significantly more enriched in negatively charged residues
(Fig. 4.1A). Thus, by including both background settings in our analysis we were able to
recapitulate the working model for CK2 substrate specificity where positions +1 to +3 are
deemed the most relevant for phosphorylation [28,29]. Next, the CK2 target sequences
were searched for motif discovery using MoMo v.5.0.5. Interestingly, several motifs were
discovered (adjusted P value <= 0.015) making it possible to cluster the CK2 target
sequences (Fig. 4.1B, Supp. Table 4.2). The observed motifs were then used to scan the
human proteome for occurrences using FIMO v.5.0.5 and we found that the discovered
motifs were widely represented, > 80,000 hits in > 42,000 sequences (P value < 0.0001)
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(Fig. 4.1B, Supp. Table 4.3). The global scope of CK2-dependent phosphorylation has
been shown in phosphoproteomic studies and in a wealth of low-throughput experiments
describing novel CK2 sites [28,30].

Figure 4.1. Motif discovery and pattern matching tools and strategies. A) Dataset
centered around the modified site, known CK2 phosphorylation target sites
(PhosphoSitePlus (PSP)) centered at +/-7 amino acids, and the corresponding sequence
logo. The sequence logo was generated using the PSP Production algorithm (sum of
absolute values equal to one, background selection: input sequences or Phosho Ser/Thr)
at http://www.phosphosite.org/sequenceLogoAction.do. B) Motif discovery (MoMo
v.5.0.5), search (FIMO v.5.0.5), and comparison (Tomtom v.5.0.5) performed on the
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centered list of CK2 target sites. Selected examples of the observed output are shown for
illustration purposes.
The discovery of the motif SDSE (adjusted P value 0.015) among CK2 substrates
suggested that other phosphorylatable residues can be found in the vicinity of CK2 target
sites. Upon close examination of the hits, we found that several of these sites also match
the CK2 consensus or are reported as known CK2 sites. Thus, by performing motif
discovery, we found that CK2 target sites can appear in clusters for example
Ser421/Ser423 of HDAC1, Ser773/Ser775 of FURIN, and Ser250/Ser252 of MYC
(Supp. Table 4.1-2). Other motifs discovered also indicated the occurrence of Ser nearby
the phosphorylation site (Supp. Table 4.2). An interesting observation made by our group
points to hierarchical phosphorylation as a regulatory event on CK2-dependent
phosphorylation where a given kinase can phosphorylate and prime a sequence for CK2mediated phosphorylation [31]. Thus, by applying motif discovery to a set of sequences
centered at the modulated sites PTM interplay could also be uncovered; this refers to the
coordination of proteins’ PTMs in cis or trans to determine a function [32]. To further
explore PTM interplay, we performed a motif comparison using Tomtom [33] which
compares discovered motifs against known motifs annotated in the Eukaryotic Linear
Motif [34] (ELM 2018) resource. We found that not only our discovery motif matched
the CK2 motif (P value 0.012), as expected, but it also matched the Caspase-3 and -7
cleavage motif (P value 0.00763) (Fig. 4.1B). Interestingly, our group described a
regulatory role of CK2 on preventing cleavage by caspases via phosphorylation of
caspase cleavage motifs [35].

4.1.2 Post-translational modification data retrieval
The quality of identifications as well as the functional relevance of the sites found in each
experiment can be assessed by retrieving information from PTM databases and extracting
sites mentioned in the literature. In addition, the patterns/motifs discovered in your list of
interest can be explored to retrieve the PTMs and enzymes targeting them. For this
purpose, several PTM databases are available; some include annotations on low- and/or
high-throughput experiments, expert-curated data from the literature, enzyme-substrate
relationships, and/or information regarding PTM interplay. Examples of PTM databases
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are PSP [9], iPTMnet [10], and PTMcode v2 [36]. PSP data can be accessed using the
Site Search functionality and the retrieved information downloaded and processed in R or
it can be automatically accessed from Cytoscape via the PhosphoSitePlugin [9].
Programmatic access to iPTMnet can be achieved using the CRAN package iptmnetr
[37], an API client for importing iPTMnet data into R. The iPTMnet data can also be
accessed using Batch Retrieval but is limited to 500 items (sites) per query. The iPTMnet
database collects information from > 10 PTM resources including PSP. The PTM
interplay data in PTMcode v2 data can be downloaded and processed in R. Importantly,
PTM databases might not be up-to-date, thus mining the literature to extract kinasesubstrate relationships becomes important. For this purpose, the information extraction
system RLIMS-P 2.0 [7] can be used for mining kinase, substrate, and phosphorylation
information from abstracts in MEDLINE and open-access manuscripts in PubMed
Central. With RLIMS-P a maximum of 200 PMIDs of interest can be analyzed in a single
run or a keyword search can be defined. The information extracted with RLIMS-P can be
downloaded in table format and processed and analyzed in R. Finally, if some of the
observed sites or the sites of interest could not be found in the databases/literature a
global prediction of PTM sites could be performed using the tool PTMscape [38] for
gathering in silico evidence.

4.1.2.1 Post-translational modification data retrieval strategies
applied to CK2 datasets
The SDSE motif, represented in a subset of CK2 target sites, was overlapped to the
phosphorylation data in PSP and 617 known phosphosites were retrieved as matches (Fig.
4.2A, Supp. Table 4.4). Given the relevance of PTMs co-occurring nearby CK2 sites we
also looked for other modification sites at a window of +/-7 amino acids from the
phosphorylatable residue in the SDSE motif. This analysis pointed to the occurrence of 8
different PTM types including a caspase cleavage site, which exemplifies what we
observed in the motif comparison experiment using Tomtom (Fig. 4.2A, Supp. Table
4.5). A complementary analysis could also be performed by searching the iPTMnet
database for the sites matching the SDSE motif. Both iPTMnet and PSP provide the
means to visualize kinase-substrate relationship data using network format (Fig. 4.2B).
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The corresponding kinase-substrate relationships of the 617 matches were retrieved from
PSP and iPTMnet databases and 11 CK2 target sites, one CDC7 target site, one
CSNK1A1 target site, and one MAPK14 target site were found (Supp. Table 4.6).
Furthermore, we searched for SDSE matches in a phosphoproteomic study of in vitro
phosphorylation by CK2 [30]. As a result, we found a total of 35 phosphosites matching
the SDSE motif found phosphorylated in vitro by CK2 in Bian et al. 2013 (Supp. Table
4.6). Thus, by searching the motif(s) discovered against PTM databases and
phosphoproteomic studies from the literature we were able to uncover information
regarding potential CK2 target sites in our list of interest.

Figure 4.2. PTM profile of CK2 substrates. A) SDSE proteome hits annotated as
phosphorylated in PhosphoSitePlus (PSP) database. PTM types annotated in the vicinity
(+/-7 amino acids) of phosphorylated SDSE hits. B) iPTMnet data network representation
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of lysine deacetylases phosphorylated by CK2; PSP data using the Cytoscape plugin C)
RLIMS-P phosphorylation mention extraction from full-text articles on CK2 published in
the last 5 years. D) Keyword RLIMS-P information extraction using the query “ck2” and
“hierarchical phosphorylation”.
Finally, we also extracted phosphorylation mentions from the literature using RLIMS-P
to complement the existing database information. To use recent publications, we
performed a PubMed search using the “Casein Kinase II” MesH term and selected 200
PMIDs belonging to the last five years and representing full-text publications (Fig. 4.2C).
This RLIMS-P search yielded at least four recent papers describing CK2-dependent
phosphorylation (Fig. 4.2C). Since hierarchical phosphorylation provides a regulatory
mechanism at the substrate level for specifying CK2-dependent phosphorylation we also
extracted relevant mentions from the literature using RLIMS-P by defining the query:
“ck2” and “hierarchical phosphorylation” (Fig. 4.2D). As a result, we identified seven
instances where hierarchical phosphorylation was described in the context of CK2 (Fig.
4.2D). For example, we found a regulatory role for hierarchical phosphorylation at the
CK2 target site Ser511 of CFTR [39,40].

4.1.3 Kinase enrichment and activity inference analyses*
Several tools apply the known kinase-substrate relationships retrieved from the
databases/literature and the direction of the change of the phosphosites/phosphopeptides
to find enriched or depleted kinase activities. Some of the available kinase enrichment
tools are KSEA (KSEAapp R package [41]), KinSwing (KinSwingR R package [42]),
PHOXTRACK [43], KEA2 [44], KinasePA (directPA R package [45]), and CLUster
Evaluation or Clue (ClueR R package [46]). Another useful tool is the algorithm KARP
[47] (no software implementation available), which uses the normalized sum of the
intensities of the phosphopeptides containing known kinase target sites that were
identified in a phosphoproteomic experiment to rank kinase activity. KSEA and
KinSwing are useful for analyzing single conditions of phosphoproteomic studies,
whereas Clue was developed for the analysis of time-course experiments.
Some important considerations when analyzing phosphoproteome data are: the
enrichment and kinase activity prediction results are limited to available PTM database
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annotations, not all of the sites identified on multiply modified peptides may be
responding to the treatment, and not all of the substrates of a kinase might be impacted by
the treatment. Tools like KSEA deal with incomplete database annotation by including
kinase-substrate prediction [41]. On the other hand, kinase enrichment analysis can also
be performed with kinase-substrate data sets provided by the researcher using the
enricher function of the Bioconductor package clusterProfiler [48]. The uncertainty
introduced by considering multiply phosphorylated peptides can be reduced by
comparing the kinase enrichment results obtained for all peptides and for the singly
modified peptides. Finally, researchers should look at evidence from other functional
analysis strategies before eliminating any modified sites from downstream functional
analysis and before obviating the contribution of kinases that did not appear modulated.

4.1.3.1 Kinase enrichment and activity inference strategies applied
to CK2 datasets*
The sample dataset provided with KSEA [41], already formatted with the correct input,
was analyzed with KSEA’s web implementation using either the PSP kinase-substrate
dataset or the PSP + NetworKIN dataset (Supp. Table 4.7). In both cases, we observed
significantly upregulated (red) and downregulated (blue) kinases (Fig. 4.3A). As
expected, selecting the PSP + NetworKIN option (cutoff: 5) impacted the results with
more relationships identified compared to PSP only (Fig. 4.3A). Among the kinases
found significantly enriched we observed CK2. Since the log2 fold change represents
treatment vs control we could observe that collectively the sites annotated as CK2 were
upregulated by the treatment (Fig. 4.3A). We also applied KinSwingR to infer kinase
activity modulation in a phosphoproteome study of CK2 inhibition using the ATPcompetitive inhibitor CX-4945 (study by Edward Cruise et al.,
https://ir.lib.uwo.ca/etd/5164). As expected, the prediction results indicated CK2 activity
inhibition (P value = 0.001) by CX-4945 (Supp. Table 4.7). Next, the sample data
provided with ClueR (R package for Clue), a profile of temporal changes in the
phosphoproteome of human embryonic stem cells during differentiation, was analyzed
[49] (Supp. Table 4.7). Several clusters were observed with cluster 1 containing 5 known
CK2 substrates (P value = 0.01) (Fig. 4.3B). Since the PSP release used by ClueR is at
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least 5 years old we modified the data for CK2 substrates to reflect the current release of
PSP. In correspondence, we identified the same cluster (cluster 1) with an additional CK2
substrate (P value = 0.0006) (Fig. 4.3B). We also observed a new cluster, cluster 12, with
5 new CK2 substrates (Fig. 4.3B). The latter highlights the importance of including upto-date information and should be extended to other kinases and tools like KinSwingR.
The changes of the CK2 sites across time can be followed by looking at the overall trend
of each of the clusters containing them (Fig. 4.3B). Of note the P value calculated for the
kinase in each cluster and can significant or not depending if the kinase substrates are
spread across different clusters like CK2, in this case.
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Figure 4.3. Kinase set enrichment analysis. A) KSEA analysis using PhosphoSitePlus
(PSP) kinase-substrate dataset (right; default parameters) or PSP kinase-substrate dataset
+ NetworKIN prediction (left; NetworKIN score cutoff: 5 and set substrate count cutoff:
15); in red, black, and blue kinases whose activity was found increased, unchanged, and
decreased, respectively. B) CLUster Evaluation (Clue) analysis of a time-course
experiment profiling the changes to the phosphoproteome during embryonic stem cell
development; clusters identified containing CK2 substrates using the old PSP release
provided with the ClueR package or a modified version to include the CK2 substrates
from the latest release; P value for a given kinase calculated using Fisher’s exact test. C)
KEA2 analysis using the literature-based kinase-substrate package as background and the
CK2 target sites reported in PSP as input.
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Finally, the list of CK2 substrates was analyzed using the literature-based kinasesubstrate library provided by KEA2. Besides CK2, other kinases were found to target the
CK2 sites reported in PSP (Fig. 4.3C). This provided information on kinase integration
and consensus sequence overlap.

4.1.4 Kinase-substrate relationship prediction*
Although PTM databases provide information on kinase-substrate relationships the
information available is limited. This imposes a knowledge gap when trying to assess the
functional relevance and the biological context of the changes observed in an experiment.
As an alternative, tools that perform kinase-substrate relationship predictions are
available in addition to those for pattern matching and motif discovery. A widely used
kinase-substrate prediction tool is NetworKIN/NetPhorest [8]. Other available tools are
GPS [50], iGPS [51], Musite [52], NetPhos [53], HPRD’s PhosphoMotif Finder [54],
KinasePhos 2.0 [55], CoPhosK [56], KSP-PUEL [57], PhosphoPICK [58], and PKIS
[59]. CoPhosK combines the NetworKIN approach of motif matching and proximity in
STRING [60] with co-phosphorylation networks. In the latter, a phosphosite is likely to
be associated with a given kinase depending on the proportion of its neighbors that are
known to be associated with the kinase [56]. Of notice, the sequence databases used by
some of these tools might not be up-to-date.

4.1.4.1 Kinase-substrate relationship prediction strategies applied
to CK2 datasets*
The list of CK2 substrates retrieved from PSP was used for kinase-substrate relationship
prediction with NetworKIN. A total of 447 out of 502 known sites (89.0%) were
predicted by NetworKIN as matches to the CK2_group (Table 4.1, Supp. Table 4.8).
After applying the >= 2 score cutoff, tool default, a total of 251 sites remained (56.2%)
(Table 4.1, Supp. Fig. 4.1A). By including the matches for the CSNK2A2 catalytic
subunit (CK2a2 id) only two sequences were found in addition to those matched to
CSNK2A1 (CK2alpha id) (Supp. Fig. 4.1B). The netphorest score was the same for sites
matching either subunit since the specificity of both CK2 catalytic subunits is considered
equal as observed in the sequence logo generated from the hit sequences (Supp. Fig.
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4.1C). The difference in the number of hits between subunits was attributed to differences
in the STRING functional profiles of both CK2 subunits. As reflected in the STRING
score portion of the NetworKIN score (Supp. Fig. 4.1D). This behavior was expected, by
incorporating STRING we hoped to include data that allows us to differentiate subunitspecific substrate pools. On the other hand, the sequence logo analysis also showed that
most of the sequences below the threshold matched the CK2 motif, as expected due to the
input data used (Supp. Fig. 4.1C). Thus, the number of sites with scoring < 2 could stem
from a lack of information on the STRING database regarding CK2 and the input
proteins to be classified as substrates.
We also performed a CoPhosK prediction using the list of CK2 substrates as input and
were able to link 50 sites back to CK2 (Supp. Table 4.8). The limited number of hits
compared to the NetworKIN prediction might be because the query sites were not
identified in the context-specific phosphoproteomic experiments used by CoPhosK to
build the co-phosphorylation network [56]. Next, we applied the iGPS (in vivo GPS)
predictor, which uses STRING and experimental molecular interaction information to
reduce false positives [51]. The inclusion of experimental protein-protein interaction
information allowed the assignment of 126 and 55 sites to CSNK2A1 and CSNK2A2,
respectively (6% false-positive rate) (Supp. Table 4.8).
Finally, we used KSP-PUEL to predict CK2 substrates using as input the sites identified
in an insulin stimulation of 3T3-L1 adipocyte cells (example dataset). This tool does not
rely on STRING or other biological annotations for prediction instead, it uses a positiveunlabeled ensemble learning model [57]. As a result, we found 1,546 hits for CK2 out of
12,062 identified sites in the input list. The chosen cut-off was 0.70 since it includes the
majority of the known substrates found in the PSP dataset of bonafide CK2 targets, 17
substrates out of 18 (Table 4.1, Supp. Table 4.8). The lowest score for all the known CK2
substrates was 0.48 like what was observed for mTOR substrates [57]. The motif found
enriched in > 1,500 hit sequences found by KSP-PUEL was [ST]D[SEDT]E which fits
the known CK2 substrates provided as input. KSP-PUEL can be used in conjunction with
CLUE or other kinase enrichment tools for finding the kinases represented and then
choosing a kinase of interest for substrate prediction with KSP-PUEL [57].
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Table 4.1. Prediction of kinase-substrate relationships for known human CK2 substrates
(PhosphoSitePlus).
Tool
NetworKIN 3.0
(Web)

Input and Database

Prediction results

Cutoff

List of Protein, Site,
and AA
Human - UniProt
2013/01 (MaxQuant)

Proteins found: 244/251 (97.2%)
CK2_group: CK2alpha (447 hits),
CK2a2 (447 hits)
>= 2 (cutoff): 251 (56.2%)
< 2 (cutoff): 196 (43.8%)
CK2alpha: Median: 3.02907
Mean: 9.87922
>= 2 (cutoff): 249 (55.7%)
< 2 (cutoff): 198 (44.3%)
CK2a2: Median: 0.6063
Mean: 1.9800
>= 2 (cutoff): 87 (19.5%)
< 2 (cutoff): 360 (80.3%)

Minimum score: 2.00 (0.99)
Max. Difference: 4.00
Max. No. of predictions: 2

CoPhosK
(Web)

List of Protein, Site

Sites found: 50/502 (9.96%)
CK2 sites: 44/50

-

iGPS 1.0
(Standalone, Java)

List of peptides with
phosphosite as
pS/pT/pY

Proteins found: 86/251 (34.26%)
Predictor Other/CK2: CK2a1 (176 hits)
CK2a2 (144 hits)
CK2a1 interaction: Exp.: 126
String: 50
CK2a2 interaction: Exp.: 1
Exp & String: 54
String: 89

Score cut-off: 3.57
(Medium: FPRs of 6%)

KSP-PUEL
(Standalone, Java)

Phosphoproteomics
data with a column of
centered peptides. List
of substrates for a given
kinase as Substrate;Site;

Known CK2 sites: 17
Predicted CK2 sites: 1,546

Score cut-off: 0.70 (17
known substrates >= cutoff)

Overall, since different tools use different biological annotations (e.g., functional
association with STRING, co-regulation in phosphoproteomics, protein-protein
interaction) the inclusion of more than one tool in the analysis strategy will provide
useful to uncover kinase-substrate relationships by considering both the overlap and the
union of their outputs. Tools like CoPhosK are of great interest since it can be adapted to
include context-specific phosphoproteomic studies that will allow for the generation of
novel co-phosphorylation networks (dynamic) and thus for the identification of
previously unknown relationships.

4.1.5 Functional association to writer enzymes
A novel and essential resource for exploring kinase-substrate relationships comes from
the ProteomeHD project [13], a co-regulation map of the human proteome. This

194

proteomic knowledge base provides quantitative information regarding changes in
abundance of > 10,000 human proteins in response to 294 biological perturbations. By
searching for a given writer enzyme, such as a kinase, experimental evidence is retrieved
functionally linking the enzyme to a subset of co-regulated proteins. Given that PTMs
can impact the stability of substrates, it is safe to assume that the list of co-regulated
proteins may include known but also unknown substrates of the enzyme of interest as
previously observed for substrates of APC/C-dependent degradation [61]. This strategy
does not provide information at the site level but in combination with any of the other
strategies discussed here provides a functional hypothesis for further validating candidate
substrates. Other methods to functionally link a writer enzyme to a list of proteins is to
apply GO similarity using the Bioconductor’s package GoSemSim [62] or to find the
proteins in the list that are co-mentioned in Pubmed abstracts and full-text PMC articles
using R’s package reutils [63]. Another way to estimate the functional association
between sites of interest and a given writer enzyme is to find potential interplaying
residues with the known target sites of the enzyme using PTMcode v2 data [36] or
PTMscape crosstalk prediction for neighboring sites [38].

4.1.5.1

Functional association to CK2

The list of known CK2 substrates from PSP and iPTMnet was overlapped to the proteins
co-regulated with the CK2 subunits in ProteomeHD (Fig. 4.4A, Supp. Table 4.9). The
ProteomeHD cutoff was selected in a way to retrieve approximately the top 150 coregulated proteins for each of the CK2 subunits (Fig. 4.4A). The top co-regulated proteins
were searched for known CK2 substrates (PSP and iPTMnet databases) and we found 8
overlapping hits for CSNK2A1 and CSNK2B and 1 and 2 unique hits for CSNK2A1 and
CSNK2B, respectively (Fig. 4.4A). Interestingly, none of the top co-regulated CK2
substrates were shared between CSNK2A1/CSNK2B and CSNK2A2 (Fig. 4.4A); 6 hits
were found for CSNK2A2 (Fig. 4.4A). Next, the list of co-regulated proteins of each
CK2 subunit was functionally linked to CK2 considering interactors, literature mention,
GO similarity, CK2 motif and subcellular localization, CK2 manipulation, etc. (see
Chapter 2). As expected, several functionally linked proteins to CK2 was observed
(outliers) (Fig. 4.4B) beyond the known CK2 substrates (Fig. 4.4B, SCORE_SUB > 1).
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As before, the difference observed in the outliers between CSNK2A2 and
CSNK2A1/CSNK2B exemplify the functional differences between CK2 subunits (Fig.
4.4A-B).

Figure 4.4. Functional association of a list of modulated phosphoproteins to CK2. A)
CK2 subunits co-regulated proteins in ProteomeHD as per the selected cutoff; known
CK2 substrates found co-regulated. B) Functional link to CK2 of co-regulated proteins by
CK2 subunits (outliers: higher ranking proteins, CK2 substrates: SCORE_SUB > 1);
summary table. C) PTMcode v2 interplay information available for known CK2 target
sites; the number of interplaying sites for each represented PTM type.Venn diagrams
generated with jvenn [64].
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Finally, we also looked at the potential interplay between CK2 target sites and other PTM
sites using information retrieved from PTMcode v2 and found 6,064 potential
interplaying sites for 267 known human CK2 target sites (Fig. 4.4D). Three PTM types:
phosphorylation, ubiquitination, and acetylation provided the most information followed
by 14 other PTM types also found represented (Fig. 4.4D). The sources for the identified
functional interplay are co-evolution evidence (6,042 hits), same residue competition (4
hits), manual evidence (2 hits), and structural distance (36 hits). This analysis points to
the need to study CK2-dependent signaling in the context of other writers and erases such
as lysine acetyltransferases and lysine deacetylases, respectively (see Chapter 2).

4.1.6 Molecular interaction
Protein-protein interactions [65,66] are necessary for cellular signaling and the
maintenance of all cellular functions. Several public databases provide molecular
interaction information for proteins like BioGrid [67]; a comprehensive list of molecular
interaction databases can be found on Pathguide [68]. The IMEx Consortium is a
collaborative effort that integrates information from major public databases providing a
non-redundant set of protein interactions [69]. The IMEx application allows retrieval of
information using the PSICQUIC service [11] (PSI (Proteome Standard Initiative)
Common Query Interface), which accesses all IMEx participating databases. The
obtained hits can be clustered to get rid of redundant binary interactions (undirected)
annotated using identifiers from a wealth of databases. A package for accessing
PSICQUIC services is available in Bioconductor. Cytoscape interface also provides builtin access to PSICQUIC services using “import network from database” [11].

4.1.6.1

Molecular interaction retrieval strategies applied to CK2*

Using PSICQUIC services from Cytoscape or R [70] we interrogated the IMEx database
for retrieving known CK2 interactors. We observed that although common interactors are
reported, clear differences exist in the interactions established by each of the CK2
subunits [71] (see Chapter 3). The molecular interaction was overlapped with coregulation information (Fig. 4.4B), highlighting functional differences between subunits
again. In this regard, CSNK2A1 and CSNK2B shared 10 co-regulated proteins as
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interactors but none was shared between these and CSNK2A2 or between the three
subunits (Supp. Table 4.10). Finally, since protein-protein interaction can be readily
retrieved it can be easily integrated to any functional analysis strategy and uncover
potential writer-substrate associations. For instance, here we identified 8, 5, and 6 CK2
co-regulated interactor proteins that have been mentioned in the literature along with
CK2 for CSNK2A1, CSNK2A2, and CSNK2B, respectively (Supp. Table 4.10). This
means that likely there is available information for exploring their association to CK2.

4.1.7 Functional relevance of modification
Proteins contain functional motifs (UniProt: a short conserved sequence, < 20 amino acid,
with associated experimental evidence) and domains (UniProt: a specific combination of
secondary structure with a characteristic 3D structure of fold). The occurrence of
modulated phosphosites inside these protein features could then indicate an effect on
protein function. Positional and non-positional information regarding protein motifs and
domains can be retrieved from UniProt, which uses InterPro [14] for predicting the
occurrence of domains [72]. InterPro provides a framework to functionally classify
proteins by predicting domains and important sites using member databases like
PROSITE, SMART, and Pfam [14]. This information can be mined to retrieve the
domain information for a given list of sites. Alternatively, the PSP database provides
domain and PTM regulatory effect information for annotated phosphosites [9].
If modification sites on kinases were expected to be modulated or to test this hypothesis,
an Activation loop analysis using Phomics [12] can be performed. This will output those
peptides that contain phosphosites localized to the activation loop of kinases which could
imply a direct modulation of the kinase’s activity and will likely impact the regulation of
dependent signaling pathways and biological processes [12]. Another useful resource is
the database PTMfunc [73], a repository for predicting the functional relevance of
confidently localized PTMs identified by mass-spectrometry for a given protein.
PTMfunc considers if a site is in a globular or unstructured region of the protein and
makes use of structural information or the frequency of nearby modifications to assess
functional relevance, respectively [73]. It annotates residues that are likely found in the
interface and if their modification impacts protein interaction. Furthermore, it also
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provides information on the presence of PTM hotspots, regions of a protein that are
enriched in PTMs [73].

4.1.7.1

Functional relevance strategies applied to CK2 datasets

An example of how these tools can be integrated to retrieve information for the CK2
target sites Ser421 and Ser423 of the histone deacetylase HDAC1 can be found in Supp.
Fig. 4.2. Briefly, information indicates that these sites are conserved and although they
localize to a disordered region outside the deacetylase domain their phosphorylation
induces HDAC1 activity and regulated HDAC interactions (Supp. Fig. 4.2). Regulation
of phosphorylation occurs in cell cycle and differentiation and is involved in cell
adhesion, differentiation, and cytoskeletal reorganization (Supp. Fig. 4.2). Additionally,
we also looked at CK2 target sites annotated in motifs or as regulatory using the
information provided by PSP and found the representation of > 60 different domains and
364 regulatory associations (Supp. Table 4.11). After mining the regulatory information
provided by PSP, it is evident that more experimental work is needed to understand the
impact of CK2-dependent phosphorylation in the function of these domains.

4.1.8 Frequently used tools
To explore the functional analysis strategies commonly applied by researchers we
automated Google Scholar searches and retrieved from the scholarly literature the
occurrences of the tools/databases discussed here (December 2019) (Supp. Table 4.12), in
studies mentioning both kinase and proteomic. The tools/databases with the most (>
1,200) hits found were: InterPro, GPS, STRING, BioGRID, NetPhos, PSP, motif-x,
MeMe suite, and ScanProSite (Fig. 4.5A). These data suggest that up to December 2019
these were among the most frequently used tools/databases by researchers in the field.
Furthermore, since applying different strategies was useful for extracting biologically
relevant information from CK2 datasets, we also looked for studies that offer information
on the integration of the analysis strategies proposed here. For this, we retrieved the comentions (pairs) between tools/databases belonging to the same or different strategies
discussed here (Fig. 4.5A). The mentions retrieved were visualized in a network and we
found that six strategies out of eight were highly interconnected (Supp. Table 4.13, Fig.
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4.5B). We could observe that ksp-ptm (kinase-substrate prediction and PTM resources:
1,349), ksp-ps (kinase-substrate prediction and pattern scan: 1256), and ksp-mi (kinasesubstrate prediction and molecular interaction: 1,089), ksp-md (kinase-substrate
prediction and motif, domain, and function: 840), md-ps (motif, domain, and function
and pattern scan: 501), and kea-ksp (kinase enrichment analysis and kinase-substrate
prediction: 245) had the highest number of co-occurrences (co-mention) between groups.
Whereas the less represented co-occurrences were fawe-md (functional association with
writer enzyme and motif, domain and function: 10), fawe-ps (functional association with
writer enzyme and pattern scan: 6), fawe-ptm (functional association with writer enzyme
and PTM resource: 4). Suggesting that fewer studies apply tools that functionally link
proteins to modifying enzymes by mining the literature or by considering GO similarities
in combination with other strategies. We also found that the tools SELPHI and INKA
(Integrative Inferred Kinase Activity) since implemented, i.e., 2015 and 2019,
respectively, have been mentioned along with other databases/tools (Fig. 4.5C). These
results point to the complementarity of the available tools but also highlights the need to
perform analysis strategies that include as many tools/databases from different strategies
as possible. Here, by doing so we were able to recapitulate known experimental
information on protein kinase CK2.
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Figure 4.5. Scholarly literature that co-mention (pairs) the tools and databases described
here. A) Cluster of strategies where nodes represent the tools/databases and the edges the
number of co-mentions retrieved from the literature; the edge width represents the
number of associations retrieved from low (thin) to high (thick). B) The number of
observations shared intra- and inter-group; the edge width represents the number of
associations retrieved from high (thin) to low (thick). C) Subnetwork representing the
number of observations retrieved for the integrative strategies SELPHI and INKA. ksp:
kinase-substrate prediction, ps: pattern scan, ptm: PTM resources, kea: kinase enrichment
analysis, fawe: functional association with enzyme writer, mi: molecular interaction, md:
motif, domain, and function.
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4.2 visualRepo implementation
A data-driven R web-based application, that I named visualRepo (currently at version 2),
was developed by me to summarize the data processing and data analysis steps of the
functional analyses performed during my studies on CK2-dependent phosphorylation and
PTM interplay. By implementing visualRepo we made sure that the data sets obtained
and the bioinformatic methods implemented could be of use to others studying CK2,
phosphorylation, acetylation, or other kinases and PTM types. Thus, visualRepo not only
facilitates the reanalysis and the reuse of data but also that of the R code. The application
visualRepo is available at www.visualrepo.cloverpath.ca/visualRepo. Alternatively, a
local copy can be started using the RStudio image provided in the repository rstudiovrepo:0.2 available at docker hub along with the code in the Appendix C (see the readme
file).

4.2.1 Development environment
The R programming language R v.3.6.3 (2020-02-29, "Holding the Windsock") [74] was
selected for coding visualRepo because it is powerful in statistics, the packages extending
R, are well documented, and can be adapted to the analysis of genomics data by installing
Bioconductor v.3.10 [15] packages. The integrated development environment or IDE
used was RStudio v.1.2.5033 [75] because it is free for academic use and is actively
maintained. The R package shiny v.1.4.0.2 [76] was used for building the application
interface and server-side. Data visualization was achieved using the R package ggplot2
[77] and the htmlwidget R packages visNetwork [78] and plotly [79]. The changes in the
application were kept track of by using the version controller program git v.2.17.1 [80]
and safely stored using Bitbucket [81], a free version control repository hosting service in
the cloud. To facilitate the use of the application, an Ubuntu Docker container image was
prepared with RStudio and Shiny installed featuring all the necessary Bioconductor [15]
and R package dependencies with the correct version. The Docker container image can be
found in dockerhub [82] as rstudio-vrepo. A summary of the technologies used is shown
in Fig. 4.6.
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Figure 4.6. Development environment for visualRepo application implementation. A)
code repository and software container technologies. B) Experimental and in silico tools
for data collection and tools for data analysis, exploration, and visualization.

4.2.2 Report objects
There are several types of biological annotations of interest when performing the
functional analysis of PTM data as mentioned in the previous section. Here we organized
and classified the information into six groups i.e., proteins, sites, genes, mutations, motif
hits, and the COSMIC Cancer Gene Census. Then, we modeled each group into six R
classes for storing the information as fields, following an object-oriented programming
approach (Fig. 4.7). For each class, we also implemented methods to process and analyze
the data to adapt it into a useful tabular or graph format (Fig. 4.7). The fields for each of
the groups are summarized in Figure 4.7. The methods and fields of a class can be
inherited from other classes using inheritance e.g., the class motifHitsRepo contains all
the fields and methods of class sitesRepo (Fig. 4.7).
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Figure 4.7. Diagram of classes of reports in the visualRepo application. The fields show
the information collected for each category and the methods the steps required to store
the information.
We also created two other classes: dataAbout and linkTo, which store information for a
given writer of interest and use this information to rank a list of proteins of a topic of
interest according to its functional association to the writer, respectively (Fig. 4.8). As an
example, data about CK2 such as its substrates, interactors, etc. can be stored in a
dataAbout class as specified by its fields. Then this data is used to specify the fields in
linkTo using the methods of linkTo. After specifying the fields in linkTo the information
can be used to rank the proteins of interest, for example, those involved in chromatin
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remodeling, to CK2, in this case (See Chapter 3). The information that can be stored in
these classes extended to any writer of interest and to any protein list of interest.

Figure 4.8. Diagram of dataAbout and linkTo classes example of data applied to each
class. Training set refers to the information collected to CK2 whereas the topic of interest
is the list of proteins or genes of interest to functionally associate to CK2.

4.2.3 User Interface
The User Interface (UI) of visualRepo is intuitive and simple and consists of a landing
page and several tabs in the navigation bar (Fig. 4.9A). The landing page contains general
information on the purpose of building the application, images retrieved from work by
our group, and some of the main findings described here. It also contains a description of
the main biological annotations used in visualRepo to perform functional analysis.
The first tab is “Repos” and contains information about the reports and analysis available
for exploring and visualizing data in the application under “Overview” (Fig. 4.9B).
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Noticeably, the number of reports in visualRepo is not fixed as new data can be added
thus making it flexible to incorporating the results of similar analyzes. For visualRepo v.2
the available reports match the analyzes described in the chapters above. The reports
available for Chapter 2 are data about CK2, the link of CK2 to acetylated proteins
identified by Scholz et al. 2015 [4], the link of CK2 to proteome-wide K motif hits, the
proteome-wide K motif hits for each position separately, and the sites found in the
phospho-acetyl dual enrichment experiments. For Chapter 3 these are the link of CK2 to
AmiGO [83] chromatin remodeling, the link of CK2 to Reactome chromatin-modifying
enzymes, and the link of CK2 to Reactome epigenetics. These reports can be accessed in
tabular format in the same tab under “Data Access” (Fig. 4.9B).

Figure 4.9. visualRepo user interface. A) Landing page and sections of the user interface
labeled. B) Repo tab with an Overview tab containing information on the repositories and
analysis available and a Data Access tab for accessing the report information in tabular
and/or graphic format.
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The other two tabs “Functional Analysis” and “KS Analysis” can be used to perform
several relevant functional analyses that take as input a list of proteins, phosphorylation
sites, and/or relevant quantification data. These were included to perform the most
common functional analysis strategies described here. For visualRepo v.2 five types of
analysis are available: overrepresentation analysis (ORA), kinase enrichment analysis
(KEA, see section 4.1.3), gene set enrichment analysis (GSEA), functional classification,
and data set comparison using ORA and functional classification [2,48]. Like the reports
the number of analyzes performed by visualRepo is flexible and new analyses can be
added without introducing important changes to the application. An example of tabular
and graph output obtained by performing KEA analysis with visualRepo v.2 can be seen
in Figure 4.10.

Figure 4.10. visualRepo functional analysis example.
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4.2.4 Reports
The reports section allows the user to interact with a myriad of tables generated in the
analyses performed in Chapters 2 and 3 and to explore the data obtained in tabular and
graphic formats. Regarding the latter, the user can also change several predefined values
to modify the default parameters of the graphic analyzes. For instance, when browsing
the ranking/link of chromatin remodeling proteins to CK2 the user can cluster the results
and identify the proteins in the vicinity of a given score (Fig. 4.9B) and/or perform outlier
detection with adjustable statistical parameters and the outlier coefficient (Fig. 4.11A).
The user can also access quantitative data from CK2 manipulation in a highlight table
format where the direction and magnitude of the fold change are represented by a
continuous red (up)-to-blue (down) palette (Fig. 4.11B). The sequence logo of CK2
substrates, or in general of the kinase of interest, and of the K motif hits can also be
visualized using chemical properties as the color style (Fig. 4.11C).
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Figure 4.11. Visualization of report data with visualRepo. A) Outliers detection applied
to reports on the link of CK2 to protein lists of interest. B) Highlight table of CK2
manipulation data. C) Sequence logo of CK2 substrates in the dataAbout CK2 report.
The advantage of defining R classes storing information of interest, for example, sites,
mutations, and motif hits is that it allows us to format any new data set of interest using
these. So, to visualRepo, if site information is added to a report or a new report
containing this information is added all together, the same tabular and graphic
functionalities can still be applied without change. This is important since reports like the
proteome-wide K motif hits are complex and require all six groups of information
mentioned above. In this case, several graphics are outputted by visualRepo for exploring
the information (Fig. 4.12).
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Figure 4.12. Visualization examples of mutation, motif hit, and site data with visualRepo
for K motif hits position +2.

4.2.5 Functional analysis
The “Functional Analysis” and the “KS Analysis” tabs provide access to enrichment
analysis, data set comparison, and functional classification utilities. The implementation
of these analysis strategies was performed using functions provided in the R libraries for
enrichment analysis: clusterProfiler v3.14.3 [48], org.Hs.eg.db v3.10.0 [84], DOSE
v3.12.0 [85], msigdbr v7.0.1 [86], meshes v1.12.0 [87]; kinase-substrate and kinase
activity prediction: KSEAapp v0.99.0 [41], ClueR v1.4 [46], KinSwingR v1.4.0 [42];
pathway analysis: ReactomePA v1.30.0 [88]; and statistical analysis: lsr v0.5 [89], and
psych v1.9.12.31 [90]. To start the analysis upload a .csv file containing the list of
proteins, sites, and/or site quantification of interest. The input utility recognizes the most
common separators besides comma. Sample input files are provided with visualRepo
describing the format required for each type of analysis or tool.
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4.2.5.1

Enrichment and classification analyses

A total of three enrichment analysis types i.e., ORA, KEA, and GSEA and GO
classification can be performed under the “Functional Analysis” tab. ORA was also
implemented for data set comparison. The difference between ORA and GSEA was
reviewed in [2]; KEA was discussed in section 4.1.3. Briefly, in ORA a list of accession
numbers representing a list of entities of biological interest e.g. proteins or
phosphoproteins found differentially modulated are searched for overrepresented or
enriched terms by using overlap statistics like the hypergeometric distribution for
calculating the P value [85,91]. In GSEA, all entities identified in an experiment are
considered for enrichment not only those differentially modified since the entities are
ranked from high to low based on the quantitative data obtained. For performing ORA
analysis, visualRepo applies functions from the clusterProfiler v3.14.3, DOSE v3.12.0,
and ReactomePA v1.30.0 packages which rely on a one-sided Fisher’s exact test to
determine enrichment. For GSEA the same libraries were used which implement the
method described in Subramanian et al. 2005 [91]. The proportion of false positives is
controlled by FDR. The ORA and GSEA enrichment results are visualized using an
enrichment map, organizes enriched terms into a network with edges connecting
overlapping gene sets [92], and a ridgeplot, visualizes the expression distributions of core
enriched genes for GSEA enriched categories [92], respectively. The ORA results for
“compare analysis” are visualized as dotplots [92], depicting the enrichment scores and
gene count or ratio by setting the dot color and size, respectively.
The available biological annotations for performing ORA and GSEA analysis in
visualRepo account for the most used including GO, KEGG PATHWAYS, Reactome,
Molecular Signature Databases, Wikipathways, Cell Markers, and DisGeNet [48]. Since
CK2 data is stored in the dataAbout class the CK2 manipulation data can be extracted
and used for ORA analysis as well. This allows the rapid identification of proteins of
interest that change in the experiment being analyzed but also when CK2 is manipulated.
It also indicates in which past experiments the proteins were observed changed by the
name of the annotation, which creates novel hypotheses by providing the overlap with
previously generated data by our group.
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Finally, the functional classification analysis annotates all the proteins of interest to GO,
which is very useful when looking for specific processes, cellular compartments, and
molecular functions expected to be targeted. It is also useful because it provides
information for single proteins whereas the enrichment analyses are limited to
annotations represented, typically, by three or more proteins of interest.

4.2.5.2

Kinase-substrate functional analysis

The “KS Analysis” tab provides several utilities to link a list of proteins and sites to
writers. The lists are uploaded to visualRepo as described for the functional analysis.
Once uploaded, a list of proteins can be functionally linked to CK2 and/or searched for
proteins changing upon CK2 modulation. A list of sites can be also searched for sites that
are annotated in the PTM databases PSP and iPTMnet, known kinase-substrates
associations, known regulatory roles, and for sites modulated when CK2 is manipulated.
This tab also provides a utility to perform hypothesis testing of sites quantified in a PTM
proteomic experiment by selecting a functional category or UniProt keyword of interest
(Fig. 4.13). This selection results in a smaller number of comparisons that need to be
adjusted for multiple comparisons. Thus when calculating the FDR adjusted P values
with the formula P value×(n/i), where i is the rank of the P value being adjusted and n is
the total number of tests [93], the n value is made smaller which results in smaller
adjusted P values and better control on false negatives. After P value calculation and
adjustment for the sites belonging to the annotation or keyword of interest e.g.,
acetylation, phosphorylation, and chromatin remodeling, the results can be visualized
(Fig. 4.13B-D). Using the visualization, the sites that increased or decreased above a
certain cutoff (Fig. 4.13B) can be identified along with their corresponding size of the
effect (Fig. 4.13C), and if they are considered outliers (Fig. 4.13D). For finding the
outliers visualRepo implements a robust Z-score where for each site the absolute
difference between the log2FC value and the median log2FC of all sites is divided by the
median absolute difference [94]. Any site with a Robust Z-score > 2 is considered an
outlier (Fig. 4.13D).
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Figure 4.13. visualRepo site quantification hypothesis testing. A) Filter by GO
annotation or UniProt keywords to perform the tests. B) Log2FC order from decreasing
to increasing magnitude. C) Effect size. D) Robust Z-score outlier detection.

4.3 Concluding remarks
Several complementary strategies can be applied for the functional lists of modified sites
observed in PTM proteomic studies. As illustrated here for sites targeted by protein
kinase CK2 or differentially modulated by CK2 inhibition. These strategies can be used
to expand upon previous working hypotheses (e.g., known consensus sequence or
response to inhibition with a chemical probe) or to uncover new trends (e.g., PTM
function, PTM interplay, and/or kinase activity in response to perturbations). Equally
important, by using R, Bioconductor, and Shiny we integrated several of these tools and
methods into the web application visualRepo that allows others to explore, reanalyze and
reuse the data generated here The application can also be adapted to allow for the
analysis of other modification types and writer enzymes. As mentioned before, the
application visualRepo is available at www.visualrepo.cloverpath.ca/visualRepo.
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Alternatively, a local copy can be started using the RStudio image provided in the
repository rstudio-vrepo:0.2 available at docker hub along with the code in the Appendix
C (see the readme file).
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4.5 Supplemental Material
Tables
Supp. Table 4.1. CK2 substrates retrieved from PhosphoSitePlus (PSP) database,
September 2019.
Sheet
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Table 1
Appendix A
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PhosphoSitePlus CK2 (CK2a1) substrates, September 2019.
Supplemental Material – Chapter 4

Supp. Table 4.2. CK2 target sequences motif discovery using MoMo v.5.0.5.
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Table 2

Appendix A

Content
MoMo motif discovery applied to CK2 substrates.
MoMo input and output.
MoMo motifs.
Supplemental Material – Chapter 4

Supp. Table 4.3. FIMO v.5.0.5 proteome scan for motifs discovered with MoMo v.5.0.5.
Sheet
Name
1
Table 3
Appendix A

Content
FIMO proteome search using MoMo output motifs as input.
Supplemental Material – Chapter 4
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Supp. Table 4.4. SDSE hits that are annotated as phosphorylated in PhosphoSitePlus
(PSP) database.
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Appendix A

Content
PhosphoSitePlus, sequence or motif: xxxxxxxSDSExxxx. Only phosphorylation sites
(December 2019).
Supplemental Material – Chapter 4

Supp. Table 4.5. PTM types annotated in the vicinity (+/-7 amino acids) of
phosphorylated SDSE hits.
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Appendix A
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PhosphoSitePlus, sequence or motif: x{7}SDSEX{4}. Nearby PTM sites to SDSE
(December 2019).
Supplemental Material – Chapter 4

Supp. Table 4.6. SDSE hits known kinase-substrate relationships and phosphorylation in
vitro by CK2.
Sheet
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Table 6

Appendix A

Content
SDSE hits: known kinase substrate-relationships, iPTMnet and PSP databases (December
2019).
SDSE hits: in vitro CK2 phosphorylation (Bian et al. 2013).
Supplemental Material – Chapter 4

Supp. Table 4.7. Kinase set enrichment analysis and activity inference.
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Appendix A

Content
Kinase set enrichment analysis and activity inference.
KSEA (Web, R package), KinSwingR (R package), CLUster Evaluation (Clue)
(R package)
Supplemental Material – Chapter 4

Supp. Table 4.8. CoPhosK, iGPS, and NetworKIN prediction using as input CK2
substrates retrieved from PhosphoSitePlus (PSP) database, September 2019.
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Table 8

Appendix A

Content
CoPhosK prediction using as input CK2 substrates retrieved from PhosphoSitePlus (PSP)
database, September 2019.
iGPS prediction using as input CK2 substrates retrieved from PhosphoSitePlus (PSP)
database, September 2019.
KSP-PUEL prediction using as input CK2 substrates retrieved from PhosphoSitePlus (PSP)
database, September 2019.
NetworKIN prediction using as input CK2 substrates retrieved from PhosphoSitePlus (PSP)
database, September 2019.
Supplemental Material – Chapter 4

Supp. Table 4.9. Co-regulated proteins of CK2 subunits retrieved from ProteomeHD.
Sheet

Name

1

Table 9

Appendix A

Content
proteomehd.net download. It contains proteins co-regulated with your query (above selected
score cut-off).
You query was: P68400. Your selected score cut-off was: 0.995.
You query was: P19784. Your selected score cut-off was: 0.95.
You query was: P67870. Your selected score cut-off was: 0.995.
Supplemental Material – Chapter 4

Supp. Table 4.10. Co-regulated proteins of CK2 subunits that are known CK2
interactors, June 2020.
Sheet
1

Name
Table 10

Content
Co-regulated proteins that are CK2 interactors by subunit, June 2020.
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Appendix A

CSNK2A1: co-regulated proteins as interactors.
CSNK2A2: co-regulated proteins as interactors.
CSNK2B: co-regulated proteins as interactors.
Overlap.
Supplemental Material – Chapter 4

Supp. Table 4.11. Regulatory CK2 target sites and domains represented, September
2019.
Sheet
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Table 11

Appendix A

Content
Regulatory CK2 target sites retrieved from PSP September 2019.
Domain containing regulatory CK2 target sites.
Supplemental Material – Chapter 4

Supp. Table 4.12. Summary of strategies and tools discussed in Chapter 4.
Sheet
Name
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Table 12
Appendix A

Content
Summary of strategies and tools discussed in Chapter 4.
Supplemental Material – Chapter 4

Supp. Table 4.13. Network representation of tools and databases included in the
strategies that are co-mentioned in the Scholarly literature.
Sheet

Name

1

Table 13

Appendix A

Figures

Content
Network of tools and databases included in the strategies that are co-mentioned in the
Scholarly literature.
Supplemental Material – Chapter 4
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Supp. Figure 4.1. Kinase-substrate prediction for CK2 sites. A) Number of sites found
for CSNK2A1 and CSNK2A2 (overlap: 100%). Summary of networkin_score. B)
Number of sequences belonging to each subset above and below the cutoff. C) Sequence
logos of sequences above and below the cut-off.
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Supp. Figure 4.2. Motif and domain information for the CK2 targets sites in HDAC1,
Ser421, and Ser423. PhosphoSitePlus (PSP) information shows no domain towards the
C-terminal where the sites are located. InterPro analysis points to a 23.4% of disorder
prediction for the whole protein occurring in the C-terminal. PTMfunc points to the
regulation of this modification in cell cycle and in human embryonic stem cell
differentiation. PSP information on PTM regulatory effects indicates the role of these
sites in the induction of HDAC1 activity and the regulation of HDAC1 interaction.
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Chapter 5

5

Discussion

Understanding the signaling networks involved in controlling cell proliferation and
survival in normal and cancer cells is necessary for devising novel and effective
therapies. Recent studies following a systems biology approach have yielded important
insights in this field, highlighting the involvement of the clinically relevant protein kinase
CK2 [1,2] in hierarchical phosphorylation [3] and in modulating cell survival by
attenuating caspase pathways through phosphorylation of residues adjacent to the
cleavage sites [4–6]. These results suggest that CK2 target sites are a breeding ground for
post-translational modifications (PTM) interplay somewhat like the histone tails.
Contrary to most kinases, CK2 is catalytically competent independent of effectors or
phosphorylation by other kinases and is constitutively expressed in cells [7]. In
correspondence and considering the hundreds of hits in the human proteome matching the
minimal CK2 consensus annotated phosphorylated in databases [8] or showing up in
phosphoproteomic experiments [9] a better understanding of CK2 specificity is crucial
for identifying true substrates.
CK2 target sites conform to the minimal acidophilic motif [ST]XX[DE] [8], where the
negative charge at position +3 downstream of the phosphorylatable residue can also be
mimicked by phosphorylated Ser or Tyr residues [8,10]. Furthermore, Pro and positive
amino acids are thought to be negative determinants at +1 and +1-+3 positions,
respectively [10]. Additional specificity determinants likely exist in the cellular context
[7] for instance regulation of specificity at the substrate level by the CK2 regulatory
subunit [11] as the minimal consensus sequence can be considered degenerate [12].
Additionally, post-translational modifications occurring in the vicinity of the target
sequence like lysine acetylation can change the local electrostatic properties and
modulate the effect of lysine as a negative determinant. Thus, the goal of this thesis is to
expand this view and explore the role of lysine and acetyllysine as determinants of CK2dependent phosphorylation at these positions and to identify potential candidate
substrates containing either determinant. The role of CK2 in chromatin organization is
also summarized considering the involvement of acetylation and phosphorylation
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networks in this process [13] and the regulatory role of CK2 on lysine acetylation erasers
[14]. In addition, the functional analysis steps performed were documented, integrating
the analytical workflow into an R Shiny data-driven application where the information
generated can be accessed, reused, and generated de novo; the latter is ideal for applying
the same logic to other enzymes were interplay at the substrate level is suspected.

5.1

Summary of findings and research impact

5.1.1 Intricate relationships of CK2 with lysine acetylation networks
Here we determined that several PTM types can target the vicinity of known CK2 target
sites including sites modified by lysine acetylation [15], a few of which were predicted to
interplay with the CK2 sites. This hinted to a functional relevance for the interplay
between CK2-dependent phosphorylation and lysine acetylation given that acetylation
removes a positive charge from lysine changing the local properties of the target
sequences [16] which then could be more permissive to CK2. Follow-up experimental
and in silico analysis performed by us showed for the first time that lysine and
acetyllysine are tolerated by CK2 at position +2 downstream the phosphorylatable
residue in the context of the linear pattern [ST][DE]X[DE]. This position is more
accommodating to the presence of non-acidic residues [8] and when acetyllysine is
present in vitro phosphorylation was rescued to 70 % of that of the CK2 peptide substrate
used as control compared to 25 % when lysine is present. These findings provide a
benchmark for assessing and exploring CK2 specificity and the interplay between CK2
and acetyllysine sites in future experiments but also in the human proteome, the data
annotated in PTM databases, the literature, and in published or accessible
phosphoproteomic and acetylome data sets. After approaching the latter, we effectively
observed that for curated CK2 target sites, sites phosphorylated in vitro by CK2, and/or
sites modulated by treatment with the ATP-competitive CK2 inhibitor CX-4945
phosphorylation by CK2 may occur at [ST][DE]X[DE] when lysine is present at position
+2. Phosphorylation by CK2 when lysine is present either at position +1 or +3 was
observed when at least four negatively charged amino acids were present. This allowed
us to generate a list of in vitro and in vivo CK2 candidates containing lysine at position
+2. As expected, based on our initial analysis of CK2 substrates several of the candidate
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sites were also observed to be targeted by lysine acetylation at positions +1-+3. This is in
accordance with our motif discovery findings in which in vivo acetylation sites identified
in [17] were observed to target negative motifs in proteins. More importantly, we
determined that treatment with pan-lysine deacetylase inhibitors, i.e., inhibitors of
acetylation erasers that increase protein acetylation in the cell [18], modulate CK2dependent signaling. Next by looking in vivo at the fraction of the phosphoproteome that
is acetylated by performing dual enrichment followed by mass spectrometry we observed
for the first time a number of phosphosites matching the CK2 consensus containing an
acetyllysine residue in their vicinity which in several instances was found to target a
lysine residue at position +2.

5.1.2 CK2-dependent regulation and chromatin organization
Among the candidate CK2 sites containing lysine at position +2 and the co-occurring
phospho-acetyl sites proteins involved in chromatin remodeling were observed.
Correspondingly, the role of CK2 in this process was investigated and summarized with
known and novel associations retrieved. For example, a known regulatory role in histone
H3 and H4 phosphorylation [19,20], heterochromatin DNA methylation patterns [21],
chromatin-remodeling [22], and transcriptional repression [23] and a potential novel role
in regulating the function of the repressor complex PRC2 and the lysine acetyltransferase
KAT7. This provides a biological context in which widely used tools for exploring
chromatin and its associations with signaling pathways can be applied to understand the
regulatory role of CK2. Beyond their association to CK2 a wealth of other
phosphorylation sites occurring in the vicinity of lysine acetylation sites or vice versa was
observed. This challenges to a point the assumption that PTMs are mutually exclusive
[24] and opens the opportunity for further validation of the occurrence of PTM interplay
at specific residues of attractive molecular targets such as HIF1A [25] and several histone
methyltransferases, kinases, and lysine-acetylated histone binders. It also points to the
importance of developing quality antibodies and proteomic-based mass spectrometry
methods to account for the presence of multiple modification sites at the region of interest
of the protein.

227

5.1.3 Proteome-wide distribution of CK2 sites containing lysine
residues
Finally, based on scans of the human proteome against linear patterns for CK2 sites
containing lysine residues at positions +1-+3 it was determined that there are likely other
functionally relevant sites not included in the candidate list, but additional information is
required. This is illustrated by the cellular and boundary properties [26] of the proteome
hits observed for positions +1-+3. For example, several of the candidate sites were
identified conserved across different species in metazoan and orthologs, the residues
matching the motifs were more conserved than the flanks, and/or they are targeted by
mutations. The observation of mutations targeting either the negative residues at positions
+1 and +3 or the lysine residue at position +2 suggests that in addition to lysine
acetylation this can be another “switch” to modulate CK2 specificity at the substrate
level; highlighting the intricacy of the genetic and modification networks at play at these
motifs in the cell.

5.1.4 visualRepo web application implementation for data processing
and analysis
Our study involved the use of different logical steps to process and analyze large data
sets including the integration of several bioinformatic tools, the literature, and biological
databases [27]. Here we provide a web application implementation using R Shiny of the
analytical workflow followed i.e., visualRepo v2. This application allows the user to
perform main functional analysis strategies using R and CRAN and Bioconductor [28]
packages for the functional analysis of lists of modified sites and proteins. These
strategies were summarized and exemplified in the context of CK2 data sets. In addition,
visualRepo v2 allows for access to several data sets of the CK2 candidates containing
lysine at positions +1-+3 and of the co-occurring phospho-acetyl sites. Some of the
functionalities provided by visualRepo v2 are enrichment analysis (such as GO,
pathways, CK2 manipulation data, kinase), kinase activity prediction, GO classification,
and data set comparison. It also allows to find in a list of modified sites the known
modification sites, the known regulatory sites, the known enzymes-substrate associations,
the known modulation by CK2 manipulation, the known PTM interplay, the position of

228

sites of interest inside proteins, and the formatting to sequence window for weblogo
analysis. For sites quantification data visualRepo v2 performs hypothesis testing, outlier
detection, and effect size analysis to identify differentially modulated sites. Importantly,
visualRepo v2 adds the capability to filter the dataset before hypothesis testing by a
keyword of interest such as acetylation of histone modification, this allows for adjusting
only the p values in the functional category of interest. Regarding protein lists,
visualRepo v2 finds known proteins that change upon CK2 modulation, the complexes in
which they are involved, and their ranking according to their functional similarity to
CK2. This last functionality utilizes different biological data sources such as kinasesubstrate relationships, molecular interaction, mentions in the literature, and co-regulation
allowing fast identification/ranking of proteins of interest in large lists that have previous
functional information linking them to CK2. Several text and graphical reports can be
downloaded from visualRepo v2. Because visualRepo v2 was dockerized it can be run
using a docker container with all required R dependencies. Overall, visualRepo v2
provides a way to easily perform valuable functional analysis essential to uncover PTM
interplay and enzyme-substrate functional associations not only for CK2 but for other
kinase/enzyme or a list of sites of interest.

5.1.5 Limitations
The limitations associated with our study relates to how mass spectrometry-based
proteomic techniques and computational proteomic methods assess the identification of
multiply-modified peptides. In the future the costs of the experiments performed may be
lower and the identification methods less stringent with the identification scores and the
false discovery rate testing. In addition, antibodies that recognize multiple modified
epitopes are not common or are more specific for phosphorylation. Nevertheless, here we
bypassed some of the limitations by incorporating the processing and analysis of a wealth
of data from diverse sources and used only the sites that have been previously identified
and annotated in the databases or the literature. One can argue that the databases are often
incomplete; therefore, we also included PTM information from relevant studies in the
literature or obtained by our group to provide a biological and experimental context to a
subset of the sites analyzed.
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5.2

Future directions

Several in silico and wet experiments can be derived from the findings presented here in
the future. Most importantly, we should continue to monitor the literature and the
phosphoproteomic data sets generated by our group to expand and refine the list of
substrates containing lysine at positions +1-+3. In this regard, it will be of interest to
profile the phosphoproteome represented by a mixture of phosphopeptide generated with
other proteases besides Trypsin such as Asp-N and their combination. Another variable
that can be changed is the cell type used for phosphoproteomic profiling which can be
expanded from U2OS and HeLa cells to leukemia, lung, and prostate cancer cells where
CK2 is an attractive molecular candidate [29]. This can be achieved in part by monitoring
the scholarly literature for new phosphoproteomic datasets on the modulation of CK2dependent signaling and documenting the experimental set up. Once processed this
information can be added to visualRepo v2 specially to be used with the CK2
manipulation enrichment functionality. Likewise, libraries complemntary to the ones
already implemented in visualRepo should be monitored and included if possible, to
extend the functionalities; any step that is performed manually should be automated
whenever a new library created by others or our group should be made available.
Additional efforts can be done to generate antibodies against a few of the candidate sites
which can be of use for immunoprecipitation and immunoblot experiments. In this case
our group has been actively developing CK2 specific antibodies and proteins like BAZ1B
are candidates. Finally, dual enrichment experiments should be further optimized to
increase the yield of modified peptides and expand to assess other lysine deacetylase
inhibitors or dual CK2-lysine deacetylase inhibitors across different cell types. The
obtained raw files should also be searched using up-to-date computational proteomic
strategies as this is a rapidly evolving area of bioinformatics research.

5.3

Concluding remarks

Overall, this thesis approaches the study of the modulation of protein kinase CK2
specificity by neighboring PTMs expressly lysine acetylation. It demonstrates that the
overlap of phosphosites and acetylation networks in the cell are extensive and that they
converge at several sites including known and tentative CK2 candidate sites in vivo. This
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highlights the importance of considering kinase consensus sequences as breeding grounds
for interplay and the potential of missing biologically relevant substrates if we fail to
expand our study to include multiple modified proteoforms in signaling networks. To
perform this intricate analysis requires the integration of many large data sets and thus
here we exemplify the importance of documenting the analytical workflow and
developing it into an application that can be used to maintain reproducibility and
facilitate reuse of the data. By combining experimental and in silico analysis we also
demonstrated that some technical limitations can be overcome by performing prediction
and/or reuse existing data. Altogether, our results bring us closer to understanding the
regulatory role of CK2 and its overlap with lysine acetylation networks at the substrate
level but also to a potential role in chromatin organization. This is of great importance to
the community as the first steps are being made to device dual CK2 and lysine
deacetylase inhibitors and chromatin organizations is a cornerstone biological process.
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